<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5543290</article-id><article-id pub-id-type="doi">10.3389/fimmu.2017.00930</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Developmental and Functional Control of Natural Killer Cells by Cytokines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/463332"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Zhigang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/287522"/></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Haiming</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1">*</xref><uri xlink:type="simple" xlink:href="http://frontiersin.org/people/u/361046"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China</institution>, <addr-line>Hefei</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China</institution>, <addr-line>Hefei</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Eleanor Riley, London School of Hygiene &amp; Tropical Medicine, United Kingdom</p></fn><fn fn-type="edited-by"><p>Reviewed by: Kamalakannan Rajasekaran, Genentech, Inc., United States; Martin R. Goodier, London School of Hygiene &amp; Tropical Medicine, United Kingdom</p></fn><corresp content-type="corresp" id="cor1">*Correspondence: Zhigang Tian, <email>tzg@ustc.edu.cn</email>; Haiming Wei, <email>ustcwhm@ustc.edu.cn</email></corresp><fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to NK and Innate Lymphoid Cell Biology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>930</elocation-id><history><date date-type="received"><day>04</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#169; 2017 Wu, Tian and Wei.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Wu, Tian and Wei</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Natural killer (NK) cells are effective in combating infections and tumors and as such are tempting for adoptive transfer therapy. However, they are not homogeneous but can be divided into three main subsets, including cytotoxic, tolerant, and regulatory NK cells, with disparate phenotypes and functions in diverse tissues. The development and functions of such NK cells are controlled by various cytokines, such as fms-like tyrosine kinase 3 ligand (FL), kit ligand (KL), interleukin (IL)-3, IL-10, IL-12, IL-18, transforming growth factor-&#946;, and common-&#947; chain family cytokines, which operate at different stages by regulating distinct signaling pathways. Nevertheless, the specific roles of each cytokine that regulates NK cell development or that shapes different NK cell functions remain unclear. In this review, we attempt to describe the characteristics of each cytokine and the existing protocols to expand NK cells using different combinations of cytokines and feeder cells. A comprehensive understanding of the role of cytokines in NK cell development and function will aid the generation of better efficacy for adoptive NK cell treatment.</p></abstract><kwd-group><kwd>natural killer cells</kwd><kwd>cytokines</kwd><kwd>development</kwd><kwd>cytotoxicity</kwd><kwd>expansion</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></funding-source><award-id rid="cn01">81330071, 91442202</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="293"/><page-count count="18"/><word-count count="17584"/></counts></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Natural killer (NK) cells were first identified as &#8220;natural killer cells&#8221; in the mid-1970s and were characterized by their vital roles in controlling cancer and viral infection (<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>). They are widely distributed in diverse tissues, such as the peripheral blood (PB), spleen, lungs, liver, and uterus (<xref rid="B4" ref-type="bibr">4</xref>). In human PB, NK cells are primarily divided into two subtypes: CD3<sup>&#8722;</sup>CD56<sup>dim</sup>CD16<sup>+</sup> and CD3<sup>&#8722;</sup>CD56<sup>bright</sup>CD16<sup>&#8722;</sup> cells. CD56<sup>dim</sup> NK cells have potent cytotoxicity and high CD16 expression, allowing them to induce antibody-dependent cell-mediated cytotoxicity (ADCC) toward target cells, whereas CD56<sup>bright</sup> NK cells are best known for producing diverse types of cytokines (<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>). Different from PB NK cells, NK cells in diverse tissues have distinct phenotypes. Through experimental parabiosis (<xref rid="B8" ref-type="bibr">8</xref>), researchers have found that, with the exception of circulating NK cells, the identification of several markers, such as CD69, CD103, and CD49a, can affirm the phenotype of tissue-resident NK cells in the liver, skin, and uterus (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B9" ref-type="bibr">9</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>). Functions of NK cells vary depending on the cellular microenvironment, mainly due to the cytokine signals of various tissues. For instance, NK cells can regulate the outcome of pregnancy (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>) through the regulation of transforming growth factor (TGF)-&#946; and interleukin (IL)-15 in the uterus (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>) or tolerate plentiful food-derived antigens or bacterial products through the regulation of abundant TGF-&#946; and IL-10 in the liver (<xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B23" ref-type="bibr">23</xref>) (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Cytokine requirements for natural killer (NK) cell development and function. NK cell development from HSCs is regulated by multiple cytokines in the fetal liver, bone marrow, and thymus. The sequential expression of receptors for different cytokines implies the functional maturation of NK cells. The proliferation and differentiation of HSCs requires FL, KL, IL-3, and IL-7, which interact with their respective receptors. The acquisition of CD122 expression is indicative of the commitment of NK cells. IL-15 is indispensable for NK cell differentiation from CLPs to mature NK cells. Mature NK cells are shaped by cytokine signals from the diverse tissue environments in which they reside. In the peripheral blood or spleen, the abundance of stimulatory cytokines, such as IL-2, IL-12, IL-15, IL-18, and IL-21, may maintain NK cells in a cytotoxic state to combat infections. Tolerant NK cells that reside in the liver, and regulatory NK cells that reside in the uterus, are primarily regulated by TGF-&#946; and IL-10 or by TGF-&#946; and IL-15, respectively. Abbreviations: FL, fms-like tyrosine kinase 3 ligand; KL, kit ligand; IL, interleukin; HSC, hematological stem cell; CLP, common lymphoid progenitor; TGF-&#946;, transforming growth factor-&#946;.</p></caption><graphic xlink:href="fimmu-08-00930-g001"/></fig></sec><sec id="S2"><title>Regulation of NK Cell Development by Cytokines</title><p>Natural killer cells can develop in many sites, including the fetal liver, bone marrow (BM), and thymus (<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>). The developmental hierarchy of NK cells has been depicted as a linear process that involves multiple stages, developing from hematopoietic stem cells (HSCs) through common lymphoid progenitors (CLPs) and NK lineage-restricted progenitors (NKPs) to mature NK cells (<xref rid="B28" ref-type="bibr">28</xref>). In contrast to the mouse, the human NK cell development hierarchy is less well characterized (<xref rid="B29" ref-type="bibr">29</xref>). Recently, human NKPs, which can exclusively differentiate into NK cells, have been clearly defined as Lin<sup>&#8722;</sup>CD34<sup>+</sup>CD38<sup>+</sup>CD123<sup>&#8722;</sup>CD45RA<sup>+</sup>CD7<sup>+</sup>CD10<sup>+</sup>CD127<sup>&#8722;</sup> in umbilical cord blood (UCB), BM, and tonsils (<xref rid="B30" ref-type="bibr">30</xref>). The development of NK cells is regulated by cell-intrinsic signals through an array of transcription factors (TFs) and extrinsic signals from multiple cytokines (<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>). The TFs, including E4BP4, T-bet, Eomes, and GATA3 can regulate NK cell differentiation and maturation (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>). However, the requirement for TFs in murine NK cells may differ in different tissues. For instance, tissue-resident liver NK cells critically require the regulation of T-bet, whereas circulating NK cells are less affected by its depletion (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Thymic NK cells depend on the regulation of GATA3, whereas circulating NK cells and tissue-resident liver NK cells do not (<xref rid="B26" ref-type="bibr">26</xref>). Nevertheless, further study of transcriptional regulation in the development of human NK cells is still required for a greater understanding of these processes. The extrinsic cytokine signals that are crucial for regulating NK cell development have been well characterized. Cytokines, such as fms-like tyrosine kinase 3 ligand (FL), kit ligand (KL), and IL-3, influence the survival, and proliferation of HSC, and are important for normal NK cell development (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). In addition, NK cells are nearly absent in IL-15<sup>&#8722;/&#8722;</sup> or IL-15R&#945;<sup>&#8722;/&#8722;</sup> mice, which implies an indispensable role for IL-15 during NK cell differentiation (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Furthermore, previous reports have shown that IL-2<sup>&#8722;/&#8722;</sup>, IL-2R&#945;<sup>&#8722;/&#8722;</sup>, IL-7<sup>&#8722;/&#8722;</sup>, IL-7R&#945;<sup>&#8722;/&#8722;</sup>, and IL-21R<sup>&#8722;/&#8722;</sup> mice have normal numbers of mature NK cells in PB, suggesting that IL-2, IL-7, and IL-21 are redundant for peripheral NK cell development (<xref rid="B45" ref-type="bibr">45</xref>&#8211;<xref rid="B48" ref-type="bibr">48</xref>). However, IL-2 and IL-21 participate in promoting NK cell activation with enhanced cytotoxicity (<xref rid="B49" ref-type="bibr">49</xref>&#8211;<xref rid="B51" ref-type="bibr">51</xref>). Additionally, IL-12, IL-18, IL-10, and TGF-&#946; also have roles in NK cell development or function (<xref rid="B33" ref-type="bibr">33</xref>). In this review, we illustrate when and how each cytokine regulates NK cell development and function (Table <xref ref-type="table" rid="T1">1</xref>). Based on a thorough understanding of relative cytokines, NK cells can be further generated in large quantities using diverse cytokine cocktails for <italic>in vitro</italic> expansion and induction in culture systems for adoptive transfer therapy.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The receptors, signaling pathways, and knockout phenotypes of cytokines.</p></caption><table-wrap-foot><p><italic>SCF, stem cell factor; KL, kit ligand; FLT3L (FL), fms-like tyrosine kinase 3 ligand; IL, interleukin; TGF-&#946;, transforming growth factor &#946;; &#946;c, common &#946; chain; &#947;c, common &#947; chain; Rap, receptor accessory protein; PI3K, phosphoinositide 3 kinase; AKT, protein kinase B; JAK, janus kinases; STAT, signal transduction and activation of transcription; ERK, extracellular regulated protein kinases; MAPK, mitogen-activated protein kinase; TYK, tyrosine kinase; MyD88, myeloid differentiation primary response protein 88; IRAK4, IL-1R-associated kinase 4; NF-&#954;b, nuclear factor kappa-light-chain-enhancer of activated B cells; HSC, hematopoietic stem cell; DC, dendritic cell; NK, natural killer; NKT, natural killer T; IEL, intraepithelial lymphocytes; Treg, regulatory T cell; Th, T helper; EAE, experimental autoimmune encephalomyelitis</italic>.</p></table-wrap-foot></table-wrap><p>Natural killer cells belong to the innate immune system due to their roles in directly combating hematopoietic and non-hematopoietic cells to maintain homeostasis throughout the body (<xref rid="B91" ref-type="bibr">91</xref>). Previous reports have divided the developmental pattern of NK cells into four stages based on expression of the cell surface markers CD34, CD117 and CD94:CD34<sup>+</sup>CD117<sup>&#8722;</sup>CD94<sup>&#8722;</sup>, CD34<sup>+</sup>CD117<sup>+</sup>CD94<sup>&#8722;</sup>, CD34<sup>&#8722;</sup>CD117<sup>+</sup>CD94<sup>&#8722;</sup>, and CD34<sup>&#8722;</sup>CD117<sup>+/&#8722;</sup>CD94<sup>+</sup> (<xref rid="B92" ref-type="bibr">92</xref>). NK cell development and function are characterized by the gradual acquisition of specific receptors. As shown above, the extrinsic signals from cytokines are vital important to regulate NK cell development and function (<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>). According to the expression pattern of cytokine receptors, we have divided NK cell development into five grading stages, including HSCs: CD34<sup>+</sup>CD117<sup>+</sup>FLT3<sup>+</sup>CD123<sup>+/&#8722;</sup>, CLPs: CD34<sup>+</sup>CD117<sup>+</sup>FLT3<sup>+</sup>CD123<sup>&#8722;</sup>CD127<sup>+</sup>, NKPs: CD34<sup>+</sup>CD117<sup>+</sup>FLT3<sup>+</sup>CD7<sup>+</sup>CD10<sup>+</sup>CD122<sup>+</sup>CD127<sup>&#8722;</sup>CD215<sup>+</sup>, immature NK cells (iNK cells): CD56<sup>+/&#8722;</sup>CD25<sup>+</sup>CD122<sup>+</sup>CD212<sup>+/&#8722;</sup>CD215<sup>+</sup>CD218<sup>+/&#8722;</sup>CD360<sup>+/&#8722;</sup>, and mature NK cells (mNK cells): CD56<sup>+</sup>CD25<sup>+/&#8722;</sup>CD122<sup>+</sup>CD212<sup>+</sup>CD215<sup>+</sup>CD218<sup>+</sup>CD360<sup>+</sup>TGF-&#946;R<sup>+</sup> IL-10R<sup>+</sup> (Figure <xref ref-type="fig" rid="F1">1</xref>). The differential expression of cytokine receptors implies that there are various demands for the relevant cytokines during NK cell development.</p><sec id="S2-1"><title>FL, KL, IL-3, and IL-7 Promote the Transition of HSCs to CLPs</title><p>Hematological stem cells are the major source of multilineage myeloid cells and lymphocytes which are vital for maintaining normal numbers and functions of immune cells (<xref rid="B93" ref-type="bibr">93</xref>). It is well established that the differentiation of NK cells is a step-wise process that is driven by the regulation of TFs and coordinated cytokine signals from HSCs (<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>). FL and KL, discovered in the early 1990s, have overlapping yet distinct effects to promote HSC survival and proliferation (<xref rid="B41" ref-type="bibr">41</xref>). Their receptors, flt3 and c-kit, belong to the family of tyrosine kinase receptors expressed primarily on cells in the very early stages of hematopoiesis (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B94" ref-type="bibr">94</xref>). KL, also known as stem cell factor (SCF), is produced in two forms: membrane-bound and soluble, through differential splicing and proteolytic cleavage (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B95" ref-type="bibr">95</xref>). <italic>Sl</italic>/<italic>Sl</italic><sup>d</sup> mutant mice expressing only soluble SCF are deficient in HSCs, indicating that membrane-bound SCF is critical for HSC maintenance (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B96" ref-type="bibr">96</xref>, <xref rid="B97" ref-type="bibr">97</xref>).</p><p>Previous reports have shown that flt3 or c-kit deficiency in mice induces a reduction in the number of CLPs (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B98" ref-type="bibr">98</xref>). In addition, the cytokine FL deficiency in mice can also induce a sharp reduction of CLPs but has no effect on the HSC pool or on common myeloid progenitors (<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Recently, it is revealed that FL can act synergistically with Hoxa9 signaling to regulate an early checkpoint of lymphopoiesis by affecting CLPs, LMPPs, and flt3<sup>+</sup> multipotent hematopoietic progenitors in the BM (<xref rid="B99" ref-type="bibr">99</xref>). Furthermore, FL and SCF can act synergistically to promote CD34<sup>+</sup> cell proliferation and are important for NK cell differentiation by inducing the expression of CD122 and increasing <italic>IL15R</italic>&#945; expression to increase their sensitivity to IL-15 (<xref rid="B100" ref-type="bibr">100</xref>). The number of NKPs is reduced in mice that are deficient in either flt3 or c-kit, implying that either of these cytokines is essential for NK-cell differentiation (<xref rid="B56" ref-type="bibr">56</xref>). These findings imply that FL and SCF have important roles in the development of lymphoid progenitor cells and are critical for the commitment of NK-cell lineage.</p><p>Interleukin-3 is a member of the beta common (&#946;c) family of cytokines, which also includes granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-5 (<xref rid="B101" ref-type="bibr">101</xref>). IL-3 is a well-known hematologic growth factor that can promote HSC survival, proliferation and differentiation (<xref rid="B62" ref-type="bibr">62</xref>). Previous research has demonstrated that IL-3 alone can rescue low HSC activity in <italic>Runx1<sup>+/&#8722;</sup></italic> AGMs (Aorta-Gonad-Mesonephros) that have a reduced HSC population (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B102" ref-type="bibr">102</xref>). Receptors for IL-3, members of the gp140 family, are composed of an IL-3 receptor-specific &#945; subunit (IL-3R&#945; or CD123) and a homo-dimeric &#946;c subunit (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B103" ref-type="bibr">103</xref>). Both CD123 and &#946;c subunits are detected on the surface of hematopoietic tissues and HSCs (<xref rid="B42" ref-type="bibr">42</xref>). After binding with the receptors, it can activate janus kinases (JAK) 2-signal transduction and activation of transcription (STAT) 5/1/3/6, phosphoinositide 3 kinase (PI3K)-protein kinase B (AKT), and Ras-extracellular regulated protein kinases (ERK) pathways (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B104" ref-type="bibr">104</xref>). In the <italic>in vitro</italic> differentiation system of human primitive progenitors, IL-3 has been reported to maintain lymphoid progenitor development and promote NK cell or B cell differentiation (<xref rid="B105" ref-type="bibr">105</xref>&#8211;<xref rid="B107" ref-type="bibr">107</xref>). Moreover, IL-3 can also preserve the engraftment and lymphoid reconstitution capacity <italic>in vivo</italic> of the transduced CD34<sup>+</sup> cells in severe combined immunodeficiency (SCID)-hu mice (<xref rid="B108" ref-type="bibr">108</xref>). Therefore, IL-3 may primarily facilitate the survival and proliferation of HSCs and the differentiation of CLPs, and further promote NK cell development.</p><p>CXCR4 signaling has been shown to regulate quiescence and long-term maintenance of HSCs upon interaction with the chemokine CXCL12 (<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B110" ref-type="bibr">110</xref>). Recently, a group of researchers found that CXCR4 can provide lineage-instructive signals to control progenitor cell differentiation (<xref rid="B111" ref-type="bibr">111</xref>). They showed that signals from CXCR4-CXCL12 interactions regulate multipotent progenitor (MPP) differentiation into CLP subsets in the BM and further affect lymphoid lineage production. Moreover, a deficiency of CXCR4 signaling resulted in a profound reduction in the number of T, B, and NK cells which suggests that the addition of CXCL12 may be helpful to promote <italic>in vitro</italic> NK cell differentiation from HSCs.</p><p>Interleukin-7 is another important cytokine for the differentiation of lymphoid lineages, mainly for the differentiation of T and B cells (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B64" ref-type="bibr">64</xref>). It induces the differentiation of HSCs into lymphoid progenitor cells and facilitates their expansion and survival. The IL-7 receptor is a heterodimeric complex composed of IL-7R&#945; (CD127) and the common &#947; chain subunit (CD132) (<xref rid="B112" ref-type="bibr">112</xref>). The IL-7-IL-7R interaction primarily activates JAK1/3-STAT5 and PI3K-AKT pathways to induce prosurvival, cell cycle, and metabolism regulation signals (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B113" ref-type="bibr">113</xref>). Previous reports have shown that knockouts of IL-7 and IL-7R&#945; do not induce significant defects in mouse NK cells from the PB or spleen (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). Thus, IL-7 may contribute in a redundant way and may not be essential for circulatory NK cell development. However, NK cells in the thymus, characterized by IL-7R&#945;<sup>+</sup>, require IL-7 for their homeostasis (<xref rid="B26" ref-type="bibr">26</xref>). Whether other NK cell subsets in different tissues require IL-7 for their effector functions or homeostasis is unknown.</p></sec><sec id="S2-2"><title>IL-15 Directs CLPs toward Mature NK Cells</title><p>Important cytokines for the development and function of immune cells are highlighted in X-SCID, characterized by mutations of <italic>IL-2RG</italic>, which encodes the common &#947; chain (&#947;c), a common receptor for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). X-SCID is characterized by extreme vulnerability to viruses and pathogens due to the developmental and functional deficiency of T, B, and NK cells, which indicates that &#947;c family cytokines play vital roles in normal immune responses.</p><p>IL-15<sup>&#8722;/&#8722;</sup> and IL-15R<sup>&#8722;/&#8722;</sup> mice have dramatically reduced populations of NK cells (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>); however, IL-2<sup>&#8722;/&#8722;</sup>Rag1<sup>&#8722;/&#8722;</sup>, IL-7<sup>&#8722;/&#8722;</sup>, and IL-21R<sup>&#8722;/&#8722;</sup> mice have normal NK cell numbers (<xref rid="B45" ref-type="bibr">45</xref>&#8211;<xref rid="B48" ref-type="bibr">48</xref>), suggesting that IL-15 is essential for NK cell commitment and maturation. Furthermore, mature NK cells fail to be maintained when transferred to IL-15<sup>&#8722;/&#8722;</sup> mice (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>). The prosurvival ability of IL-15 is potentially mediated by upregulated expression of antiapoptotic B cell lymphoma 2 (BCL-2) family members and downregulated expression of proapoptotic proteins (<xref rid="B116" ref-type="bibr">116</xref>). IL-15 has extensive roles in immune cells. For example, it can regulate NKT cell development and maintain normal memory phenotypes of CD8<sup>+</sup> cells (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B117" ref-type="bibr">117</xref>&#8211;<xref rid="B120" ref-type="bibr">120</xref>).</p><p>Interleukin-15 can be produced by hematopoietic and non-hematopoietic cells, such as activated DCs, macrophages, monocytes, and stromal cells (<xref rid="B121" ref-type="bibr">121</xref>). IL-15R is a heterotrimeric receptor including a unique IL-15R&#945; (CD215) subunit, a shared &#946; chain with IL-2 (CD122), and CD132 (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>). The expression of CD122 is a major phenotypic marker of NKPs, which allows the cells to respond to IL-15 (<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>). IL-15 has a special manner of transducing its signals through trans-presentation, whereby the IL-15-producing cells support IL-15 by binding IL-15R&#945;, and then present it to activate neighboring cells expressing CD122/CD132 (<xref rid="B126" ref-type="bibr">126</xref>&#8211;<xref rid="B130" ref-type="bibr">130</xref>). Enlightened by these findings, researchers have designed NK cells expressing membrane-bound IL-15 that have autonomous growth and increased cytotoxicity toward tumor cells, which can help to enhance the antitumor effects of NK cells and avoid the side effects of cytokine administration (<xref rid="B131" ref-type="bibr">131</xref>). The activation of IL-15R induces the autophosphorylation and activation of JAK1/3 and downstream cascades, including the JAK-STAT, the mitogen-activated protein kinase (MAPK), and PI3K/AKT-mTOR signaling pathways, in order to fulfill its different functions (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B132" ref-type="bibr">132</xref>). The IL-15-STAT5 signaling pathway is indispensable for NK cell development and homeostasis, as mice that are deficient in this pathway have dramatically reduced mature NK cell numbers. In addition, both <italic>Stat5</italic>-deficient and NK cell-specific <italic>Stat5</italic>-deficient mice have an absence of NK cells in peripheral blood and tissues (<xref rid="B133" ref-type="bibr">133</xref>&#8211;<xref rid="B135" ref-type="bibr">135</xref>). A patient with a <italic>STAT5b</italic> mutation also showed a severe reduction in NK cell numbers (<xref rid="B136" ref-type="bibr">136</xref>). The PI3K/AKT-mTOR pathway also plays a role in NK cell development. A recently published paper has shown that PDK1, a kinase upstream of mTOR, is a critical component that connects IL-15 signaling to E4BP4, an indispensable TF for NK cell development (<xref rid="B137" ref-type="bibr">137</xref>). The early depletion of PDK1 induces a severe loss of NK cells with much weaker mTOR activation, E4BP4 induction after IL-15 stimulation and the reduced expression of CD122 (<xref rid="B137" ref-type="bibr">137</xref>). These findings underscore the importance of the IL-15-PI3K-PDK1-mTOR-E4BP4-CD122 positive feedback loop in the development of NK cells. Other factors can also affect NK cell development by influencing their responsiveness to IL-15. The TF ID2 can affect NK cell development by antagonizing E-protein function and altering lineage fate (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>). Recently, researchers have found that ID2 can suppress E-protein target gene SOCS3 expression to maintain IL-15 receptor signaling for normal NK cells development, and strong IL-15 receptor stimulation can overcome this requirement for ID2 (<xref rid="B140" ref-type="bibr">140</xref>). The abovementioned findings strengthen the roles of IL-15 in NK cell development and explain how IL-15 induces its effects.</p></sec></sec><sec id="S3"><title>Polarization of NK Cell Function by Cytokines</title><p>Natural killer cells have diverse functions in different tissues, which can be divided into three subsets: cytotoxic, regulatory, and tolerant NK cells (<xref rid="B141" ref-type="bibr">141</xref>). Different NK cell subsets are primarily affected by signals from diverse cellular microenvironments and signals from cytokines are important in shaping their unique functions. In an inflammatory or virus-infected situation, activated T cells and dendritic cells (DCs) secrete abundant IL-2, IL-12, IL-18, and IL-21, which drive NK cell activation with enhanced secretion of cytotoxic cytokines and the ability to directly kill transformed targets (<xref rid="B142" ref-type="bibr">142</xref>&#8211;<xref rid="B144" ref-type="bibr">144</xref>). As mentioned above, NK cells in their physical environment play leading roles in maintaining normal pregnancy in the uterus and tolerating a significant amount of food-derived or gut-derived antigens in the liver, which are mainly determined by the regulation of different cytokine cocktails.</p><sec id="S3-1"><title>IL-2 and IL-15 Induce NK Cell &#8220;Priming&#8221;</title><p>Natural killer cells serve as the first line of defense during viral infection or the elimination of transformed cells, which is characterized by the production of cytokines, such as IFN-&#947; and TNF-&#945;, and granzyme-mediated cytotoxicity (<xref rid="B3" ref-type="bibr">3</xref>). Comprehensive activation is necessary for NK cells to fulfill their roles as sentinels (<xref rid="B145" ref-type="bibr">145</xref>). Previous reports have demonstrated that IL-2, IL-15, IL-12, IL-18, and IL-21 all play roles in activating NK cells. Therefore, we discuss how these cytokines function and how to achieve better efficacy in adoptive NK cell therapy.</p><p>Interleukin-2 is an immune-stimulatory cytokine that was first identified as a &#8220;T cell growth factor&#8221; (<xref rid="B67" ref-type="bibr">67</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B146" ref-type="bibr">146</xref>). Subsequently, it has been shown that activated T cell-derived IL-2 can enhance NK cell responses toward infection <italic>in vivo</italic> and can activate NK cells <italic>in vitro</italic> (<xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B147" ref-type="bibr">147</xref>). Furthermore, researchers found that NK cell responses are impaired in IL-2&#946;<sup>&#8722;/&#8722;</sup> mice suggesting that IL-2 may have an important role in maintaining NK cell activity (<xref rid="B148" ref-type="bibr">148</xref>). However, IL-2-deficient mice have normal NK cell development and numbers, which implies that it is needed for NK cell effector functions but is not indispensable for their development (<xref rid="B45" ref-type="bibr">45</xref>). IL-2 achieves its functions predominantly through the JAK1/3-STAT5 signaling pathway by binding with the heterotrimeric receptor, which is composed of IL-2R&#945; (CD25), CD122, and CD132 (<xref rid="B70" ref-type="bibr">70</xref>). Interestingly, IL-2 has different affinities for the different receptors. IL-2 binding to a single CD25 (Kd&#8201;=&#8201;10<sup>&#8722;8</sup>&#8201;M) or CD122 (Kd&#8201;=&#8201;10<sup>&#8722;6</sup>&#8201;M) has a low affinity. There is an intermediate binding affinity with the CD25/CD122 heterodimer (Kd&#8201;=&#8201;10<sup>&#8722;9</sup>&#8201;M), and the greatest binding affinity is seen with the IL-2R&#945;&#946;&#947; trimeric complex (Kd&#8201;=&#8201;10<sup>&#8722;11</sup>&#8201;M) (<xref rid="B149" ref-type="bibr">149</xref>&#8211;<xref rid="B151" ref-type="bibr">151</xref>). NK cells primarily express CD122 and CD132 receptor components that can respond to high concentrations of IL-2. To achieve better IL-2 application efficacy, one group of researchers developed an IL-2 &#8220;superkine,&#8221; also called super-2, with increased affinity for CD122 (<xref rid="B152" ref-type="bibr">152</xref>). Super-2 has a vigorous role in promoting activation and proliferation irrespective of CD25 expression. In addition, previous reports have shown that preactivation with IL-12, IL-15, and IL-18 induces CD25 expression on NK cells, which suggests that pretreatment of NK cells with the above cytokines can enhance NK cell responsiveness to IL-2 and may lead to better IL-2 treatment efficacy (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>). However, high-dose IL-2 induces a selective expansion of regulatory T (Treg) cells, which limits the activity of NK cells, resulting in poor clinical responses to IL-2 therapy (<xref rid="B155" ref-type="bibr">155</xref>). The depletion of Treg cells leads to increased IL-2 availability for NK cells to increase IFN-&#947; production and cytotoxicity (<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>). To overcome Treg cell inhibition, researchers have produced a mutant form of IL-2 that preferentially binds to CD122/CD132 and that has reduced binding to CD25 (<xref rid="B157" ref-type="bibr">157</xref>). In contrast to wild-type IL-2, the mutant form efficiently induces NK cell proliferation and activation with a dramatic reduction in Treg cells, and achieves better responses to tumors.</p><p>Interleukin-15 is discovered by its &#8220;IL-2-like&#8221; stimulatory role and is important for NK cell development and function (<xref rid="B158" ref-type="bibr">158</xref>&#8211;<xref rid="B160" ref-type="bibr">160</xref>). IL-15 and IL-2 share the common &#946; and &#947; chain receptor subunits and only differ due to an &#945; chain, as IL-2R&#945; (CD25) binds to IL-2 and IL-15R&#945; binds to IL-15 (<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B161" ref-type="bibr">161</xref>, <xref rid="B162" ref-type="bibr">162</xref>). However, IL-15R&#945; alone binds to IL-15 with a high affinity (Kd&#8201;=&#8201;10<sup>&#8722;11</sup>&#8201;M), which is comparable to that of the binding of IL-2R&#945;&#946;&#947; to IL-2 (<xref rid="B162" ref-type="bibr">162</xref>). The high affinity between IL-15 and IL-15R&#945; makes it possible, when compared with IL-2, to activate NK cells with relatively lower concentrations.</p><p>Prior exposure to IL-15 sensitizes NK cells to secondary stimuli, referred to as &#8220;priming,&#8221; thereby resulting in exaggerated responses (<xref rid="B163" ref-type="bibr">163</xref>, <xref rid="B164" ref-type="bibr">164</xref>). Previous studies have shown that IL-12 can induce elevated IFN-&#947; production in IL-15-primed NK cells. Other cytokines, such as IL-2, IL-4, IL-21, and type I IFN, can also induce heightened functions (<xref rid="B165" ref-type="bibr">165</xref>). As mentioned above, the JAK-STAT5 signaling pathway is important for IL-15-mediated NK cell development and viability (<xref rid="B133" ref-type="bibr">133</xref>&#8211;<xref rid="B136" ref-type="bibr">136</xref>). However, the PI3K-AKT-mTOR signaling pathway is critical for the IL-15-induced priming effect (<xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B165" ref-type="bibr">165</xref>). Inhibition of the PI3K-mTOR signal would abrogate enhanced IL-12- and IL-21-induced phosphorylation of STATs and stronger responses in IL-15-primed NK cells (<xref rid="B165" ref-type="bibr">165</xref>). Nevertheless, the inhibited mTOR pathway does not affect the phosphorylation of STATs in na&#239;ve NK cells, suggesting that this pathway specifically functions in IL-15-primed NK cells (<xref rid="B165" ref-type="bibr">165</xref>). The crosstalk between the PI3K-mTOR signaling pathway and the STAT pathway is critical for efficient NK cell priming; however, the mechanism by which this occurs remains unclear.</p><p>A previous report has shown that IL-15 promotes NK cells to be fully equipped to respond to infections through the rapid induction of granzymes and perforin (<xref rid="B166" ref-type="bibr">166</xref>). However, the induced production of granzymes/perforin is reduced in NK-mTOR<sup>&#8722;/&#8722;</sup> cells, suggesting that mTOR is significant for mediating NK cell cytotoxicity (<xref rid="B167" ref-type="bibr">167</xref>). Researchers have also shown that IL-15, but not IL-2, can maintain NK cell cytolytic functions after cytokine withdrawal to simulate postinfusion performance (<xref rid="B168" ref-type="bibr">168</xref>). The IL-15-induced functional advantages are dependent on activated mTOR-regulated signaling (<xref rid="B168" ref-type="bibr">168</xref>). The mTOR-regulated IL-15-induced maintenance of NK cell functions suggests a beneficial implementation of IL-15 in adoptive NK-cell clinical therapy.</p></sec><sec id="S3-2"><title>IL-12, IL-18, and IL-21 Strengthen NK Cell Cytotoxicity</title><p>Interleukin-12 was first named NK cell stimulating factor based on its ability to induce NK cells to secrete high levels of IFN-&#947; (<xref rid="B169" ref-type="bibr">169</xref>). It is composed of two subunits, IL-12p35 and IL-12p40, and these two subunits must be coexpressed in the same cell to form the disulfide-linked bioactive IL-12p70 (<xref rid="B170" ref-type="bibr">170</xref>). The cytokine is mainly produced by antigen-presenting cells, such as DCs, monocytes and macrophages (<xref rid="B171" ref-type="bibr">171</xref>&#8211;<xref rid="B173" ref-type="bibr">173</xref>). NK cells and activated T cells express the high-affinity heterodimeric receptor (IL-12R&#946;1/&#946;2) for interaction with IL-12, which can activate tyrosine kinase 2 (TYK2) and JAK2, leading to phosphorylation of STATs (mainly STAT4) and the eventual promotion of IFN-&#947; production and other biological reactions (<xref rid="B71" ref-type="bibr">71</xref>&#8211;<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B174" ref-type="bibr">174</xref>).</p><p>One previous report suggested that NK cells can mediate a long-lived contact hypersensitivity response to haptens in mice devoid of T and B cells; thus, the concept of &#8220;memory NK cells&#8221; was established (<xref rid="B175" ref-type="bibr">175</xref>). However, the mechanism by which memory NK cells develop is unknown. The group of Lewis L. Lanier observed that IL-12-STAT4-dependent-IFN-&#947;-independent signaling is indispensable for the generation of mouse cytomegalovirus-specific memory NK cells (<xref rid="B176" ref-type="bibr">176</xref>). As memory NK cells are long-lived and have relatively higher responses compared with na&#239;ve NK cells (<xref rid="B175" ref-type="bibr">175</xref>, <xref rid="B177" ref-type="bibr">177</xref>&#8211;<xref rid="B179" ref-type="bibr">179</xref>), developing memory NK cells for clinical therapy is an attractive approach. Wayne M. Yokoyama&#8217;s group first showed that preactivation of mice NK cells with IL-12 and IL-18, along with low-dose IL-15 to maintain survival, could produce cytokine-induced memory-like NK cells (<xref rid="B180" ref-type="bibr">180</xref>). The memory-like cells could respond more robustly to reactivation without inducing enhanced cytotoxicity toward tumor cells (<xref rid="B180" ref-type="bibr">180</xref>). However, Adelheid Cerwenka laboratory observed that IL-12/15/18 preactivated NK cells, when combined with irradiation, could achieve greater efficacy, as determined by reduced growth of established mouse tumors (<xref rid="B153" ref-type="bibr">153</xref>). They also showed that the antitumor effect is mediated by IL-2 produced by CD4<sup>+</sup> T cells. As the abovementioned memory-like NK cells were all established in mice, Romee et al. showed that human NK cells can also display memory characteristics after short-term preactivation with IL-12/15/18 (<xref rid="B181" ref-type="bibr">181</xref>). Subsequently, they also found that the memory-like NK cells induce prolonged expression of CD25, forming a high affinity IL-2R complex to respond to IL-2 at picomolar concentrations (<xref rid="B154" ref-type="bibr">154</xref>). However, single cytokine, like IL-12, IL-15, or IL-18 preactivation cannot induce a higher expression of CD25. Moreover, prior treatment with low-dose IL-2 before adoptive transfer can enhance proliferation and effector function of memory-like NK cells, which supports an additional immunotherapy strategy. Recently, this group performed a phase 1 study to treat active rel/ref AML patients with memory-like NK cells (<xref rid="B182" ref-type="bibr">182</xref>). They found that donor memory-like NK cells exhibited enhanced IFN-&#947; production and yielded an overall response rate of 55%. This result reminds us that preactivation with cytokines can indeed strengthen NK cell antitumor functionality and can be used as a therapeutic method to treat tumors. Nevertheless, understanding the appropriate cell doses still requires further study.</p><p>The NK cells without expressing any inhibitory MHC-I-specific receptors, such as killer cell immunoglobulin-like receptors (KIRs) in humans and Ly49 receptors in mice, are hyporesponsive. The signals from KIRs and Ly49 receptors are critical for NK cells to be functionally competent (<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>). This process is also termed &#8220;NK cell licensing.&#8221; A recent report has shown that the unlicensed NK cells display enhanced functionality after preactivation with IL-12, IL-15, and IL-18 (<xref rid="B185" ref-type="bibr">185</xref>). It has also been reported that human CD56<sup>bright</sup>KIR<sup>&#8722;</sup> and CD56<sup>dim</sup>KIR<sup>&#8722;</sup> NK cells can acquire KIR expression upon stimulation with IL-15 in the presence of stromal cells (<xref rid="B186" ref-type="bibr">186</xref>). Furthermore, the developed KIR<sup>+</sup> NK cells display enhanced cytotoxicity and cytokine-producing potential compared to the KIR<sup>&#8722;</sup> NK cells. Later, another group has identified that activation with cytokines such as IL-2, IL-15, or IL-12 can induce the <italic>de novo</italic> expression of KIR and/or NKG2A on KIR<sup>&#8722;</sup>NKG2A<sup>&#8722;</sup> NK cells without feeder cells (<xref rid="B187" ref-type="bibr">187</xref>, <xref rid="B188" ref-type="bibr">188</xref>). Similar to human NK cells, the responsive capacity of unlicensed murine NK cells can be restored as licensed cells when stimulated <italic>in vitro</italic> with high doses of IL-12 and IL-18 or IL-2 (<xref rid="B183" ref-type="bibr">183</xref>). These findings suggest that cytokine stimulation can induce the hypo-responsive unlicensed NK cells to be re-educated and acquire stronger responses toward target cells.</p><p>Interleukin-12 has also been shown to promote further maturation of <italic>in vitro-</italic>differentiated NK cells with enhanced cytotoxicity. One group has shown that low-dose IL-12 can decrease the fluorescence intensity of CD56 and can induce the expansion of more mature CD56<sup>dim</sup>CD16<sup>+</sup> and CD56<sup>dim</sup>KIR<sup>+</sup> NK cells (<xref rid="B189" ref-type="bibr">189</xref>). Subsequently, another group identified that <italic>in vitro</italic>-derived NK cells display enhanced cytotoxicity toward primary AML cells and have improved antileukemic responses in MHC class I-positive AML mice after IL-12 culturing (<xref rid="B190" ref-type="bibr">190</xref>). These findings suggest that IL-12 can not only regulate the functions of mature NK cells but also promote the differentiation level and function of developing NK cells.</p><p>Interleukin-18 is a proinflammatory cytokine belonging to the IL-1 cytokine family and was originally defined as an IFN-&#947;-inducing-factor (<xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B192" ref-type="bibr">192</xref>). It is constitutively produced by hematopoietic cells, such as DCs, macrophages and neutrophils (<xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B193" ref-type="bibr">193</xref>&#8211;<xref rid="B195" ref-type="bibr">195</xref>), and non-hematopoietic cells, such as microglial cells and epithelial cells (<xref rid="B196" ref-type="bibr">196</xref>). IL-18 is initially produced as an inactive precursor, pro-IL-18, which requires cleavage by caspase-1 of the N-terminal fragment to become the mature, biologically active form (<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B198" ref-type="bibr">198</xref>). Mature IL-18 binds to its receptor, composed of IL-18R1 and IL-18R accessory protein in a heterodimeric receptor complex, to initiate signal transduction by myeloid differentiation primary response protein 88 (MyD88). Then, IL-1R-associated kinase 4 (IRAK4) and TNFR-associated factor 6 (TRAF6) are recruited, leading to the activation of the nuclear factor (NF) kappa-light-chain-enhancer of activated B cells (&#954;B) and MAPK pathways to promote IFN-&#947; transcription and stabilization of <italic>IFNG</italic> mRNA (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B199" ref-type="bibr">199</xref>).</p><p>Interleukin-18 is important for promoting the production of IFN-&#947; by NK cells against viral, fungal, bacterial, and parasitic infections (<xref rid="B200" ref-type="bibr">200</xref>&#8211;<xref rid="B203" ref-type="bibr">203</xref>). NK cells display reduced secretion of IFN-&#947; and compromised cytotoxicity in IL-18-deficient, IL-18R1-deficient, or IRAK4-deficient mice (<xref rid="B75" ref-type="bibr">75</xref>&#8211;<xref rid="B77" ref-type="bibr">77</xref>). Furthermore, IL-18 is essential for upregulating CD25 expression in NK cells, and the increased production of IFN-&#947; is enhanced by IL-2 during <italic>Plasmodium yoelii</italic> infection in mice (<xref rid="B204" ref-type="bibr">204</xref>). Similarly, low-dose IL-18, through synergistic interactions with IL-2, IL-12, IL-15, or IL-21, can induce potent CD25 and IFN-&#947; upregulation to strengthen human NK cell effector function (<xref rid="B205" ref-type="bibr">205</xref>). A previous report has shown that T and B cells can upregulate IL-18R expression upon IL-12 treatment, and the combination of IL-18 and IL-12 synergistically induces their IFN-&#947; production (<xref rid="B206" ref-type="bibr">206</xref>). Recently, researchers also found that the combination of these two cytokines can reverse NK cell anergy and increase the survival rate of mice bearing MHC-deficient tumors (<xref rid="B207" ref-type="bibr">207</xref>). These findings imply that IL-18 can play stronger roles when combined with other stimulatory cytokines; therefore, combining cytokines together is better for achieving enhanced efficacy.</p><p>Interleukin-21 is a pleiotropic cytokine mainly produced by T follicular helper cells, Th17&#8201;cells, and NKT cells (<xref rid="B208" ref-type="bibr">208</xref>). It acts through a receptor complex, including IL-21R and &#947;c (<xref rid="B209" ref-type="bibr">209</xref>, <xref rid="B210" ref-type="bibr">210</xref>), to activate JAK1 and JAK3, which leads to recruitment and phosphorylation of STAT (predominantly STAT3 but also STAT1 and STAT5) to promote the expression of IFN-&#947; and other factors (<xref rid="B81" ref-type="bibr">81</xref>). The IL-21 signal can also be transduced by the MAPK and PI3K/AKT pathways (<xref rid="B81" ref-type="bibr">81</xref>).</p><p>Interleukin-21 has diverse effects in immune cells, which can affect the differentiation of inflammatory T cells, immunoglobulin production of B cells, and development and functions of NK cells (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B211" ref-type="bibr">211</xref>). IL-21, combined with FL and IL-15, can specifically promote the differentiation and expansion of CD16<sup>+</sup>CD56<sup>+</sup> cytotoxic NK cells from BM progenitors <italic>in vitro</italic> (<xref rid="B210" ref-type="bibr">210</xref>). It also promotes rapid differentiation and acquisition of killer Ig-like receptors of NK cells from cord blood CD34-positive cells (<xref rid="B212" ref-type="bibr">212</xref>). Additionally, it induces mature mouse NK cells to develop a large granular lymphocyte phenotype with increased production of cytokines, such as IFN-&#947;, and perforin through coactivation with IL-2 or IL-15, resulting in enhanced cytotoxicity (<xref rid="B213" ref-type="bibr">213</xref>). Similarly, human NK cells cocultured with IL-21 and therapeutic antibody-coated breast cancer cells secrete higher levels of IFN-&#947;, TNF-&#945;, IL-8, CCL3, and CCL5, and the supernatants are able to drive the migration of na&#239;ve and activated T cells <italic>in vitro</italic> (<xref rid="B214" ref-type="bibr">214</xref>). The administration of IL-21 and antibody-coated tumor cells leads to synergistic cytotoxic effects of NK cells toward tumor cells, which suggests that IL-21 may be an effective adjuvant for antibody treatment (<xref rid="B214" ref-type="bibr">214</xref>). Interestingly, IL-21 limits IL-15-mediated NK cell expansion and viability; nevertheless, it can stimulate IFN-&#947; production and cytotoxicity in NK cells previously activated with poly I:C or IL-15 (<xref rid="B48" ref-type="bibr">48</xref>). This finding reminds us that it may be important to apply cytokine cocktails sequentially.</p><p>Insulin-like growth factor 1 (IGF-1) is an important growth factor to regulate longevity and immunity (<xref rid="B215" ref-type="bibr">215</xref>). And it was also shown to promote NK cell development from CD34<sup>+</sup> cells and increase NK cell cytotoxicity by promoting the production of perforin by STAT3 activation (<xref rid="B216" ref-type="bibr">216</xref>). Furthermore, foxO1, which negatively regulates NK cell maturation and function, is a key molecule of IGF-1 signaling pathway (<xref rid="B217" ref-type="bibr">217</xref>, <xref rid="B218" ref-type="bibr">218</xref>). Therefore, IGF-1 may also strengthen NK cell function through IGF-1-induced foxO1 inactivation, which is mediated by increased phosphorylation of foxO1 at Ser256 and Thr24 (<xref rid="B219" ref-type="bibr">219</xref>). Such information about IGF-1 may present new opportunities to boost NK cell cytotoxicity therapeutically.</p></sec><sec id="S3-3"><title>TGF-&#946; and IL-10 Shape Tolerant NK Cells</title><p>Natural killer cells are not homogenous, and cells with low cytotoxicity, residing in the liver or a chronic pathogenic microenvironment, are termed tolerant NK cells (<xref rid="B141" ref-type="bibr">141</xref>). The liver is an important immune-tolerant organ, as no severe inflammation occurs despite constant stimulation by bacterial products and antigens from the gut (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B220" ref-type="bibr">220</xref>, <xref rid="B221" ref-type="bibr">221</xref>). NK cells, composed of CD56<sup>dim</sup> and CD56<sup>bright</sup> subtypes, occupy up to 30&#8211;40% of all hepatic lymphocytes located in human liver sinusoids (<xref rid="B222" ref-type="bibr">222</xref>, <xref rid="B223" ref-type="bibr">223</xref>). CD56<sup>dim</sup> hepatic NK cells share many similarities with PB CD56<sup>dim</sup> NK cells that may frequently circulate throughout the body. By contrast, CD56<sup>bright</sup> cells with CD69 and CD49a expression are more specifically retained in the liver (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B224" ref-type="bibr">224</xref>). Similarly, one subset of DX5<sup>&#8722;</sup>CD49a<sup>+</sup> mouse NK cells specifically resides in the liver with adaptive-like properties (<xref rid="B10" ref-type="bibr">10</xref>). However, the specific roles of CD56<sup>bright</sup> and CD56<sup>dim</sup> human intrahepatic NK cells still require further study. One important function of intrahepatic NK cells is to tolerate harmless antigens that can help maintain liver homeostasis (<xref rid="B225" ref-type="bibr">225</xref>). IL-10 and TGF-&#946;, which are produced by DCs, Kupffer cells, hepatic sinusoidal endothelial cells, and stellate cells, are important for shaping tolerant NK cells.</p><p>Interleukin-10, first recognized for its ability to inhibit the activation and cytokine secretion of Th1&#8201;cells, is described as a cytokine synthesis inhibitory factor (<xref rid="B83" ref-type="bibr">83</xref>&#8211;<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B226" ref-type="bibr">226</xref>). It is an important immune-regulatory cytokine that is produced by T cells, B cells, NK cells, DCs and macrophages (<xref rid="B227" ref-type="bibr">227</xref>, <xref rid="B228" ref-type="bibr">228</xref>). The receptors for IL-10 mainly contain two subunits, IL-10R1 and IL-10R2, and are expressed on many hematopoietic and non-hematopoietic cells (<xref rid="B229" ref-type="bibr">229</xref>). Once IL-10 and IL-10R bind together, JAK1 and TYK2 are activated, which leads to the phosphorylation and activation of STAT3, STAT1, and STAT5 (<xref rid="B86" ref-type="bibr">86</xref>). As mentioned above, IL-10 is important for allowing liver NK cells to maintain immune-tolerant states. Indeed, one study demonstrated that intrahepatic IL-10 can maintain NK cells in a functionally hypo-responsive state with a phenotype of NKG2A<sup>+</sup>Ly49<sup>&#8722;</sup> cells (<xref rid="B22" ref-type="bibr">22</xref>). NKG2A is critical for NK cells, when cocultured with non-transformed hepatocytes, to prime DC cells. Furthermore, the primed-DCs can result in the induction of regulatory CD4<sup>+</sup>CD25<sup>+</sup> T cells, a subset responsible for inhibiting excessive immune activation (<xref rid="B230" ref-type="bibr">230</xref>, <xref rid="B231" ref-type="bibr">231</xref>). Even transferred splenic NK cells migrating into the liver show changes in phenotype and function, suggesting that the liver environment reshapes NK cells to maintain a steady state (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>Transforming growth factor-&#946; includes three isoforms, TGF-&#946;1, 2, and 3, which are highly homologous (<xref rid="B232" ref-type="bibr">232</xref>). TGF-&#946;1 is the primary isoform expressed in the immune system (<xref rid="B233" ref-type="bibr">233</xref>). If deficient, mice die of systemic inflammation by 3&#8211;4&#8201;weeks of age, suggesting that TGF-&#946; plays important roles in maintaining normal immune responses (<xref rid="B87" ref-type="bibr">87</xref>&#8211;<xref rid="B89" ref-type="bibr">89</xref>). TGF-&#946; binds to its receptors, primarily TGF-&#946;RI and TGF-&#946;RII, to activate a downstream cascade (<xref rid="B234" ref-type="bibr">234</xref>). First, the intracellular receptor Smad (R-Smad) proteins Smad2/3 are recruited and phosphorylated, and the phosphorylated Smad2/3 then combine with Smad4 or TIF1&#947; to form a trimeric complex. The trimeric complex translocates to the nucleus to regulate relative gene expression by binding to the responsive regulatory regions (<xref rid="B90" ref-type="bibr">90</xref>). TGF-&#946; can also activate Smad-independent pathways, such as small GTPases, MAPK, and PI3K pathways (<xref rid="B235" ref-type="bibr">235</xref>).</p><p>Tolerant NK cells can mediate benign effects to maintain physiological homeostasis. However, cells induced in the context of chronic infection or the cancer microenvironment are harmful for the treatment of related diseases (<xref rid="B236" ref-type="bibr">236</xref>, <xref rid="B237" ref-type="bibr">237</xref>). For example, TGF-&#946; upregulation induces reduced secretion of IFN-&#947; by repressing the normal expression of T-bet in the pathologic niche (<xref rid="B238" ref-type="bibr">238</xref>). High levels of TGF-&#946; induce a weak NKG2D/DAP10 and CD244/SAP signal, leading to NK cells that are unable to eliminate hepatitis B virus (HBV) infection in chronic hepatitis B (CHB) (<xref rid="B239" ref-type="bibr">239</xref>, <xref rid="B240" ref-type="bibr">240</xref>). Later, another report showed that TGF-&#946; and IL-10 in CHB-infected and hepatic carcinoma patients induce the expression of microRNA (miR)-146a, which causes reduced IFN-&#947; production and cytotoxicity, resulting in a poorer prognosis (<xref rid="B241" ref-type="bibr">241</xref>). Furthermore, TGF-&#946;-induced miR-183 represses DAP12 transcription and translation (<xref rid="B242" ref-type="bibr">242</xref>), or reduces the expression of NKp30 and NKG2D (<xref rid="B243" ref-type="bibr">243</xref>), to further weaken NK cell cytotoxic functions in the tumor microenvironment. The abnormal tolerant NK cells cannot eliminate infected or transformed cells, which leads to immune evasion by these cells.</p></sec><sec id="S3-4"><title>TGF-&#946; and IL-15 Develop Regulatory NK Cells</title><p>Decidual NK cells (dNK) are distinguishable from PB NK cells because more than 90% of these cells are characterized by a CD56<sup>bright</sup>CD16<sup>&#8722;</sup>CD49a<sup>+</sup>CD9<sup>+</sup> phenotype with a low cytotoxic effect and high cytokine secretion ability (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B244" ref-type="bibr">244</xref>, <xref rid="B245" ref-type="bibr">245</xref>). Previous reports have shown that they constitute 50&#8211;90% of decidual lymphocytes during the first trimester of pregnancy (<xref rid="B244" ref-type="bibr">244</xref>, <xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B247" ref-type="bibr">247</xref>). The accumulated NK cells can control extravillous trophoblast invasion and vascular remodeling by secreting different amounts of molecules, such as GM-CSF, colony-stimulating factor 1, angiopoietin-2, vascular endothelial cell growth factor, and placental growth factor (<xref rid="B248" ref-type="bibr">248</xref>, <xref rid="B249" ref-type="bibr">249</xref>). Furthermore, dNK cell-derived IFN-&#947; has been shown to be critical for vessel modification and decidual cellularity in mice (<xref rid="B250" ref-type="bibr">250</xref>). Inflammatory responses in decidual, caused by allogenic fetal cell invasion and other factors, can result in abortion (<xref rid="B246" ref-type="bibr">246</xref>, <xref rid="B251" ref-type="bibr">251</xref>). To ensure a normal pregnancy, researchers have determined that regulatory T cells can mediate an inhibitory response to the aggressive alloantigen (<xref rid="B252" ref-type="bibr">252</xref>), and CD86 blockage (<xref rid="B253" ref-type="bibr">253</xref>) and PD-1 (<xref rid="B254" ref-type="bibr">254</xref>) involvement can both play protective roles in pregnancy outcomes. As the dominant member of decidual lymphocytes, dNK cells can provide immune-regulatory mechanisms to maintain a regular uterine environment. Indeed, IFN-&#947; derived from CD27<sup>+</sup>CD56<sup>bright</sup> dNK cells dampens Th17-induced inflammation to maintain a normal pregnancy (<xref rid="B255" ref-type="bibr">255</xref>). The abnormalities in the proportion and IFN-&#947; secretion of dNK cells in patients with recurrent spontaneous abortions result in long-term Th17-induced inflammation and eventual pregnancy failure (<xref rid="B255" ref-type="bibr">255</xref>). Another study subsequently showed that the crosstalk between dNK cells and CD14<sup>+</sup> myelomonocytic cells results in the generation of regulatory T cells for the inhibition of abnormal inflammation in the uterus (<xref rid="B256" ref-type="bibr">256</xref>).</p><p>The above findings demonstrate the important regulatory roles of dNK cells; however, whether dNK cells are derived from the differentiation of local NKPs or the migration of PB NK cells or both still needs to be studied. Nevertheless, under hypoxic conditions, endometrium-derived TGF-&#946; and stromal cell-derived IL-15 may function to shape unique dNK cells (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B257" ref-type="bibr">257</xref>). Indeed, TGF-&#946; promotes the conversion of CD16<sup>+</sup> PB NK cells to CD16<sup>&#8722;</sup> cells and inhibits the expression of NKp30 to further inhibit cytotoxic functions, both of which lead to cells with similarities to dNK cells (<xref rid="B17" ref-type="bibr">17</xref>). Furthermore, TGF-&#946; can induce the expression of CD103 and CD49a to increase the likelihood of the cells residing in the uterus (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B258" ref-type="bibr">258</xref>). Moreover, one study applied TGF-&#946;1, IL-15 and a demethylating agent under hypoxic conditions to successfully transform PB NK cells into dNK-like cells (<xref rid="B18" ref-type="bibr">18</xref>). These findings imply that the specific hypoxic state of the uterus, combined with the help of TGF-&#946; and IL-15, shapes particular regulatory NK cells.</p></sec></sec><sec id="S4"><title>Cytokine Cocktails Promote <italic>In Vitro</italic> Expansion of NK Cells</title><p>As mentioned above, multiple cytokines can regulate NK cell development, proliferation and activation. Previous studies have observed that NK cells can exert graft-versus-leukemia reactions without causing graft-versus-host disease (GVHD) in allogeneic hematopoietic transplantation (<xref rid="B259" ref-type="bibr">259</xref>). Furthermore, pioneering work by the Miller group showed that infusion of haplo-identical NK cell infusions activated by IL-2 can induce remission in AML patients (<xref rid="B260" ref-type="bibr">260</xref>). NK cells, therefore, are promising candidates for the treatment of hematological malignancies. However, the generation of sufficient NK cell quantities with robust effectiveness remains challenging. Therefore, strategies to expand or induce NK cells from primary NK cells or CD34<sup>+</sup> cells with high cytotoxicity using different combinations of cytokines are actively being developed (<xref rid="B261" ref-type="bibr">261</xref>, <xref rid="B262" ref-type="bibr">262</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Cytokine regulation of natural killer (NK) cell expansion and cytotoxicity. Genetically modified K562 cells and IL-2 or IL-2 and OKT-3 without feeder cells, applied for the expansion of primary NK cells, can generate significant amounts of functional NK cells. The differentiation and expansion of NK cells from CD34<sup>+</sup> HSCs are regulated by early activating cytokines, such as FL, KL, and IL-7, to promote HSC proliferation and differentiation, as well as by cytokines to activate NK cells, such as IL-15, IL-12, IL-21, and IGF-1. To improve NK cell survival or antitumor function, relative signals, such as the expression of mbIL-15 or preactivation with IL-12/15/18, strengthen activating or block inhibitory signals. These are vital for improving NK cell efficacy in adoptive cell therapy. Abbreviations: PBMC, peripheral blood mononuclear cell; CBMC, cord blood mononuclear cell; BMMC, bone marrow mononuclear cell; IL, interleukin; mbIL-15, membrane-bound IL-15; 4-1BBL, 4-1BB ligand; IGF-1, insulin-like growth factor 1; NKG2D, natural killer group 2D; DAP10, DNAX-activating protein 10; KIR, killer cell immunoglobulin-like receptors; NKG2A, natural killer group 2A.</p></caption><graphic xlink:href="fimmu-08-00930-g002"/></fig><sec id="S4-1"><title>Expansion of NK Cells from PB or UCB NK Cells</title><p>The most effective protocols to expand NK cells from primary NK cells depend on the presence of feeder cells, such as genetically modified K562 cells, Epstein-Barr virus-transformed lymphoblastoid B cell lines (EBV-BLCL) and irradiated autologous cells (<xref rid="B263" ref-type="bibr">263</xref>&#8211;<xref rid="B265" ref-type="bibr">265</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). One group has utilized double-transduced K562 cells with membrane-bound IL-15 and costimulating ligand 4-1BBL (K562-mbIL15-41BBL) as feeder cells along with low concentrations of IL-2, which results in dramatic PB NK cell expansion with negligible T cell expansion (<xref rid="B264" ref-type="bibr">264</xref>, <xref rid="B266" ref-type="bibr">266</xref>, <xref rid="B267" ref-type="bibr">267</xref>). K562-mbIL15-41BBL cell-stimulated NK cells can continually proliferate for 8&#8211;12&#8201;weeks, acquire up to 10<sup>8</sup> percent of the number of originally seeded NK cells and maintain high cytotoxic capacity (<xref rid="B268" ref-type="bibr">268</xref>). The K562-mbIL15-4-1BBL-based expansion method has been adapted for use under Good Manufacturing Practice conditions that can be used in the clinic (<xref rid="B264" ref-type="bibr">264</xref>, <xref rid="B269" ref-type="bibr">269</xref>). K562-mbIL-15-4-1BBL cells can also be used to expand UCB NK cells with enhanced proliferation and cytotoxicity (<xref rid="B270" ref-type="bibr">270</xref>). Other gene-modified K562 cells are also used in expansion systems. K562-IL-15R&#945;-4-1BBL feeder cells, in combination with soluble IL-15, stimulate NK cell expansion with increased expression of natural cytotoxicity receptors, correlating with enhanced cytolytic functions (<xref rid="B271" ref-type="bibr">271</xref>, <xref rid="B272" ref-type="bibr">272</xref>). Furthermore, K562-mbIL-21 cells can be developed to act as feeders and are reported to promote more vigorous NK cell expansion compared with K562-mbIL-15 cells (<xref rid="B273" ref-type="bibr">273</xref>). EBV-BLCL and autologous cells are also used as feeder cells, combined with the addition of IL-2, IL-15 and OKT3 (anti-CD3 antibody to inhibit T cell expansion) (<xref rid="B263" ref-type="bibr">263</xref>, <xref rid="B274" ref-type="bibr">274</xref>). The protocols that expand NK cells without feeder cells are also applied for NK cell treatment. The PB mononuclear cells from healthy donors or leukemia patients are cultured in stem cell growth medium supplemented with 5% human serum with the addition of IL-2 and OKT3 (<xref rid="B275" ref-type="bibr">275</xref>&#8211;<xref rid="B277" ref-type="bibr">277</xref>). Moreover, the expanded NK cells show significant cytotoxicity toward primary leukemia cells and K562 cells. Overall, primary NK cell expansion is primarily based on the help of feeder cells to provide appropriate signals from cytokines and activating ligands and can also be expanded merely with cytokines.</p></sec><sec id="S4-2"><title>Differentiation and Expansion of NK Cells from BM or UCB CD34<sup>+</sup> Cells</title><p>Initially, BM CD34<sup>+</sup> cells were widely used for the generation of NK cells, but UCB CD34<sup>+</sup> cells have become more frequently utilized as UCB is easier to obtain and is rich in HSCs (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B278" ref-type="bibr">278</xref>&#8211;<xref rid="B282" ref-type="bibr">282</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). An efficient protocol to expand NK cells from CD34<sup>+</sup> cells was established by the group of Spanholtz et al. (<xref rid="B283" ref-type="bibr">283</xref>, <xref rid="B284" ref-type="bibr">284</xref>). They separated UCB CD34<sup>+</sup> cells and then cultured them in a clinical-grade culture medium with human serum and a mixture of cytokines, such as FL, KL, IL-7, GM-CSF, TPO, IL-15, and IL-2, and heparin in the absence of feeder cells. They can acquire up to 10<sup>9</sup> CD34<sup>+</sup>cell-derived NK cells in fully closed static cell culture bags and automated bioreactors that can effectively kill leukemia cells <italic>in vitro</italic> or <italic>in vivo</italic>. These NK cell products have been used in a phase I trial to treat elderly AML patients (CCMO nr. NL31699 and Dutch Trial Register nr. 2818). Other protocols that improve NK cell development and function by adding methylprednisolone to induce preferential differentiation of HSCs toward NK cells or by adding IL-12 or IL-21 to promote NK cell maturation and cytotoxicity to tumor cells are developing (<xref rid="B189" ref-type="bibr">189</xref>, <xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B285" ref-type="bibr">285</xref>). The improvement of protocols to acquire functional NK cells with high quantity can be efficiently applied in the clinic.</p></sec><sec id="S4-3"><title>Improving NK Cell Survival and Function in Clinical Treatments</title><p>Natural killer cells, which are derived and expanded from autologous or allogeneic blood samples, can be applied in adoptive therapy. However, the low concentration or absence of cytokines in the body has often limited NK cell persistence postinfusion. To improve <italic>in vivo</italic> expansion, the Dario Campana group linked the human <italic>IL15</italic> gene to the gene encoding the transmembrane domain of <italic>CD8</italic>&#945; (mbIL15) (<xref rid="B131" ref-type="bibr">131</xref>). The mbIL-15-NK cells can survive and proliferate <italic>in vitro</italic> or <italic>in vivo</italic> without exogenous cytokines. They have superior cytotoxicity against solid tumors and leukemia cells <italic>in vitro</italic> and against leukemia cells in xenograft models, indicating that the expression of mbIL15 may improve the postinfusion cytotoxic capacity of NK cells. Similarly, we have noted that IL-15 can induce prolonged NK cell antitumor effects after cytokine withdrawal, which suggests that IL-15 can be widely used in adoptive NK cell therapy (<xref rid="B168" ref-type="bibr">168</xref>). Moreover, the super-agonist IL-15-IL-15R&#945;-Sushi-Fc fusion protein (ALT-803) potently stimulates NK cell cytotoxic activity than native IL-15 (<xref rid="B286" ref-type="bibr">286</xref>) and has been used in the clinical trail to evaluate its safety and efficacy (NCT02099539). Additionally, preactivation of NK cells with IL-12/15/18 can induce memory-like NK cells with enhanced cytotoxicity toward tumors. The cells have been used in the clinical treatment with AML patients (NCT01898793). IL-12 and IL-21 can promote NK cell maturation with improved functions, which are good candidates to be applied in NK cell adoptive therapy (<xref rid="B189" ref-type="bibr">189</xref>, <xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B212" ref-type="bibr">212</xref>).</p><p>Chimeric antigen receptor (CAR)-modified NK cells display a new possibility for the application of adoptive NK cell-based therapy (<xref rid="B287" ref-type="bibr">287</xref>). Preclinical studies to utilize CAR-expressing NK cells targeting CD19 or CD20 in B cell leukemia show effective killing toward tumor cells (<xref rid="B267" ref-type="bibr">267</xref>). In addition, CD19-CAR NK cells have been applied in treating B-ALL (NCT01974479) or ALL and CLL (NCT03056339) in clinical trails. To improve the efficacy of CAR-NK cells, the efforts to add genes that can elicit IL-15 production or other activating signals are now underway (<xref rid="B288" ref-type="bibr">288</xref>). However, new strategies still need to be developed to overcome the low transfection efficiency of NK cells.</p><p>Negative regulators can be treated as immune-checkpoints to shape immune responses. KIR and NKG2A are well-studied immune-checkpoints of NK cells, which can be blocked to gain better NK cell efficacy (<xref rid="B289" ref-type="bibr">289</xref>, <xref rid="B290" ref-type="bibr">290</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). The combination of anti-KIR mAbs lirilumab and lenalidomide has been used in a Phase I clinical trial (NCT01217203) with multiple myeloma patients. However, the outcomes need further study. Furthermore, anti-NKG2A antibody has also been applied in multiple clinical trials for patients with chronic lymphocytic leukemia (NCT02557516), squamous cell carcinoma of the head and neck (NCT02643550), gynecologic malignancies (NCT02459301), and squamous cell carcinoma of the oral cavity (NCT02331875). Other strategies are developing to upregulate activating signals that can significantly prolong antitumor activity of NK cells, such as retroviral transduction of NKG2D-DAP10-CD3&#950; in NK cells (<xref rid="B291" ref-type="bibr">291</xref>) (Figure <xref ref-type="fig" rid="F2">2</xref>). The design of bi-specific antibodies that link the antigens on tumor cells, such as CD33, CD20, and CD19, together with CD16 on NK cells direct NK cells toward tumors and elicit efficient tumor cell killing(<xref rid="B292" ref-type="bibr">292</xref>). Additionally, the tri-specific antibody that integrates IL-15 in the existing bi-specific antibody further promotes NK cell activation to facilitate NK cell cytotoxicity (<xref rid="B293" ref-type="bibr">293</xref>). Overall, the developments to improve the efficacy of NK cell adoptive therapy are ongoing and may result in broader clinical applications in the near future.</p></sec></sec><sec id="S5"><title>Conclusion</title><p>The development and functional maturation of NK cells are controlled by diverse cytokines. Different cytokine cocktails are needed for distinct NK cell developmental stages that are guided by the expression pattern of relative cytokine receptors. NK cells are heterogeneous and can be divided into cytotoxic, tolerant and regulatory NK cells. They distribute throughout the body in different tissues and can be shaped by their specific tissue environment via diverse combinations of cytokines. Given a robust understanding of each cytokine in NK cell development and function, NK cells can be differentiated and expanded <italic>in vitro</italic> to generate sufficient numbers for clinical treatment. NK cells derived from primary NK cells mainly require cytokines to promote NK cell expansion and function, such as IL-2, IL-12, and IL-15. Cells from HSC differentiation need cytokines to promote the survival and proliferation of HSCs, such as FL, KL, and IL-3, and to specify differentiation to NK cells with high cytotoxicity, such as IL-15, IL-2, IL-12, and IL-21. The application of IL-15 or IL-12/15/18 can further enhance NK cell cytotoxicity to induce greater efficacy for adoptive transfer therapy. Overall, understanding the primary roles and modes of action of each cytokine is critical to apply them more effectively in the clinic.</p></sec><sec id="S6"><title>Author Contributions</title><p>YW wrote the manuscript. ZT and HW designed the review and revised the manuscript.</p></sec><sec id="S7"><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer, MG, and handling editor declared their shared affiliation, and the handling editor states that the process nevertheless met the standards of a fair and objective review.</p></sec></body><back><ack><p>This study was supported by the key project of Natural Science Foundation of China (81330071 and 91442202).</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herberman</surname><given-names>RB</given-names></name><name><surname>Nunn</surname><given-names>ME</given-names></name><name><surname>Lavrin</surname><given-names>DH</given-names></name></person-group>
<article-title>Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity</article-title>. <source>Int J Cancer</source> (<year>1975</year>) <volume>16</volume>(<issue>2</issue>):<fpage>216</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.2910160204</pub-id><pub-id pub-id-type="pmid">50294</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiessling</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>E</given-names></name><name><surname>Wigzell</surname><given-names>H</given-names></name></person-group>
<article-title>&#8220;Natural&#8221; killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype</article-title>. <source>Eur J Immunol</source> (<year>1975</year>) <volume>5</volume>(<issue>2</issue>):<fpage>112</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1002/eji.1830050208</pub-id><pub-id pub-id-type="pmid">1234049</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Tomasello</surname><given-names>E</given-names></name><name><surname>Baratin</surname><given-names>M</given-names></name><name><surname>Walzer</surname><given-names>T</given-names></name><name><surname>Ugolini</surname><given-names>S</given-names></name></person-group>. <article-title>Functions of natural killer cells</article-title>. <source>Nat Immunol</source> (<year>2008</year>) <volume>9</volume>(<issue>5</issue>):<fpage>503</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1038/ni1582</pub-id><?supplied-pmid 18425107?><pub-id pub-id-type="pmid">18425107</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjorkstrom</surname><given-names>NK</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Michaelsson</surname><given-names>J</given-names></name></person-group>
<article-title>Emerging insights into natural killer cells in human peripheral tissues</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>(<issue>5</issue>):<fpage>310</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1038/nri.2016.34</pub-id><pub-id pub-id-type="pmid">27121652</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Le</surname><given-names>AM</given-names></name><name><surname>Civin</surname><given-names>CI</given-names></name><name><surname>Loken</surname><given-names>MR</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name></person-group>
<article-title>The relationship of Cd16 (Leu-11) and Leu-19 (Nkh-1) antigen expression on human peripheral-blood NK cells and cytotoxic lymphocytes-T</article-title>. <source>J Immunol</source> (<year>1986</year>) <volume>136</volume>(<issue>12</issue>):<fpage>4480</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">3086432</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Fehniger</surname><given-names>TA</given-names></name><name><surname>Turner</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>KS</given-names></name><name><surname>Ghaheri</surname><given-names>BA</given-names></name><name><surname>Ghayur</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset</article-title>. <source>Blood</source> (<year>2001</year>) <volume>97</volume>(<issue>10</issue>):<fpage>3146</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1182/blood.V97.10.3146</pub-id><?supplied-pmid 11342442?><pub-id pub-id-type="pmid">11342442</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fauriat</surname><given-names>C</given-names></name><name><surname>Long</surname><given-names>EO</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Bryceson</surname><given-names>YT</given-names></name></person-group>
<article-title>Regulation of human NK-cell cytokine and chemokine production by target cell recognition</article-title>. <source>Blood</source> (<year>2010</year>) <volume>115</volume>(<issue>11</issue>):<fpage>2167</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2009-08-238469</pub-id><pub-id pub-id-type="pmid">19965656</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinert</surname><given-names>EM</given-names></name><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Fraser</surname><given-names>KA</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Manlove</surname><given-names>LS</given-names></name><name><surname>Igyarto</surname><given-names>BZ</given-names></name><etal/></person-group>
<article-title>Quantifying memory CD8 T cells reveals regionalization of immunosurveillance</article-title>. <source>Cell</source> (<year>2015</year>) <volume>161</volume>(<issue>4</issue>):<fpage>737</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2015.03.031</pub-id><?supplied-pmid 25957682?><pub-id pub-id-type="pmid">25957682</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>LK</given-names></name><name><surname>Rahimpour</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Stock</surname><given-names>AT</given-names></name><name><surname>Hafon</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>The developmental pathway for CD103(+)CD8(+) tissue-resident memory T cells of skin</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>(<issue>12</issue>):<fpage>1294</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2744</pub-id><pub-id pub-id-type="pmid">24162776</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>XJ</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Sojka</surname><given-names>DK</given-names></name><name><surname>Wei</surname><given-names>HM</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Liver-resident NK cells confer adaptive immunity in skin-contact inflammation</article-title>. <source>J Clin Invest</source> (<year>2013</year>) <volume>123</volume>(<issue>4</issue>):<fpage>1444</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1172/JCI66381</pub-id><?supplied-pmid 23524967?><pub-id pub-id-type="pmid">23524967</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortez</surname><given-names>VS</given-names></name><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group>. <article-title>Cutting edge: salivary gland NK cells develop independently of Nfil3 in steady-state</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>(<issue>10</issue>):<fpage>4487</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1303469</pub-id><?supplied-pmid 24740507?><pub-id pub-id-type="pmid">24740507</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sojka</surname><given-names>DK</given-names></name><name><surname>Plougastel-Douglas</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>LP</given-names></name><name><surname>Pak-Wittel</surname><given-names>MA</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Ivanova</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells</article-title>. <source>Elife</source> (<year>2014</year>) <volume>3</volume>:<fpage>e01659</fpage>.<pub-id pub-id-type="doi">10.7554/eLife.01659</pub-id><?supplied-pmid 24714492?><pub-id pub-id-type="pmid">24714492</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquardt</surname><given-names>N</given-names></name><name><surname>Beziat</surname><given-names>V</given-names></name><name><surname>Nystrom</surname><given-names>S</given-names></name><name><surname>Hengst</surname><given-names>J</given-names></name><name><surname>Ivarsson</surname><given-names>MA</given-names></name><name><surname>Kekalainen</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Cutting edge: identification and characterization of human intrahepatic CD49a(+) NK cells</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>(<issue>6</issue>):<fpage>2467</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1402756</pub-id><pub-id pub-id-type="pmid">25672754</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Wisse</surname><given-names>E</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name></person-group>
<article-title>Liver natural killer cells: subsets and roles in liver immunity</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>) <volume>13</volume>(<issue>3</issue>):<fpage>328</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2015.96</pub-id><pub-id pub-id-type="pmid">26639736</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabiasco</surname><given-names>J</given-names></name><name><surname>Rabot</surname><given-names>M</given-names></name><name><surname>Aguerre-Girr</surname><given-names>M</given-names></name><name><surname>El Costa</surname><given-names>H</given-names></name><name><surname>Berrebi</surname><given-names>A</given-names></name><name><surname>Parant</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Human decidual NK cells: unique phenotype and functional properties &#8211; a review</article-title>. <source>Placenta</source> (<year>2006</year>) <volume>27</volume>:<fpage>S34</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.placenta.2006.01.009</pub-id><pub-id pub-id-type="pmid">16516963</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffett</surname><given-names>A</given-names></name><name><surname>Colucci</surname><given-names>F</given-names></name></person-group>. <article-title>Uterine NK cells: active regulators at the maternal-fetal interface</article-title>. <source>J Clin Invest</source> (<year>2014</year>) <volume>124</volume>(<issue>5</issue>):<fpage>1872</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1172/JCI68107</pub-id><?supplied-pmid 24789879?><pub-id pub-id-type="pmid">24789879</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keskin</surname><given-names>DB</given-names></name><name><surname>Allan</surname><given-names>DSJ</given-names></name><name><surname>Rybalov</surname><given-names>B</given-names></name><name><surname>Andzelm</surname><given-names>MM</given-names></name><name><surname>Stern</surname><given-names>JNH</given-names></name><name><surname>Kopcow</surname><given-names>HD</given-names></name><etal/></person-group>
<article-title>TGF beta promotes conversion of CD16(+) peripheral blood NK cells into CD16(-) NK cells with similarities to decidual NK cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2007</year>) <volume>104</volume>(<issue>9</issue>):<fpage>3378</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.061198104</pub-id><pub-id pub-id-type="pmid">17360654</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerdeira</surname><given-names>AS</given-names></name><name><surname>Rajakumar</surname><given-names>A</given-names></name><name><surname>Royle</surname><given-names>CM</given-names></name><name><surname>Lo</surname><given-names>A</given-names></name><name><surname>Husain</surname><given-names>Z</given-names></name><name><surname>Thadhani</surname><given-names>RI</given-names></name><etal/></person-group>
<article-title>Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>190</volume>(<issue>8</issue>):<fpage>3939</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1202582</pub-id><?supplied-pmid 23487420?><pub-id pub-id-type="pmid">23487420</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkens</surname><given-names>J</given-names></name><name><surname>Male</surname><given-names>V</given-names></name><name><surname>Ghazal</surname><given-names>P</given-names></name><name><surname>Forster</surname><given-names>T</given-names></name><name><surname>Gibson</surname><given-names>DA</given-names></name><name><surname>Williams</surname><given-names>ARW</given-names></name><etal/></person-group>
<article-title>Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>(<issue>5</issue>):<fpage>2226</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1300958</pub-id><?supplied-pmid 23913972?><pub-id pub-id-type="pmid">23913972</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eksteen</surname><given-names>B</given-names></name><name><surname>Afford</surname><given-names>SC</given-names></name><name><surname>Wigmore</surname><given-names>SJ</given-names></name><name><surname>Holt</surname><given-names>AP</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name></person-group>. <article-title>Immune-mediated liver injury</article-title>. <source>Semin Liver Dis</source> (<year>2007</year>) <volume>27</volume>(<issue>4</issue>):<fpage>351</fpage>&#8211;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1055/s-2007-991512</pub-id><?supplied-pmid 17979072?><pub-id pub-id-type="pmid">17979072</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>Z</given-names></name><name><surname>Bozorgzadeh</surname><given-names>A</given-names></name><name><surname>Pierce</surname><given-names>RH</given-names></name><name><surname>Kurtis</surname><given-names>J</given-names></name><name><surname>Crispe</surname><given-names>IN</given-names></name><name><surname>Orloff</surname><given-names>MS</given-names></name></person-group>. <article-title>TLR-dependent cross talk between human Kupffer cells and NK cells</article-title>. <source>J Exp Med</source> (<year>2008</year>) <volume>205</volume>(<issue>1</issue>):<fpage>233</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20072195</pub-id><?supplied-pmid 18195076?><pub-id pub-id-type="pmid">18195076</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>MG</given-names></name><name><surname>Lukens</surname><given-names>JR</given-names></name><name><surname>Dolina</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>MG</given-names></name><name><surname>Hahn</surname><given-names>YS</given-names></name></person-group>
<article-title>Intrahepatic IL-10 maintains NKG2A(+)Ly49(-) liver NK cells in a functionally hyporesponsive state</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>184</volume>(<issue>5</issue>):<fpage>2693</fpage>&#8211;<lpage>701</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0901362</pub-id><pub-id pub-id-type="pmid">20124099</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>HY</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name><name><surname>Xiao</surname><given-names>WH</given-names></name></person-group>
<article-title>NK cells in immunotolerant organs</article-title>. <source>Cell Mol Immunol</source> (<year>2013</year>) <volume>10</volume>(<issue>3</issue>):<fpage>202</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2013.9</pub-id><pub-id pub-id-type="pmid">23563087</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Benezra</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>M</given-names></name><name><surname>Sonnenfeld</surname><given-names>G</given-names></name></person-group>
<article-title>Natural killer cells in mice treated with Sr-89 &#8211; normal target-binding cell numbers but inability to kill even after interferon administration</article-title>. <source>J Immunol</source> (<year>1979</year>) <volume>123</volume>(<issue>4</issue>):<fpage>1832</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">383842</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Vosshenrich</surname><given-names>CAJ</given-names></name></person-group>. <article-title>Bone marrow versus thymic pathways of natural killer cell development</article-title>. <source>Immunol Rev</source> (<year>2006</year>) <volume>214</volume>:<fpage>35</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00461.x</pub-id><?supplied-pmid 17100874?><pub-id pub-id-type="pmid">17100874</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vosshenrich</surname><given-names>CAJ</given-names></name><name><surname>Garcia-Ojeda</surname><given-names>ME</given-names></name><name><surname>Samson-Villeger</surname><given-names>SI</given-names></name><name><surname>Pasqualetto</surname><given-names>V</given-names></name><name><surname>Enault</surname><given-names>L</given-names></name><name><surname>Goff</surname><given-names>ORL</given-names></name><etal/></person-group>
<article-title>A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127</article-title>. <source>Nat Immunol</source> (<year>2006</year>) <volume>7</volume>(<issue>11</issue>):<fpage>1217</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1038/ni1395</pub-id><?supplied-pmid 17013389?><pub-id pub-id-type="pmid">17013389</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroso</surname><given-names>V</given-names></name><name><surname>Famili</surname><given-names>F</given-names></name><name><surname>Papazian</surname><given-names>N</given-names></name><name><surname>Cupedo</surname><given-names>T</given-names></name><name><surname>van der Laan</surname><given-names>LJW</given-names></name><name><surname>Kazemier</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>NK cells can generate from precursors in the adult human liver</article-title>. <source>Eur J Immunol</source> (<year>2011</year>) <volume>41</volume>(<issue>11</issue>):<fpage>3340</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201141760</pub-id><?supplied-pmid 21830211?><pub-id pub-id-type="pmid">21830211</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vosshenrich</surname><given-names>CAJ</given-names></name><name><surname>Samson-Villeger</surname><given-names>SI</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name></person-group>. <article-title>Distinguishing features of developing natural killer cells</article-title>. <source>Curr Opin Immunol</source> (<year>2005</year>) <volume>17</volume>(<issue>2</issue>):<fpage>151</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2005.01.005</pub-id><?supplied-pmid 15766674?><pub-id pub-id-type="pmid">15766674</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurenti</surname><given-names>E</given-names></name><name><surname>Doulatov</surname><given-names>S</given-names></name><name><surname>Zandi</surname><given-names>S</given-names></name><name><surname>Plumb</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>April</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>(<issue>7</issue>):<fpage>756</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2615</pub-id><pub-id pub-id-type="pmid">23708252</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renoux</surname><given-names>VM</given-names></name><name><surname>Zriwil</surname><given-names>A</given-names></name><name><surname>Peitzsch</surname><given-names>C</given-names></name><name><surname>Michaelsson</surname><given-names>J</given-names></name><name><surname>Friberg</surname><given-names>D</given-names></name><name><surname>Soneji</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Identification of a human natural killer cell lineage-restricted progenitor in fetal and adult tissues</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>43</volume>(<issue>2</issue>):<fpage>394</fpage>&#8211;<lpage>407</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.011</pub-id><?supplied-pmid 26287684?><pub-id pub-id-type="pmid">26287684</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaled</surname><given-names>AR</given-names></name><name><surname>Durum</surname><given-names>SK</given-names></name></person-group>
<article-title>Lymphocide: cytokines and the control of lymphoid homeostasis</article-title>. <source>Nat Rev Immunol</source> (<year>2002</year>) <volume>2</volume>(<issue>11</issue>):<fpage>817</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1038/Nri931</pub-id><pub-id pub-id-type="pmid">12415306</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boos</surname><given-names>MD</given-names></name><name><surname>Ramirez</surname><given-names>K</given-names></name><name><surname>Kee</surname><given-names>BL</given-names></name></person-group>
<article-title>Extrinsic and intrinsic regulation of early natural killer cell development</article-title>. <source>Immunol Res</source> (<year>2008</year>) <volume>40</volume>(<issue>3</issue>):<fpage>193</fpage>&#8211;<lpage>207</lpage>.<pub-id pub-id-type="doi">10.1007/s12026-007-8006-9</pub-id><pub-id pub-id-type="pmid">18266115</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcais</surname><given-names>A</given-names></name><name><surname>Viel</surname><given-names>S</given-names></name><name><surname>Grau</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>T</given-names></name><name><surname>Marvel</surname><given-names>J</given-names></name><name><surname>Walzer</surname><given-names>T</given-names></name></person-group>. <article-title>Regulation of mouse NK cell development and function by cytokines</article-title>. <source>Front Immunol</source> (<year>2013</year>) <volume>4</volume>:<fpage>450</fpage>.<pub-id pub-id-type="doi">10.3389/Fimmu.2013.00450</pub-id><?supplied-pmid 24376448?><pub-id pub-id-type="pmid">24376448</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Male</surname><given-names>V</given-names></name><name><surname>Brady</surname><given-names>HJM</given-names></name></person-group>
<article-title>Transcriptional control of NK cell differentiation and function</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2014</year>) <volume>381</volume>:<fpage>173</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="doi">10.1007/82_2014_376</pub-id><pub-id pub-id-type="pmid">24850220</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>JC</given-names></name></person-group>. <article-title>Transcriptional control of NK cells</article-title>. <source>Nat Killer Cells</source> (<year>2016</year>) <volume>395</volume>:<fpage>1</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1007/82_2015_452</pub-id><?supplied-pmid 26177585?><pub-id pub-id-type="pmid">26177585</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samson</surname><given-names>SI</given-names></name><name><surname>Richard</surname><given-names>O</given-names></name><name><surname>Tavian</surname><given-names>M</given-names></name><name><surname>Ranson</surname><given-names>T</given-names></name><name><surname>Vosshenrich</surname><given-names>CAJ</given-names></name><name><surname>Colucci</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells</article-title>. <source>Immunity</source> (<year>2003</year>) <volume>19</volume>(<issue>5</issue>):<fpage>701</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(03)00294-2</pub-id><?supplied-pmid 14614857?><pub-id pub-id-type="pmid">14614857</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>MJ</given-names></name><name><surname>Weinmann</surname><given-names>AS</given-names></name><name><surname>Matsuda</surname><given-names>JL</given-names></name><name><surname>Salomon</surname><given-names>R</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name><name><surname>Biron</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>T-bet regulates the terminal maturation and homeostasis of NK and V alpha 14i NKT cells</article-title>. <source>Immunity</source> (<year>2004</year>) <volume>20</volume>(<issue>4</issue>):<fpage>477</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(04)00076-7</pub-id><?supplied-pmid 15084276?><pub-id pub-id-type="pmid">15084276</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gascoyne</surname><given-names>DM</given-names></name><name><surname>Long</surname><given-names>E</given-names></name><name><surname>Veiga-Fernandes</surname><given-names>H</given-names></name><name><surname>de Boer</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>O</given-names></name><name><surname>Seddon</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development</article-title>. <source>Nat Immunol</source> (<year>2009</year>) <volume>10</volume>(<issue>10</issue>):<fpage>1118</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1787</pub-id><pub-id pub-id-type="pmid">19749763</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daussy</surname><given-names>C</given-names></name><name><surname>Faure</surname><given-names>F</given-names></name><name><surname>Mayol</surname><given-names>K</given-names></name><name><surname>Viel</surname><given-names>S</given-names></name><name><surname>Gasteiger</surname><given-names>G</given-names></name><name><surname>Charrier</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow</article-title>. <source>J Exp Med</source> (<year>2014</year>) <volume>211</volume>(<issue>3</issue>):<fpage>563</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20131560</pub-id><?supplied-pmid 24516120?><pub-id pub-id-type="pmid">24516120</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>SM</given-names></name><name><surname>Chaix</surname><given-names>J</given-names></name><name><surname>Rupp</surname><given-names>LJ</given-names></name><name><surname>Wu</surname><given-names>JM</given-names></name><name><surname>Madera</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>The transcription factors T-bet and eomes control key checkpoints of natural killer cell maturation</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>36</volume>(<issue>1</issue>):<fpage>55</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2011.11.016</pub-id><?supplied-pmid 22261438?><pub-id pub-id-type="pmid">22261438</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyman</surname><given-names>SD</given-names></name><name><surname>Jacobsen</surname><given-names>SE</given-names></name></person-group>
<article-title>c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities</article-title>. <source>Blood</source> (<year>1998</year>) <volume>91</volume>(<issue>4</issue>):<fpage>1101</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">9454740</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>C</given-names></name><name><surname>Durand</surname><given-names>C</given-names></name></person-group>
<article-title>The roles of BMP and IL-3 signaling pathways in the control of hematopoietic stem cells in the mouse embryo</article-title>. <source>Int J Dev Biol</source> (<year>2010</year>) <volume>54</volume>(<issue>6&#8211;7</issue>):<fpage>1189</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1387/ijdb.093040cr</pub-id><pub-id pub-id-type="pmid">20711995</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodolce</surname><given-names>JP</given-names></name><name><surname>Boone</surname><given-names>DL</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Swain</surname><given-names>RE</given-names></name><name><surname>Dassopoulos</surname><given-names>T</given-names></name><name><surname>Trettin</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation</article-title>. <source>Immunity</source> (<year>1998</year>) <volume>9</volume>(<issue>5</issue>):<fpage>669</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80664-0</pub-id><pub-id pub-id-type="pmid">9846488</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>MK</given-names></name><name><surname>Glaccum</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>SN</given-names></name><name><surname>Butz</surname><given-names>EA</given-names></name><name><surname>Viney</surname><given-names>JL</given-names></name><name><surname>Embers</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice</article-title>. <source>J Exp Med</source> (<year>2000</year>) <volume>191</volume>(<issue>5</issue>):<fpage>771</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1084/jem.191.5.771</pub-id><pub-id pub-id-type="pmid">10704459</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundig</surname><given-names>TM</given-names></name><name><surname>Schorle</surname><given-names>H</given-names></name><name><surname>Bachmann</surname><given-names>MF</given-names></name><name><surname>Hengartner</surname><given-names>H</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name><name><surname>Horak</surname><given-names>I</given-names></name></person-group>
<article-title>Immune-responses in interleukin-2 deficient mice</article-title>. <source>Science</source> (<year>1993</year>) <volume>262</volume>(<issue>5136</issue>):<fpage>1059</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1126/science.8235625</pub-id><pub-id pub-id-type="pmid">8235625</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Freeden-Jeffry</surname><given-names>U</given-names></name><name><surname>Vieira</surname><given-names>P</given-names></name><name><surname>Lucian</surname><given-names>LA</given-names></name><name><surname>McNeil</surname><given-names>T</given-names></name><name><surname>Burdach</surname><given-names>SE</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name></person-group>. <article-title>Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine</article-title>. <source>J Exp Med</source> (<year>1995</year>) <volume>181</volume>(<issue>4</issue>):<fpage>1519</fpage>.<pub-id pub-id-type="doi">10.1084/jem.181.4.1519</pub-id><?supplied-pmid 7699333?><pub-id pub-id-type="pmid">7699333</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maki</surname><given-names>K</given-names></name><name><surname>Sunaga</surname><given-names>S</given-names></name><name><surname>Komagata</surname><given-names>Y</given-names></name><name><surname>Kodaira</surname><given-names>Y</given-names></name><name><surname>Mabuchi</surname><given-names>A</given-names></name><name><surname>Karasuyama</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Interleukin 7 receptor-deficient mice lack gamma delta T cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1996</year>) <volume>93</volume>(<issue>14</issue>):<fpage>7172</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.93.14.7172</pub-id><?supplied-pmid 8692964?><pub-id pub-id-type="pmid">8692964</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasaian</surname><given-names>MT</given-names></name><name><surname>Whitters</surname><given-names>MJ</given-names></name><name><surname>Carter</surname><given-names>LL</given-names></name><name><surname>Lowe</surname><given-names>LD</given-names></name><name><surname>Jussif</surname><given-names>JM</given-names></name><name><surname>Deng</surname><given-names>BJ</given-names></name><etal/></person-group>
<article-title>IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>16</volume>(<issue>4</issue>):<fpage>559</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(02)00295-9</pub-id><?supplied-pmid 11970879?><pub-id pub-id-type="pmid">11970879</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotzova</surname><given-names>E</given-names></name><name><surname>Savary</surname><given-names>CA</given-names></name><name><surname>Herberman</surname><given-names>RB</given-names></name></person-group>
<article-title>Induction of NK cell-activity against fresh human-leukemia in culture with interleukin-2</article-title>. <source>J Immunol</source> (<year>1987</year>) <volume>138</volume>(<issue>8</issue>):<fpage>2718</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="pmid">3494084</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biron</surname><given-names>CA</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Kasaian</surname><given-names>MT</given-names></name></person-group>
<article-title>Interleukin-2-induced proliferation of murine natural-killer cells in vivo</article-title>. <source>J Exp Med</source> (<year>1990</year>) <volume>171</volume>(<issue>1</issue>):<fpage>173</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1084/jem.171.1.173</pub-id><pub-id pub-id-type="pmid">1688606</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skak</surname><given-names>K</given-names></name><name><surname>Frederiksen</surname><given-names>KS</given-names></name><name><surname>Lundsgaard</surname><given-names>D</given-names></name></person-group>. <article-title>Interleukin-21 activates human natural killer cells and modulates their surface receptor expression</article-title>. <source>Immunology</source> (<year>2008</year>) <volume>123</volume>(<issue>4</issue>):<fpage>575</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02730.x</pub-id><?supplied-pmid 18005035?><pub-id pub-id-type="pmid">18005035</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dexter</surname><given-names>TM</given-names></name><name><surname>Moore</surname><given-names>MA</given-names></name></person-group>
<article-title>In vitro duplication and &#8220;cure&#8221; of haemopoietic defects in genetically anaemic mice</article-title>. <source>Nature</source> (<year>1977</year>) <volume>269</volume>(<issue>5627</issue>):<fpage>412</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/269412a0</pub-id><pub-id pub-id-type="pmid">561894</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>Y</given-names></name><name><surname>Go</surname><given-names>S</given-names></name></person-group>
<article-title>Decreased production of mast-cells in S1-S1d anemic mice</article-title>. <source>Blood</source> (<year>1979</year>) <volume>53</volume>(<issue>3</issue>):<fpage>492</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">367470</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group>
<article-title>Signal transduction by receptors with tyrosine kinase-activity</article-title>. <source>Cell</source> (<year>1990</year>) <volume>61</volume>(<issue>2</issue>):<fpage>203</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1016/0092-8674(90)90801-K</pub-id><pub-id pub-id-type="pmid">2158859</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>JE</given-names></name></person-group>
<article-title>Sl/Sl(D) hematopoietic progenitors are deficient in-situ</article-title>. <source>Exp Hematol</source> (<year>1994</year>) <volume>22</volume>(<issue>2</issue>):<fpage>174</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">7507859</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colucci</surname><given-names>F</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name></person-group>. <article-title>The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells</article-title>. <source>Blood</source> (<year>2000</year>) <volume>95</volume>(<issue>3</issue>):<fpage>984</fpage>&#8211;<lpage>91</lpage>.<?supplied-pmid 10648413?><pub-id pub-id-type="pmid">10648413</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosnet</surname><given-names>O</given-names></name><name><surname>Marchetto</surname><given-names>S</given-names></name><name><surname>Delapeyriere</surname><given-names>O</given-names></name><name><surname>Birnbaum</surname><given-names>D</given-names></name></person-group>
<article-title>Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family</article-title>. <source>Oncogene</source> (<year>1991</year>) <volume>6</volume>(<issue>9</issue>):<fpage>1641</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="pmid">1656368</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackarehtschian</surname><given-names>K</given-names></name><name><surname>Hardin</surname><given-names>JD</given-names></name><name><surname>Moore</surname><given-names>KA</given-names></name><name><surname>Boast</surname><given-names>S</given-names></name><name><surname>Goff</surname><given-names>SP</given-names></name><name><surname>Lemischka</surname><given-names>IR</given-names></name></person-group>. <article-title>Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors</article-title>. <source>Immunity</source> (<year>1995</year>) <volume>3</volume>(<issue>1</issue>):<fpage>147</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/1074-7613(95)90167-1</pub-id><?supplied-pmid 7621074?><pub-id pub-id-type="pmid">7621074</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>HJ</given-names></name><name><surname>Stocking</surname><given-names>KL</given-names></name><name><surname>Miller</surname><given-names>RE</given-names></name><name><surname>Brasel</surname><given-names>K</given-names></name><name><surname>De Smedt</surname><given-names>T</given-names></name><name><surname>Maraskovsky</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells</article-title>. <source>Blood</source> (<year>2000</year>) <volume>95</volume>(<issue>11</issue>):<fpage>3489</fpage>&#8211;<lpage>97</lpage>.<?supplied-pmid 10828034?><pub-id pub-id-type="pmid">10828034</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitnicka</surname><given-names>E</given-names></name><name><surname>Bryder</surname><given-names>D</given-names></name><name><surname>Theilgaard-Monch</surname><given-names>K</given-names></name><name><surname>Buza-Vidas</surname><given-names>N</given-names></name><name><surname>Adolfsson</surname><given-names>J</given-names></name><name><surname>Jacobsen</surname><given-names>SEW</given-names></name></person-group>
<article-title>Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>17</volume>(<issue>4</issue>):<fpage>463</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(02)00419-3</pub-id><pub-id pub-id-type="pmid">12387740</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lantz</surname><given-names>CS</given-names></name><name><surname>Boesiger</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>CH</given-names></name><name><surname>Mach</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Mulligan</surname><given-names>RC</given-names></name><etal/></person-group>
<article-title>Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites</article-title>. <source>Nature</source> (<year>1998</year>) <volume>392</volume>(<issue>6671</issue>):<fpage>90</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1038/32190</pub-id><?supplied-pmid 9510253?><pub-id pub-id-type="pmid">9510253</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>EP</given-names></name><name><surname>Korapati</surname><given-names>A</given-names></name><name><surname>Chaturvedi</surname><given-names>P</given-names></name><name><surname>Rane</surname><given-names>S</given-names></name></person-group>
<article-title>IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled</article-title>. <source>Oncogene</source> (<year>2000</year>) <volume>19</volume>(<issue>21</issue>):<fpage>2532</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1038/sj.onc.1203594</pub-id><pub-id pub-id-type="pmid">10851052</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>C</given-names></name><name><surname>Ottersbach</surname><given-names>K</given-names></name><name><surname>Durand</surname><given-names>C</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Vanes</surname><given-names>L</given-names></name><name><surname>Tybulewicz</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>An unexpected role for IL-3 in the embryonic development of hematopoietic stem cells</article-title>. <source>Dev Cell</source> (<year>2006</year>) <volume>11</volume>(<issue>2</issue>):<fpage>171</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1016/j.devcel.2006.07.002</pub-id><?supplied-pmid 16890157?><pub-id pub-id-type="pmid">16890157</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschon</surname><given-names>JJ</given-names></name><name><surname>Morrissey</surname><given-names>PJ</given-names></name><name><surname>Grabstein</surname><given-names>KH</given-names></name><name><surname>Ramsdell</surname><given-names>FJ</given-names></name><name><surname>Maraskovsky</surname><given-names>E</given-names></name><name><surname>Gliniak</surname><given-names>BC</given-names></name><etal/></person-group>
<article-title>Early lymphocyte expansion is severely impaired in interleukin-7 receptor-deficient mice</article-title>. <source>J Exp Med</source> (<year>1994</year>) <volume>180</volume>(<issue>5</issue>):<fpage>1955</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1084/jem.180.5.1955</pub-id><pub-id pub-id-type="pmid">7964471</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>MJ</given-names></name><name><surname>Mahajan</surname><given-names>VS</given-names></name><name><surname>Trajman</surname><given-names>LC</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Chen</surname><given-names>JZ</given-names></name></person-group>. <article-title>Interleukin-7 receptor signaling network: an integrated systems perspective</article-title>. <source>Cell Mol Immunol</source> (<year>2008</year>) <volume>5</volume>(<issue>2</issue>):<fpage>79</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2008.10</pub-id><?supplied-pmid 18445337?><pub-id pub-id-type="pmid">18445337</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovanen</surname><given-names>PE</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name></person-group>. <article-title>Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways</article-title>. <source>Immunol Rev</source> (<year>2004</year>) <volume>202</volume>:<fpage>67</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00203.x</pub-id><?supplied-pmid 15546386?><pub-id pub-id-type="pmid">15546386</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadlack</surname><given-names>B</given-names></name><name><surname>Merz</surname><given-names>H</given-names></name><name><surname>Schorle</surname><given-names>H</given-names></name><name><surname>Schimpl</surname><given-names>A</given-names></name><name><surname>Feller</surname><given-names>AC</given-names></name><name><surname>Horak</surname><given-names>I</given-names></name></person-group>. <article-title>Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene</article-title>. <source>Cell</source> (<year>1993</year>) <volume>75</volume>(<issue>2</issue>):<fpage>253</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1016/0092-8674(93)80067-O</pub-id><?supplied-pmid 8402910?><pub-id pub-id-type="pmid">8402910</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Kundig</surname><given-names>TM</given-names></name><name><surname>Furlonger</surname><given-names>C</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Timms</surname><given-names>E</given-names></name><name><surname>Matsuyama</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Deregulated T-cell activation and autoimmunity in mice lacking interleukin-2 receptor-beta</article-title>. <source>Science</source> (<year>1995</year>) <volume>268</volume>(<issue>5216</issue>):<fpage>1472</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1126/science.7770771</pub-id><pub-id pub-id-type="pmid">7770771</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willerford</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>JZ</given-names></name><name><surname>Ferry</surname><given-names>JA</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name></person-group>
<article-title>Interleukin-2 receptor-alpha chain regulates the size and content of the peripheral lymphoid compartment</article-title>. <source>Immunity</source> (<year>1995</year>) <volume>3</volume>(<issue>4</issue>):<fpage>521</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1016/1074-7613(95)90180-9</pub-id><pub-id pub-id-type="pmid">7584142</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>GC</given-names></name><name><surname>Radvanyi</surname><given-names>L</given-names></name></person-group>
<article-title>The IL-2 cytokine family in cancer immunotherapy</article-title>. <source>Cytokine Growth Factor Rev</source> (<year>2014</year>) <volume>25</volume>(<issue>4</issue>):<fpage>377</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.07.018</pub-id><pub-id pub-id-type="pmid">25200249</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>MH</given-names></name><name><surname>Sun</surname><given-names>YL</given-names></name><name><surname>Hoey</surname><given-names>T</given-names></name><name><surname>Grusby</surname><given-names>MJ</given-names></name></person-group>. <article-title>Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice</article-title>. <source>Nature</source> (<year>1996</year>) <volume>382</volume>(<issue>6587</issue>):<fpage>174</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/382174a0</pub-id><?supplied-pmid 8700209?><pub-id pub-id-type="pmid">8700209</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattner</surname><given-names>F</given-names></name><name><surname>Magram</surname><given-names>J</given-names></name><name><surname>Ferrante</surname><given-names>J</given-names></name><name><surname>Launois</surname><given-names>P</given-names></name><name><surname>DiPadova</surname><given-names>K</given-names></name><name><surname>Behin</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Genetically resistant mice lacking interleukin-12 are susceptible to infection with <italic>Leishmania major</italic> and mount a polarized Th2 cell response</article-title>. <source>Eur J Immunol</source> (<year>1996</year>) <volume>26</volume>(<issue>7</issue>):<fpage>1553</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/eji.1830260722</pub-id><?supplied-pmid 8766560?><pub-id pub-id-type="pmid">8766560</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>KW</given-names></name><name><surname>Shuster</surname><given-names>DJ</given-names></name><name><surname>Gillooly</surname><given-names>KM</given-names></name><name><surname>Warrier</surname><given-names>RR</given-names></name><name><surname>Connaughton</surname><given-names>SE</given-names></name><name><surname>Hall</surname><given-names>LB</given-names></name><etal/></person-group>
<article-title>Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice</article-title>. <source>Eur J Immunol</source> (<year>1996</year>) <volume>26</volume>(<issue>12</issue>):<fpage>2933</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/eji.1830261219</pub-id><?supplied-pmid 8977288?><pub-id pub-id-type="pmid">8977288</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Pflanz</surname><given-names>S</given-names></name><name><surname>Kastelein</surname><given-names>RA</given-names></name></person-group>
<article-title>The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses</article-title>. <source>Immunity</source> (<year>2003</year>) <volume>19</volume>(<issue>5</issue>):<fpage>641</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(03)00296-6</pub-id><pub-id pub-id-type="pmid">14614851</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Yoshimoto</surname><given-names>T</given-names></name><name><surname>Adachi</surname><given-names>O</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Defective NK cell activity and Th1 response in IL-18-deficient mice</article-title>. <source>Immunity</source> (<year>1998</year>) <volume>8</volume>(<issue>3</issue>):<fpage>383</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80543-9</pub-id><pub-id pub-id-type="pmid">9529155</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>K</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>162</volume>(<issue>9</issue>):<fpage>5041</fpage>&#8211;<lpage>4</lpage>.<?supplied-pmid 10227969?><pub-id pub-id-type="pmid">10227969</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>NJ</given-names></name><name><surname>Millar</surname><given-names>DG</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Horacek</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>IL-1 receptor-associated kinase 4 is essential for IL-18-mediated NK and Th1&#8201;cell responses</article-title>. <source>J Immunol</source> (<year>2003</year>) <volume>170</volume>(<issue>8</issue>):<fpage>4031</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.170.8.4031</pub-id><?supplied-pmid 12682231?><pub-id pub-id-type="pmid">12682231</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lewis</surname><given-names>EC</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Reznikov</surname><given-names>LL</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group>. <article-title>Differences in signaling pathways by IL-1 beta and IL-18</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2004</year>) <volume>101</volume>(<issue>23</issue>):<fpage>8815</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0402800101</pub-id><?supplied-pmid 15161979?><pub-id pub-id-type="pmid">15161979</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>K</given-names></name><name><surname>Spolski</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>CG</given-names></name><name><surname>Qi</surname><given-names>CF</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A critical role for IL-21 in regulating immunoglobulin production</article-title>. <source>Science</source> (<year>2002</year>) <volume>298</volume>(<issue>5598</issue>):<fpage>1630</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1126/science.1077002</pub-id><pub-id pub-id-type="pmid">12446913</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurieva</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>XXO</given-names></name><name><surname>Martinez</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Panopoulos</surname><given-names>AD</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Essential autocrine regulation by IL-21 in the generation of inflammatory T cells</article-title>. <source>Nature</source> (<year>2007</year>) <volume>448</volume>(<issue>7152</issue>):<fpage>480</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nature05969</pub-id><?supplied-pmid 17581589?><pub-id pub-id-type="pmid">17581589</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>R</given-names></name><name><surname>Spolski</surname><given-names>R</given-names></name><name><surname>Casas</surname><given-names>E</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name></person-group>. <article-title>The molecular basis of IL-21-mediated proliferation</article-title>. <source>Blood</source> (<year>2007</year>) <volume>109</volume>(<issue>10</issue>):<fpage>4135</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2006-10-054973</pub-id><?supplied-pmid 17234735?><pub-id pub-id-type="pmid">17234735</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>LA</given-names></name><name><surname>Ivanov</surname><given-names>II</given-names></name><name><surname>Spolski</surname><given-names>R</given-names></name><name><surname>Min</surname><given-names>R</given-names></name><name><surname>Shenderov</surname><given-names>K</given-names></name><name><surname>Egawa</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways</article-title>. <source>Nat Immunol</source> (<year>2007</year>) <volume>8</volume>(<issue>9</issue>):<fpage>967</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1038/ni1488</pub-id><pub-id pub-id-type="pmid">17581537</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>R</given-names></name><name><surname>Lohler</surname><given-names>J</given-names></name><name><surname>Rennick</surname><given-names>D</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Muller</surname><given-names>W</given-names></name></person-group>. <article-title>Interleukin-10-deficient mice develop chronic enterocolitis</article-title>. <source>Cell</source> (<year>1993</year>) <volume>75</volume>(<issue>2</issue>):<fpage>263</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/0092-8674(93)80068-P</pub-id><?supplied-pmid 8402911?><pub-id pub-id-type="pmid">8402911</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>DJ</given-names></name><name><surname>Davidson</surname><given-names>N</given-names></name><name><surname>Kuhn</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>W</given-names></name><name><surname>Menon</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses</article-title>. <source>J Clin Invest</source> (<year>1996</year>) <volume>98</volume>(<issue>4</issue>):<fpage>1010</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1172/Jci118861</pub-id><?supplied-pmid 8770874?><pub-id pub-id-type="pmid">8770874</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>NJ</given-names></name><name><surname>Leach</surname><given-names>MW</given-names></name><name><surname>Fort</surname><given-names>MM</given-names></name><name><surname>Thompson-Snipes</surname><given-names>L</given-names></name><name><surname>K&#252;hn</surname><given-names>R</given-names></name><name><surname>M&#252;ller</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice</article-title>. <source>J Exp Med</source> (<year>1996</year>) <volume>184</volume>(<issue>1</issue>):<fpage>241</fpage>.<pub-id pub-id-type="doi">10.1084/jem.184.1.241</pub-id><?supplied-pmid 8691138?><pub-id pub-id-type="pmid">8691138</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>Malefyt</surname><given-names>RD</given-names></name><name><surname>Coffman</surname><given-names>RL</given-names></name><name><surname>O&#8217;Garra</surname><given-names>A</given-names></name></person-group>
<article-title>Interleukin-10 and the interleukin-10 receptor</article-title>. <source>Annu Rev Immunol</source> (<year>2001</year>) <volume>19</volume>:<fpage>683</fpage>&#8211;<lpage>765</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.683</pub-id><pub-id pub-id-type="pmid">11244051</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shull</surname><given-names>MM</given-names></name><name><surname>Ormsby</surname><given-names>I</given-names></name><name><surname>Kier</surname><given-names>AB</given-names></name><name><surname>Pawlowski</surname><given-names>S</given-names></name><name><surname>Diebold</surname><given-names>RJ</given-names></name><name><surname>Yin</surname><given-names>MY</given-names></name><etal/></person-group>
<article-title>Targeted disruption of the mouse transforming growth factor-beta-1 gene results in multifocal inflammatory disease</article-title>. <source>Nature</source> (<year>1992</year>) <volume>359</volume>(<issue>6397</issue>):<fpage>693</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/359693a0</pub-id><pub-id pub-id-type="pmid">1436033</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>AB</given-names></name><name><surname>Huh</surname><given-names>CG</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Geiser</surname><given-names>A</given-names></name><name><surname>Lyght</surname><given-names>M</given-names></name><name><surname>Flanders</surname><given-names>KC</given-names></name><etal/></person-group>
<article-title>Transforming growth factor-beta-1 null mutation in mice causes excessive inflammatory response and early death</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1993</year>) <volume>90</volume>(<issue>2</issue>):<fpage>770</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.90.2.770</pub-id><pub-id pub-id-type="pmid">8421714</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorelik</surname><given-names>L</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group>
<article-title>Abrogation of TGF beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease</article-title>. <source>Immunity</source> (<year>2000</year>) <volume>12</volume>(<issue>2</issue>):<fpage>171</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80170-3</pub-id><pub-id pub-id-type="pmid">10714683</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>YG</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group>
<article-title>Mechanisms of TGF-beta signaling from cell membrane to the nucleus</article-title>. <source>Cell</source> (<year>2003</year>) <volume>113</volume>(<issue>6</issue>):<fpage>685</fpage>&#8211;<lpage>700</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(03)00432-X</pub-id><pub-id pub-id-type="pmid">12809600</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group>
<article-title>The biology of innate lymphoid cells</article-title>. <source>Nature</source> (<year>2015</year>) <volume>517</volume>(<issue>7534</issue>):<fpage>293</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="doi">10.1038/nature14189</pub-id><pub-id pub-id-type="pmid">25592534</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freud</surname><given-names>AG</given-names></name><name><surname>Yokohama</surname><given-names>A</given-names></name><name><surname>Becknell</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>MT</given-names></name><name><surname>Mao</surname><given-names>HC</given-names></name><name><surname>Ferketich</surname><given-names>AK</given-names></name><etal/></person-group>
<article-title>Evidence for discrete stages of human natural killer cell differentiation in vivo</article-title>. <source>J Exp Med</source> (<year>2006</year>) <volume>203</volume>(<issue>4</issue>):<fpage>1033</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20052507</pub-id><?supplied-pmid 16606675?><pub-id pub-id-type="pmid">16606675</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawai</surname><given-names>CM</given-names></name><name><surname>Babovic</surname><given-names>S</given-names></name><name><surname>Upadhaya</surname><given-names>S</given-names></name><name><surname>Knapp</surname><given-names>DJHF</given-names></name><name><surname>Lavin</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Hematopoietic stem cells are the major source of multilineage hematopoiesis in adult animals</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>(<issue>3</issue>):<fpage>597</fpage>&#8211;<lpage>609</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.007</pub-id><?supplied-pmid 27590115?><pub-id pub-id-type="pmid">27590115</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>SJ</given-names></name><name><surname>Zsebo</surname><given-names>KM</given-names></name><name><surname>Geissler</surname><given-names>EN</given-names></name></person-group>
<article-title>The kit-ligand, stem-cell factor</article-title>. <source>Adv Immunol</source> (<year>1994</year>) <volume>55</volume>:<fpage>1</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1016/S0065-2776(08)60508-8</pub-id><pub-id pub-id-type="pmid">7508174</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broudy</surname><given-names>VC</given-names></name></person-group>
<article-title>Stem cell factor and hematopoiesis</article-title>. <source>Blood</source> (<year>1997</year>) <volume>90</volume>(<issue>4</issue>):<fpage>1345</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">9269751</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>JG</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name></person-group>
<article-title>Transmembrane form of the kit ligand growth-factor is determined by alternative splicing and is missing in the Si(D) mutant</article-title>. <source>Cell</source> (<year>1991</year>) <volume>64</volume>(<issue>5</issue>):<fpage>1025</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1016/0092-8674(91)90326-T</pub-id><pub-id pub-id-type="pmid">1705866</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toksoz</surname><given-names>D</given-names></name><name><surname>Zsebo</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Brankow</surname><given-names>D</given-names></name><name><surname>Suggs</surname><given-names>SV</given-names></name><etal/></person-group>
<article-title>Support of human hematopoiesis in long-term bone-marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene-product, stem-cell factor</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1992</year>) <volume>89</volume>(<issue>16</issue>):<fpage>7350</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.89.16.7350</pub-id><pub-id pub-id-type="pmid">1380155</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waskow</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Haller</surname><given-names>C</given-names></name><name><surname>Gassmann</surname><given-names>M</given-names></name><name><surname>Rodewald</surname><given-names>HR</given-names></name></person-group>
<article-title>Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>17</volume>(<issue>3</issue>):<fpage>277</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(02)00386-2</pub-id><pub-id pub-id-type="pmid">12354381</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gwin</surname><given-names>KA</given-names></name><name><surname>Shapiro</surname><given-names>MB</given-names></name><name><surname>Dolence</surname><given-names>JJ</given-names></name><name><surname>Huang</surname><given-names>ZXL</given-names></name><name><surname>Medina</surname><given-names>KL</given-names></name></person-group>. <article-title>Hoxa9 and Flt3 signaling synergistically regulate an early checkpoint in lymphopoiesis</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>(<issue>2</issue>):<fpage>745</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1203294</pub-id><?supplied-pmid 23772038?><pub-id pub-id-type="pmid">23772038</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>HX</given-names></name><name><surname>Fehniger</surname><given-names>TA</given-names></name><name><surname>Fuchshuber</surname><given-names>P</given-names></name><name><surname>Thiel</surname><given-names>KS</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Carson</surname><given-names>WE</given-names></name><etal/></person-group>
<article-title>Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15</article-title>. <source>Blood</source> (<year>1998</year>) <volume>92</volume>(<issue>10</issue>):<fpage>3647</fpage>&#8211;<lpage>57</lpage>.<?supplied-pmid 9808558?><pub-id pub-id-type="pmid">9808558</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broughton</surname><given-names>SE</given-names></name><name><surname>Dhagat</surname><given-names>U</given-names></name><name><surname>Hercus</surname><given-names>TR</given-names></name><name><surname>Nero</surname><given-names>TL</given-names></name><name><surname>Grimbaldeston</surname><given-names>MA</given-names></name><name><surname>Bonder</surname><given-names>CS</given-names></name><etal/></person-group>
<article-title>The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling</article-title>. <source>Immunol Rev</source> (<year>2012</year>) <volume>250</volume>:<fpage>277</fpage>&#8211;<lpage>302</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01164.x</pub-id><?supplied-pmid 23046136?><pub-id pub-id-type="pmid">23046136</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>ZL</given-names></name><name><surname>de Bruijn</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>XQ</given-names></name><name><surname>Dortland</surname><given-names>B</given-names></name><name><surname>Luteijn</surname><given-names>T</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo</article-title>. <source>Immunity</source> (<year>2000</year>) <volume>13</volume>(<issue>4</issue>):<fpage>423</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)00042-X</pub-id><?supplied-pmid 11070161?><pub-id pub-id-type="pmid">11070161</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyajima</surname><given-names>A</given-names></name><name><surname>Mui</surname><given-names>ALF</given-names></name><name><surname>Ogorochi</surname><given-names>T</given-names></name><name><surname>Sakamaki</surname><given-names>K</given-names></name></person-group>
<article-title>Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5</article-title>. <source>Blood</source> (<year>1993</year>) <volume>82</volume>(<issue>7</issue>):<fpage>1960</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">8400249</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ihle</surname><given-names>JN</given-names></name></person-group>
<article-title>Cytokine receptor signaling</article-title>. <source>Nature</source> (<year>1995</year>) <volume>377</volume>(<issue>6550</issue>):<fpage>591</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/377591a0</pub-id><pub-id pub-id-type="pmid">7566171</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JS</given-names></name><name><surname>McCullar</surname><given-names>V</given-names></name><name><surname>Verfaillie</surname><given-names>CM</given-names></name></person-group>
<article-title>Ex vivo culture of CD34(+)/Lin(-)/DR- cells in stroma-derived soluble factors, interleukin-3, and macrophage inflammatory protein-1 alpha maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay</article-title>. <source>Blood</source> (<year>1998</year>) <volume>91</volume>(<issue>12</issue>):<fpage>4516</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">9616147</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JS</given-names></name><name><surname>McCullar</surname><given-names>V</given-names></name><name><surname>Punzel</surname><given-names>M</given-names></name><name><surname>Lemischka</surname><given-names>IR</given-names></name><name><surname>Moore</surname><given-names>KA</given-names></name></person-group>
<article-title>Single adult human CD34(+)/Lin(-)/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells</article-title>. <source>Blood</source> (<year>1999</year>) <volume>93</volume>(<issue>1</issue>):<fpage>96</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="pmid">9864151</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muench</surname><given-names>MO</given-names></name><name><surname>Humeau</surname><given-names>L</given-names></name><name><surname>Paek</surname><given-names>B</given-names></name><name><surname>Ohkubo</surname><given-names>T</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Albanese</surname><given-names>CT</given-names></name><etal/></person-group>
<article-title>Differential effects of interleukin-3, interleukin-7, interleukin 15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors</article-title>. <source>Exp Hematol</source> (<year>2000</year>) <volume>28</volume>(<issue>8</issue>):<fpage>961</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/S0301-472x(00)00490-2</pub-id><pub-id pub-id-type="pmid">10989197</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ficara</surname><given-names>F</given-names></name><name><surname>Superchi</surname><given-names>DB</given-names></name><name><surname>Hernandez</surname><given-names>RJ</given-names></name><name><surname>Mocchetti</surname><given-names>C</given-names></name><name><surname>Carballido-Perrig</surname><given-names>N</given-names></name><name><surname>Andolfi</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34(+) cells while maintaining in vivo lymphoid potential</article-title>. <source>Mol Ther</source> (<year>2004</year>) <volume>10</volume>(<issue>6</issue>):<fpage>1096</fpage>&#8211;<lpage>108</lpage>.<pub-id pub-id-type="doi">10.1016/j.ymthe.2004.08.014</pub-id><pub-id pub-id-type="pmid">15564141</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenbaum</surname><given-names>A</given-names></name><name><surname>Hsu</surname><given-names>YMS</given-names></name><name><surname>Day</surname><given-names>RB</given-names></name><name><surname>Schuettpelz</surname><given-names>LG</given-names></name><name><surname>Christopher</surname><given-names>MJ</given-names></name><name><surname>Borgerding</surname><given-names>JN</given-names></name><etal/></person-group>
<article-title>CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance</article-title>. <source>Nature</source> (<year>2013</year>) <volume>495</volume>(<issue>7440</issue>):<fpage>227</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1038/nature11926</pub-id><?supplied-pmid 23434756?><pub-id pub-id-type="pmid">23434756</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunisaki</surname><given-names>Y</given-names></name><name><surname>Bruns</surname><given-names>I</given-names></name><name><surname>Scheiermann</surname><given-names>C</given-names></name><name><surname>Ahmed</surname><given-names>J</given-names></name><name><surname>Pinho</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>DC</given-names></name><etal/></person-group>
<article-title>Arteriolar niches maintain haematopoietic stem cell quiescence</article-title>. <source>Nature</source> (<year>2013</year>) <volume>502</volume>(<issue>7473</issue>):<fpage>637</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1038/nature12612</pub-id><pub-id pub-id-type="pmid">24107994</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>AC</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Lim</surname><given-names>VY</given-names></name><name><surname>Herndler-Brandstetter</surname><given-names>D</given-names></name><name><surname>Nevius</surname><given-names>E</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Hematopoietic stem cell niches produce lineage-instructive signals to control multipotent progenitor differentiation</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>45</volume>(<issue>6</issue>):<fpage>1219</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2016.11.004</pub-id><?supplied-pmid 27913094?><pub-id pub-id-type="pmid">27913094</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzucchelli</surname><given-names>R</given-names></name><name><surname>Durum</surname><given-names>SK</given-names></name></person-group>. <article-title>Interleukin-7 receptor expression: intelligent design</article-title>. <source>Nat Rev Immunol</source> (<year>2007</year>) <volume>7</volume>(<issue>2</issue>):<fpage>144</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1038/nri2023</pub-id><?supplied-pmid 17259970?><pub-id pub-id-type="pmid">17259970</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>K</given-names></name><name><surname>Jameson</surname><given-names>SC</given-names></name></person-group>. <article-title>Naive T cell homeostasis: from awareness of space to a sense of place</article-title>. <source>Nat Rev Immunol</source> (<year>2009</year>) <volume>9</volume>(<issue>12</issue>):<fpage>823</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1038/nri2657</pub-id><?supplied-pmid 19935802?><pub-id pub-id-type="pmid">19935802</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>WJ</given-names></name></person-group>. <article-title>Cytokines and immunodeficiency diseases</article-title>. <source>Nat Rev Immunol</source> (<year>2001</year>) <volume>1</volume>(<issue>3</issue>):<fpage>200</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/35105066</pub-id><?supplied-pmid 11905829?><pub-id pub-id-type="pmid">11905829</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>RH</given-names></name></person-group>. <article-title>Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution</article-title>. <source>Annu Rev Immunol</source> (<year>2004</year>) <volume>22</volume>:<fpage>625</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104614</pub-id><?supplied-pmid 15032591?><pub-id pub-id-type="pmid">15032591</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Bush</surname><given-names>JE</given-names></name><name><surname>Fehniger</surname><given-names>TA</given-names></name><name><surname>VanDeusen</surname><given-names>JB</given-names></name><name><surname>Waite</surname><given-names>RE</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells</article-title>. <source>Blood</source> (<year>2002</year>) <volume>100</volume>(<issue>10</issue>):<fpage>3633</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2001-12-0293</pub-id><?supplied-pmid 12393617?><pub-id pub-id-type="pmid">12393617</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koka</surname><given-names>R</given-names></name><name><surname>Burkett</surname><given-names>PR</given-names></name><name><surname>Chien</surname><given-names>M</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>F</given-names></name><name><surname>Lodolce</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Interleukin (IL)-15R&#945;-deficient natural killer cells survive in normal but not IL-15R&#945;-deficient mice</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>197</volume>(<issue>8</issue>):<fpage>977</fpage><pub-id pub-id-type="doi">10.1084/jem.20021836</pub-id><pub-id pub-id-type="pmid">12695489</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Sun</surname><given-names>SQ</given-names></name><name><surname>Hwang</surname><given-names>IK</given-names></name><name><surname>Tough</surname><given-names>DF</given-names></name><name><surname>Sprent</surname><given-names>J</given-names></name></person-group>
<article-title>Potent and selective stimulation of memory-phenotype CD8(+) T cells in vivo by IL-15</article-title>. <source>Immunity</source> (<year>1998</year>) <volume>8</volume>(<issue>5</issue>):<fpage>591</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80564-6</pub-id><pub-id pub-id-type="pmid">9620680</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname><given-names>CC</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Sakamato</surname><given-names>A</given-names></name><name><surname>Kappler</surname><given-names>J</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name></person-group>
<article-title>Control of homeostasis of CD8(+) memory T cells by opposing cytokines</article-title>. <source>Science</source> (<year>2000</year>) <volume>288</volume>(<issue>5466</issue>):<fpage>675</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.288.5466.675</pub-id><pub-id pub-id-type="pmid">10784451</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>JL</given-names></name><name><surname>Gapin</surname><given-names>L</given-names></name><name><surname>Sidobre</surname><given-names>S</given-names></name><name><surname>Kieper</surname><given-names>WC</given-names></name><name><surname>Tan</surname><given-names>JYT</given-names></name><name><surname>Ceredig</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Homeostasis of V(alpha)14i NKT cells</article-title>. <source>Nat Immunol</source> (<year>2002</year>) <volume>3</volume>(<issue>10</issue>):<fpage>966</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1038/ni837</pub-id><pub-id pub-id-type="pmid">12244311</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becknell</surname><given-names>B</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name></person-group>. <article-title>Interleukin-2, interleukin-15, and their roles in human natural killer cells</article-title>. <source>Adv Immunol</source> (<year>2005</year>) <volume>86</volume>:<fpage>209</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1016/S0065-2776(04)86006-1</pub-id><?supplied-pmid 15705423?><pub-id pub-id-type="pmid">15705423</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giri</surname><given-names>JG</given-names></name><name><surname>Ahdieh</surname><given-names>M</given-names></name><name><surname>Eisenman</surname><given-names>J</given-names></name><name><surname>Shanebeck</surname><given-names>K</given-names></name><name><surname>Grabstein</surname><given-names>K</given-names></name><name><surname>Kumaki</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Utilization of the beta-chain and gamma-chain of the Il-2 receptor by the novel cytokine-Il-15</article-title>. <source>EMBO J</source> (<year>1994</year>) <volume>13</volume>(<issue>12</issue>):<fpage>2822</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">8026467</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabstein</surname><given-names>KH</given-names></name><name><surname>Eisenman</surname><given-names>J</given-names></name><name><surname>Shanebeck</surname><given-names>K</given-names></name><name><surname>Rauch</surname><given-names>C</given-names></name><name><surname>Srinivasan</surname><given-names>S</given-names></name><name><surname>Fung</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Cloning of a T-cell growth-factor that interacts with the beta-chain of the interleukin-2 receptor</article-title>. <source>Science</source> (<year>1994</year>) <volume>264</volume>(<issue>5161</issue>):<fpage>965</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1126/science.8178155</pub-id><pub-id pub-id-type="pmid">8178155</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JS</given-names></name><name><surname>Alley</surname><given-names>KA</given-names></name><name><surname>Mcglave</surname><given-names>P</given-names></name></person-group>
<article-title>Differentiation of natural-killer (Nk) cells from human primitive marrow progenitors in a stroma-based long-term culture system &#8211; identification of a Cd34(+)7(+) NK progenitor</article-title>. <source>Blood</source> (<year>1994</year>) <volume>83</volume>(<issue>9</issue>):<fpage>2594</fpage>&#8211;<lpage>601</lpage>.<pub-id pub-id-type="pmid">7513206</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freud</surname><given-names>AG</given-names></name><name><surname>Becknell</surname><given-names>B</given-names></name><name><surname>Roychowdhury</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>HC</given-names></name><name><surname>Ferketich</surname><given-names>AK</given-names></name><name><surname>Nuovo</surname><given-names>GJ</given-names></name><etal/></person-group>
<article-title>A human CD34(+) subset resides in lymph nodes and differentiates into CD56(bright) natural killer cells</article-title>. <source>Immunity</source> (<year>2005</year>) <volume>22</volume>(<issue>3</issue>):<fpage>295</fpage>&#8211;<lpage>304</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2005.01.013</pub-id><pub-id pub-id-type="pmid">15780987</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>S</given-names></name><name><surname>Mariner</surname><given-names>J</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Tagaya</surname><given-names>Y</given-names></name></person-group>. <article-title>IL-15R alpha recycles and presents IL-15 in trans to neighboring cells</article-title>. <source>Immunity</source> (<year>2002</year>) <volume>17</volume>(<issue>5</issue>):<fpage>537</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(02)00429-6</pub-id><?supplied-pmid 12433361?><pub-id pub-id-type="pmid">12433361</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkett</surname><given-names>PR</given-names></name><name><surname>Koka</surname><given-names>R</given-names></name><name><surname>Chien</surname><given-names>M</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Boone</surname><given-names>DL</given-names></name><name><surname>Ma</surname><given-names>A</given-names></name></person-group>
<article-title>Coordinate expression and trans presentation of interleukin (IL)-15R alpha and IL-15 supports natural killer cell and memory CD8(+) T cell homeostasis</article-title>. <source>J Exp Med</source> (<year>2004</year>) <volume>200</volume>(<issue>7</issue>):<fpage>825</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20041389</pub-id><pub-id pub-id-type="pmid">15452177</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortier</surname><given-names>E</given-names></name><name><surname>Woo</surname><given-names>T</given-names></name><name><surname>Advincula</surname><given-names>R</given-names></name><name><surname>Gozalo</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>A</given-names></name></person-group>. <article-title>IL-15R alpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation</article-title>. <source>J Exp Med</source> (<year>2008</year>) <volume>205</volume>(<issue>5</issue>):<fpage>1213</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20071913</pub-id><?supplied-pmid 18458113?><pub-id pub-id-type="pmid">18458113</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huntington</surname><given-names>ND</given-names></name><name><surname>Legrand</surname><given-names>N</given-names></name><name><surname>Alves</surname><given-names>NL</given-names></name><name><surname>Jaron</surname><given-names>B</given-names></name><name><surname>Weijer</surname><given-names>K</given-names></name><name><surname>Plet</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>IL-15 trans-presentation promotes human NK cell development and differentiation in vivo</article-title>. <source>J Exp Med</source> (<year>2009</year>) <volume>206</volume>(<issue>1</issue>):<fpage>25</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20082013</pub-id><?supplied-pmid 19103877?><pub-id pub-id-type="pmid">19103877</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobbala</surname><given-names>D</given-names></name><name><surname>Mayhue</surname><given-names>M</given-names></name><name><surname>Menendez</surname><given-names>A</given-names></name><name><surname>Ilangumaran</surname><given-names>S</given-names></name><name><surname>Ramanathan</surname><given-names>S</given-names></name></person-group>
<article-title>Trans-presentation of interleukin-15 by interleukin-15 receptor alpha is dispensable for the pathogenesis of autoimmune type 1 diabetes</article-title>. <source>Cell Mol Immunol</source> (<year>2017</year>) <volume>14</volume>(<issue>7</issue>):<fpage>590</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2015.102</pub-id><pub-id pub-id-type="pmid">26853723</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>M</given-names></name><name><surname>Shook</surname><given-names>D</given-names></name><name><surname>Kamiya</surname><given-names>T</given-names></name><name><surname>Shimasaki</surname><given-names>N</given-names></name><name><surname>Chai</surname><given-names>SMH</given-names></name><name><surname>Coustan-Smith</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15</article-title>. <source>Blood</source> (<year>2014</year>) <volume>124</volume>(<issue>7</issue>):<fpage>1081</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2014-02-556837</pub-id><?supplied-pmid 25006133?><pub-id pub-id-type="pmid">25006133</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>AK</given-names></name><name><surname>Nandagopal</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group>. <article-title>IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells</article-title>. <source>Front Immunol</source> (<year>2015</year>) <volume>6</volume>:<fpage>355</fpage>.<pub-id pub-id-type="doi">10.3389/Fimmu.2015.00355</pub-id><?supplied-pmid 26257729?><pub-id pub-id-type="pmid">26257729</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imada</surname><given-names>K</given-names></name><name><surname>Bloom</surname><given-names>ET</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Horvath-Arcidiacono</surname><given-names>JA</given-names></name><name><surname>Udy</surname><given-names>GB</given-names></name><name><surname>Davey</surname><given-names>HW</given-names></name><etal/></person-group>
<article-title>Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity</article-title>. <source>J Exp Med</source> (<year>1998</year>) <volume>188</volume>(<issue>11</issue>):<fpage>2067</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1084/jem.188.11.2067</pub-id><pub-id pub-id-type="pmid">9841920</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Topham</surname><given-names>DJ</given-names></name><name><surname>Teglund</surname><given-names>S</given-names></name><name><surname>Sexl</surname><given-names>V</given-names></name><name><surname>McKay</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells</article-title>. <source>Immunity</source> (<year>1999</year>) <volume>10</volume>(<issue>2</issue>):<fpage>249</fpage>&#8211;<lpage>59</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80025-4</pub-id><?supplied-pmid 10072077?><pub-id pub-id-type="pmid">10072077</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckelhart</surname><given-names>E</given-names></name><name><surname>Warsch</surname><given-names>W</given-names></name><name><surname>Zebedin</surname><given-names>E</given-names></name><name><surname>Simma</surname><given-names>O</given-names></name><name><surname>Stoiber</surname><given-names>D</given-names></name><name><surname>Kolbe</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>(<issue>5</issue>):<fpage>1565</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-06-291633</pub-id><?supplied-pmid 21127177?><pub-id pub-id-type="pmid">21127177</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernasconi</surname><given-names>A</given-names></name><name><surname>Marino</surname><given-names>R</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>J</given-names></name><name><surname>Ciaccio</surname><given-names>M</given-names></name><name><surname>Oleastro</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation</article-title>. <source>Pediatrics</source> (<year>2006</year>) <volume>118</volume>(<issue>5</issue>):<fpage>e1584</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1542/peds.2005-2882</pub-id><?supplied-pmid 17030597?><pub-id pub-id-type="pmid">17030597</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>MX</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>ZZ</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name><name><surname>Dong</surname><given-names>ZJ</given-names></name></person-group>. <article-title>PDK1 orchestrates early NK cell development through induction of E4BP4 expression and maintenance of IL-15 responsiveness</article-title>. <source>J Exp Med</source> (<year>2015</year>) <volume>212</volume>(<issue>2</issue>):<fpage>253</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20141703</pub-id><?supplied-pmid 25624444?><pub-id pub-id-type="pmid">25624444</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>Y</given-names></name><name><surname>Mansouri</surname><given-names>A</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Sugawara</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>S</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2</article-title>. <source>Nature</source> (<year>1999</year>) <volume>397</volume>(<issue>6721</issue>):<fpage>702</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/17812</pub-id><?supplied-pmid 10067894?><pub-id pub-id-type="pmid">10067894</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boos</surname><given-names>MD</given-names></name><name><surname>Yokota</surname><given-names>Y</given-names></name><name><surname>Eberl</surname><given-names>G</given-names></name><name><surname>Kee</surname><given-names>BL</given-names></name></person-group>. <article-title>Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity</article-title>. <source>J Exp Med</source> (<year>2007</year>) <volume>204</volume>(<issue>5</issue>):<fpage>1119</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20061959</pub-id><?supplied-pmid 17452521?><pub-id pub-id-type="pmid">17452521</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delconte</surname><given-names>RB</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Sathe</surname><given-names>P</given-names></name><name><surname>Ushiki</surname><given-names>T</given-names></name><name><surname>Seillet</surname><given-names>C</given-names></name><name><surname>Minnich</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The helix-loop-helix protein ID2 governs NK cell fate by tuning their sensitivity to interleukin-15</article-title>. <source>Immunity</source> (<year>2016</year>) <volume>44</volume>(<issue>1</issue>):<fpage>103</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.12.007</pub-id><pub-id pub-id-type="pmid">26795246</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>BQ</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name><name><surname>Wei</surname><given-names>HM</given-names></name></person-group>. <article-title>Subsets of human natural killer cells and their regulatory effects</article-title>. <source>Immunology</source> (<year>2014</year>) <volume>141</volume>(<issue>4</issue>):<fpage>483</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/imm.12224</pub-id><?supplied-pmid 24303897?><pub-id pub-id-type="pmid">24303897</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehniger</surname><given-names>TA</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Nuovo</surname><given-names>GJ</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>CD56(bright) natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>(<issue>8</issue>):<fpage>3052</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2002-09-2876</pub-id><pub-id pub-id-type="pmid">12480696</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walzer</surname><given-names>T</given-names></name><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Robbins</surname><given-names>SH</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name></person-group>
<article-title>Natural-killer cells and dendritic cells: &#8220;l&#8217; union fait la force&#8221;</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>7</issue>):<fpage>2252</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2005-03-1154</pub-id><pub-id pub-id-type="pmid">15933055</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>EO</given-names></name></person-group>. <article-title>Ready for prime time: NK cell priming by dendritic cells</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>26</volume>(<issue>4</issue>):<fpage>385</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2007.04.001</pub-id><?supplied-pmid 17459805?><pub-id pub-id-type="pmid">17459805</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>EO</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>ME</given-names></name><name><surname>Rajagopalan</surname><given-names>S</given-names></name></person-group>. <article-title>Controlling natural killer cell responses: integration of signals for activation and inhibition</article-title>. <source>Annu Rev Immunol</source> (<year>2013</year>) <volume>31</volume>:<fpage>227</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075005</pub-id><?supplied-pmid 23516982?><pub-id pub-id-type="pmid">23516982</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matek</surname><given-names>TR</given-names></name></person-group>. <article-title>The biology of interleukin-2</article-title>. <source>Annu Rev Immunol</source> (<year>2008</year>) <volume>26</volume>:<fpage>453</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090357</pub-id><?supplied-pmid 18062768?><pub-id pub-id-type="pmid">18062768</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinchieri</surname><given-names>G</given-names></name></person-group>
<article-title>Biology of natural-killer cells</article-title>. <source>Adv Immunol</source> (<year>1989</year>) <volume>47</volume>:<fpage>187</fpage>&#8211;<lpage>376</lpage>.<pub-id pub-id-type="doi">10.1016/S0065-2776(08)60664-1</pub-id><pub-id pub-id-type="pmid">2683611</pub-id></mixed-citation></ref><ref id="B148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minagawa</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Miyaji</surname><given-names>C</given-names></name><name><surname>Tomiyama</surname><given-names>K</given-names></name><name><surname>Shimura</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor beta-chain-deficient mice</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>169</volume>(<issue>8</issue>):<fpage>4153</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.169.8.4153</pub-id><?supplied-pmid 12370344?><pub-id pub-id-type="pmid">12370344</pub-id></mixed-citation></ref><ref id="B149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HM</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name></person-group>
<article-title>The interleukin-2 receptor &#8211; functional consequences of its bimolecular structure</article-title>. <source>J Exp Med</source> (<year>1987</year>) <volume>166</volume>(<issue>4</issue>):<fpage>1055</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1084/jem.166.4.1055</pub-id><pub-id pub-id-type="pmid">3116143</pub-id></mixed-citation></ref><ref id="B150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeshita</surname><given-names>T</given-names></name><name><surname>Asao</surname><given-names>H</given-names></name><name><surname>Ohtani</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Kumaki</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Cloning of the gamma-chain of the human Il-2 receptor</article-title>. <source>Science</source> (<year>1992</year>) <volume>257</volume>(<issue>5068</issue>):<fpage>379</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1126/science.1631559</pub-id><pub-id pub-id-type="pmid">1631559</pub-id></mixed-citation></ref><ref id="B151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickert</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>XQ</given-names></name><name><surname>Boulanger</surname><given-names>MJ</given-names></name><name><surname>Goriatcheva</surname><given-names>N</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group>. <article-title>The structure of interleukin-2 complexed with its alpha receptor</article-title>. <source>Science</source> (<year>2005</year>) <volume>308</volume>(<issue>5727</issue>):<fpage>1477</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1126/science.1109745</pub-id><?supplied-pmid 15933202?><pub-id pub-id-type="pmid">15933202</pub-id></mixed-citation></ref><ref id="B152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>AM</given-names></name><name><surname>Bates</surname><given-names>DL</given-names></name><name><surname>Ring</surname><given-names>AM</given-names></name><name><surname>Krieg</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>JT</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Exploiting a natural conformational switch to engineer an interleukin-2 &#8216;superkine&#8217;</article-title>. <source>Nature</source> (<year>2012</year>) <volume>484</volume>(<issue>7395</issue>):<fpage>529</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1038/nature10975</pub-id><?supplied-pmid 22446627?><pub-id pub-id-type="pmid">22446627</pub-id></mixed-citation></ref><ref id="B153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Stojanovic</surname><given-names>A</given-names></name><name><surname>Garbi</surname><given-names>N</given-names></name><name><surname>Cerwenka</surname><given-names>A</given-names></name></person-group>. <article-title>Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>(<issue>13</issue>):<fpage>2351</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20120944</pub-id><?supplied-pmid 23209317?><pub-id pub-id-type="pmid">23209317</pub-id></mixed-citation></ref><ref id="B154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>JW</given-names></name><name><surname>Chase</surname><given-names>JM</given-names></name><name><surname>Romee</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>SE</given-names></name><name><surname>Sullivan</surname><given-names>RP</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells</article-title>. <source>Biol Blood Marrow Transplant</source> (<year>2014</year>) <volume>20</volume>(<issue>4</issue>):<fpage>463</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbmt.2014.01.006</pub-id><pub-id pub-id-type="pmid">24434782</pub-id></mixed-citation></ref><ref id="B155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sitrin</surname><given-names>J</given-names></name><name><surname>Ring</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group>. <article-title>Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2</article-title>. <source>J Exp Med</source> (<year>2013</year>) <volume>210</volume>(<issue>6</issue>):<fpage>1153</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20122248</pub-id><?supplied-pmid 23650440?><pub-id pub-id-type="pmid">23650440</pub-id></mixed-citation></ref><ref id="B156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Perry</surname><given-names>JSA</given-names></name><name><surname>Jakhete</surname><given-names>NR</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bielekova</surname><given-names>B</given-names></name></person-group>. <article-title>An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells</article-title>. <source>J Immunol</source> (<year>2010</year>) <volume>185</volume>(<issue>2</issue>):<fpage>1311</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0902238</pub-id><?supplied-pmid 20543101?><pub-id pub-id-type="pmid">20543101</pub-id></mixed-citation></ref><ref id="B157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>GC</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Creasy</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>IL-2 variant circumvents ICOS+ regulatory T cell expansion and promotes NK cell activation</article-title>. <source>Cancer Immunol Res</source> (<year>2016</year>) <volume>4</volume>(<issue>11</issue>):<fpage>983</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0195</pub-id><pub-id pub-id-type="pmid">27697858</pub-id></mixed-citation></ref><ref id="B158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>JD</given-names></name><name><surname>Bamford</surname><given-names>RN</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>AJ</given-names></name><name><surname>Kurys</surname><given-names>G</given-names></name><name><surname>Goldman</surname><given-names>CK</given-names></name><etal/></person-group>
<article-title>A lymphokine, provisionally designated interleukin-T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer-cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1994</year>) <volume>91</volume>(<issue>11</issue>):<fpage>4935</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.91.11.4935</pub-id><pub-id pub-id-type="pmid">8197160</pub-id></mixed-citation></ref><ref id="B159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>WE</given-names></name><name><surname>Giri</surname><given-names>JG</given-names></name><name><surname>Lindemann</surname><given-names>MJ</given-names></name><name><surname>Linett</surname><given-names>ML</given-names></name><name><surname>Ahdieh</surname><given-names>M</given-names></name><name><surname>Paxton</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Interleukin (Il)-15 is a novel cytokine that activates human natural-killer-cells via components of the Il-2 receptor</article-title>. <source>J Exp Med</source> (<year>1994</year>) <volume>180</volume>(<issue>4</issue>):<fpage>1395</fpage>&#8211;<lpage>403</lpage>.<pub-id pub-id-type="doi">10.1084/jem.180.4.1395</pub-id><pub-id pub-id-type="pmid">7523571</pub-id></mixed-citation></ref><ref id="B160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>Koka</surname><given-names>R</given-names></name><name><surname>Burkett</surname><given-names>P</given-names></name></person-group>
<article-title>Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis</article-title>. <source>Annu Rev Immunol</source> (<year>2006</year>) <volume>24</volume>:<fpage>657</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.24.021605.090727</pub-id><pub-id pub-id-type="pmid">16551262</pub-id></mixed-citation></ref><ref id="B161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamford</surname><given-names>RN</given-names></name><name><surname>Grant</surname><given-names>AJ</given-names></name><name><surname>Burton</surname><given-names>JD</given-names></name><name><surname>Peters</surname><given-names>C</given-names></name><name><surname>Kurys</surname><given-names>G</given-names></name><name><surname>Goldman</surname><given-names>CK</given-names></name><etal/></person-group>
<article-title>The interleukin (Il)-2 receptor-beta chain is shared by Il-2 and a cytokine, provisionally designated Il-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer-cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1994</year>) <volume>91</volume>(<issue>11</issue>):<fpage>4940</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.91.11.4940</pub-id><pub-id pub-id-type="pmid">8197161</pub-id></mixed-citation></ref><ref id="B162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giri</surname><given-names>JG</given-names></name><name><surname>Kumaki</surname><given-names>S</given-names></name><name><surname>Ahdieh</surname><given-names>M</given-names></name><name><surname>Friend</surname><given-names>DJ</given-names></name><name><surname>Loomis</surname><given-names>A</given-names></name><name><surname>Shanebeck</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Identification and cloning of a novel Il-15 binding-protein that is structurally related to the alpha-chain of the Il-2 receptor</article-title>. <source>EMBO J</source> (<year>1995</year>) <volume>14</volume>(<issue>15</issue>):<fpage>3654</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">7641685</pub-id></mixed-citation></ref><ref id="B163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehniger</surname><given-names>TA</given-names></name><name><surname>Shah</surname><given-names>MH</given-names></name><name><surname>Turner</surname><given-names>MJ</given-names></name><name><surname>VanDeusen</surname><given-names>JB</given-names></name><name><surname>Whitman</surname><given-names>SP</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>162</volume>(<issue>8</issue>):<fpage>4511</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">10201989</pub-id></mixed-citation></ref><ref id="B164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>M</given-names></name><name><surname>Schachterle</surname><given-names>W</given-names></name><name><surname>Oberle</surname><given-names>K</given-names></name><name><surname>Aichele</surname><given-names>P</given-names></name><name><surname>Diefenbach</surname><given-names>A</given-names></name></person-group>. <article-title>Dendritic cells prime natural killer cells by trans-presenting interleukin 15</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>26</volume>(<issue>4</issue>):<fpage>503</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2007.03.006</pub-id><?supplied-pmid 17398124?><pub-id pub-id-type="pmid">17398124</pub-id></mixed-citation></ref><ref id="B165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandagopal</surname><given-names>N</given-names></name><name><surname>Ali</surname><given-names>AK</given-names></name><name><surname>Komal</surname><given-names>AK</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name></person-group>. <article-title>The critical role of IL-15-PI3K-mTOR pathway in natural killer cell effector functions</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<fpage>187</fpage>.<pub-id pub-id-type="doi">10.3389/Fimmu.2014.00187</pub-id><?supplied-pmid 24795729?><pub-id pub-id-type="pmid">24795729</pub-id></mixed-citation></ref><ref id="B166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehniger</surname><given-names>TA</given-names></name><name><surname>Cai</surname><given-names>SF</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Bredemeyer</surname><given-names>AJ</given-names></name><name><surname>Presti</surname><given-names>RI</given-names></name><name><surname>French</surname><given-names>AR</given-names></name><etal/></person-group>
<article-title>Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>26</volume>(<issue>6</issue>):<fpage>798</fpage>&#8211;<lpage>811</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2007.04.010</pub-id><?supplied-pmid 17540585?><pub-id pub-id-type="pmid">17540585</pub-id></mixed-citation></ref><ref id="B167"><label>167</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marais</surname><given-names>A</given-names></name><name><surname>Cherfils-Vicini</surname><given-names>J</given-names></name><name><surname>Viant</surname><given-names>C</given-names></name><name><surname>Degouve</surname><given-names>S</given-names></name><name><surname>Viel</surname><given-names>S</given-names></name><name><surname>Fenis</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells</article-title>. <source>Nat Immunol</source> (<year>2014</year>) <volume>15</volume>(<issue>8</issue>):<fpage>749</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2936</pub-id><?supplied-pmid 24973821?><pub-id pub-id-type="pmid">24973821</pub-id></mixed-citation></ref><ref id="B168"><label>168</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>YM</given-names></name><name><surname>van Hoef</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>XN</given-names></name><name><surname>Wennerberg</surname><given-names>E</given-names></name><name><surname>Lorent</surname><given-names>J</given-names></name><name><surname>Witt</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells</article-title>. <source>Blood</source> (<year>2016</year>) <volume>128</volume>(<issue>11</issue>):<fpage>1475</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2016-02-698027</pub-id><?supplied-pmid 27465917?><pub-id pub-id-type="pmid">27465917</pub-id></mixed-citation></ref><ref id="B169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Fitz</surname><given-names>L</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Hewick</surname><given-names>RM</given-names></name><name><surname>Clark</surname><given-names>SC</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Identification and purification of natural-killer cell stimulatory factor (Nksf), a cytokine with multiple biologic effects on human-lymphocytes</article-title>. <source>J Exp Med</source> (<year>1989</year>) <volume>170</volume>(<issue>3</issue>):<fpage>827</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1084/jem.170.3.827</pub-id><pub-id pub-id-type="pmid">2504877</pub-id></mixed-citation></ref><ref id="B170"><label>170</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalah</surname><given-names>R</given-names></name><name><surname>Rosati</surname><given-names>M</given-names></name><name><surname>Ganneru</surname><given-names>B</given-names></name><name><surname>Pilkington</surname><given-names>GR</given-names></name><name><surname>Valentin</surname><given-names>A</given-names></name><name><surname>Kulkarni</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit implications for improved IL-12 cytokine production</article-title>. <source>J Biol Chem</source> (<year>2013</year>) <volume>288</volume>(<issue>9</issue>):<fpage>6763</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M112.436675</pub-id><pub-id pub-id-type="pmid">23297419</pub-id></mixed-citation></ref><ref id="B171"><label>171</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CS</given-names></name><name><surname>Macatonia</surname><given-names>SE</given-names></name><name><surname>Tripp</surname><given-names>CS</given-names></name><name><surname>Wolf</surname><given-names>SF</given-names></name><name><surname>Ogarra</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group>
<article-title>Development of Th1 Cd4+ T-cells through Il-12 produced by <italic>Listeria</italic>-induced macrophages</article-title>. <source>Science</source> (<year>1993</year>) <volume>260</volume>(<issue>5107</issue>):<fpage>547</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1126/science.8097338</pub-id><pub-id pub-id-type="pmid">8097338</pub-id></mixed-citation></ref><ref id="B172"><label>172</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macatonia</surname><given-names>SE</given-names></name><name><surname>Hosken</surname><given-names>NA</given-names></name><name><surname>Litton</surname><given-names>M</given-names></name><name><surname>Vieira</surname><given-names>P</given-names></name><name><surname>Hsieh</surname><given-names>CS</given-names></name><name><surname>Culpepper</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Dendritic cells produce Il-12 and direct the development of Th1&#8201;cells from naive Cd4(+) T-cells</article-title>. <source>J Immunol</source> (<year>1995</year>) <volume>154</volume>(<issue>10</issue>):<fpage>5071</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7730613</pub-id></mixed-citation></ref><ref id="B173"><label>173</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Scheidegger</surname><given-names>D</given-names></name><name><surname>PalmerLehmann</surname><given-names>K</given-names></name><name><surname>Lane</surname><given-names>P</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Alber</surname><given-names>G</given-names></name></person-group>
<article-title>Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation</article-title>. <source>J Exp Med</source> (<year>1996</year>) <volume>184</volume>(<issue>2</issue>):<fpage>747</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1084/jem.184.2.747</pub-id><pub-id pub-id-type="pmid">8760829</pub-id></mixed-citation></ref><ref id="B174"><label>174</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>CA</given-names></name></person-group>. <article-title>New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>(<issue>7</issue>):<fpage>521</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1038/nri1648</pub-id><?supplied-pmid 15999093?><pub-id pub-id-type="pmid">15999093</pub-id></mixed-citation></ref><ref id="B175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Leary</surname><given-names>JG</given-names></name><name><surname>Goodarzi</surname><given-names>M</given-names></name><name><surname>Drayton</surname><given-names>DL</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group>. <article-title>T cell- and B cell-independent adaptive immunity mediated by natural killer cells</article-title>. <source>Nat Immunol</source> (<year>2006</year>) <volume>7</volume>(<issue>5</issue>):<fpage>507</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1038/ni1332</pub-id><?supplied-pmid 16617337?><pub-id pub-id-type="pmid">16617337</pub-id></mixed-citation></ref><ref id="B176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Madera</surname><given-names>S</given-names></name><name><surname>Bezman</surname><given-names>NA</given-names></name><name><surname>Beilke</surname><given-names>JN</given-names></name><name><surname>Kaplan</surname><given-names>MH</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group>
<article-title>Proinflammatory cytokine signaling required for the generation of natural killer cell memory</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>(<issue>5</issue>):<fpage>947</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20111760</pub-id><pub-id pub-id-type="pmid">22493516</pub-id></mixed-citation></ref><ref id="B177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paust</surname><given-names>S</given-names></name><name><surname>Gill</surname><given-names>HS</given-names></name><name><surname>Wang</surname><given-names>BZ</given-names></name><name><surname>Flynn</surname><given-names>MP</given-names></name><name><surname>Moseman</surname><given-names>EA</given-names></name><name><surname>Senman</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>(<issue>12</issue>):<fpage>1127</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1953</pub-id><?supplied-pmid 20972432?><pub-id pub-id-type="pmid">20972432</pub-id></mixed-citation></ref><ref id="B178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>JC</given-names></name><name><surname>Beilke</surname><given-names>JN</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group>. <article-title>Immune memory redefined: characterizing the longevity of natural killer cells</article-title>. <source>Immunol Rev</source> (<year>2010</year>) <volume>236</volume>:<fpage>83</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00900.x</pub-id><?supplied-pmid 20636810?><pub-id pub-id-type="pmid">20636810</pub-id></mixed-citation></ref><ref id="B179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E</given-names></name><name><surname>Raulet</surname><given-names>DH</given-names></name><name><surname>Moretta</surname><given-names>A</given-names></name><name><surname>Caligiuri</surname><given-names>MA</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><etal/></person-group>
<article-title>Innate or adaptive immunity? The example of natural killer cells</article-title>. <source>Science</source> (<year>2011</year>) <volume>331</volume>(<issue>6013</issue>):<fpage>44</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1126/science.1198687</pub-id><?supplied-pmid 21212348?><pub-id pub-id-type="pmid">21212348</pub-id></mixed-citation></ref><ref id="B180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Elliott</surname><given-names>JM</given-names></name><name><surname>Keyel</surname><given-names>PA</given-names></name><name><surname>Yang</surname><given-names>LP</given-names></name><name><surname>Carrero</surname><given-names>JA</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name></person-group>
<article-title>Cytokine-induced memory-like natural killer cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2009</year>) <volume>106</volume>(<issue>6</issue>):<fpage>1915</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0813192106</pub-id><pub-id pub-id-type="pmid">19181844</pub-id></mixed-citation></ref><ref id="B181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romee</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>SE</given-names></name><name><surname>Leong</surname><given-names>JW</given-names></name><name><surname>Chase</surname><given-names>JM</given-names></name><name><surname>Keppel</surname><given-names>CR</given-names></name><name><surname>Sullivan</surname><given-names>RP</given-names></name><etal/></person-group>
<article-title>Cytokine activation induces human memory-like NK cells</article-title>. <source>Blood</source> (<year>2012</year>) <volume>120</volume>(<issue>24</issue>):<fpage>4751</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2012-04-419283</pub-id><?supplied-pmid 22983442?><pub-id pub-id-type="pmid">22983442</pub-id></mixed-citation></ref><ref id="B182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romee</surname><given-names>R</given-names></name><name><surname>Rosario</surname><given-names>M</given-names></name><name><surname>Berrien-Elliott</surname><given-names>MM</given-names></name><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Jewell</surname><given-names>BA</given-names></name><name><surname>Schappe</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia</article-title>. <source>Sci Transl Med</source> (<year>2016</year>) <volume>8</volume>(<issue>357</issue>): <fpage>357ra123</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf2341</pub-id></mixed-citation></ref><ref id="B183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Poursine-Laurent</surname><given-names>J</given-names></name><name><surname>Truscott</surname><given-names>SM</given-names></name><name><surname>Lybarger</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>LP</given-names></name><etal/></person-group>
<article-title>Licensing of natural killer cells by host major histocompatibility complex class I molecules</article-title>. <source>Nature</source> (<year>2005</year>) <volume>436</volume>(<issue>7051</issue>):<fpage>709</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1038/nature03847</pub-id><?supplied-pmid 16079848?><pub-id pub-id-type="pmid">16079848</pub-id></mixed-citation></ref><ref id="B184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anfossi</surname><given-names>N</given-names></name><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Guia</surname><given-names>S</given-names></name><name><surname>Falk</surname><given-names>CS</given-names></name><name><surname>Roetynck</surname><given-names>S</given-names></name><name><surname>Stewart</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>Human NK cell education by inhibitory receptors for MHC class I</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>25</volume>(<issue>2</issue>):<fpage>331</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2006.06.013</pub-id><?supplied-pmid 16901727?><pub-id pub-id-type="pmid">16901727</pub-id></mixed-citation></ref><ref id="B185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>JA</given-names></name><name><surname>Berrien-Elliott</surname><given-names>MM</given-names></name><name><surname>Rosario</surname><given-names>M</given-names></name><name><surname>Leong</surname><given-names>JW</given-names></name><name><surname>Jewell</surname><given-names>BA</given-names></name><name><surname>Schappe</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Cytokine-induced memory-like differentiation enhances unlicensed natural killer cell antileukemia and Fc gamma RIIIa-triggered responses</article-title>. <source>Biol Blood Marrow Transplant</source> (<year>2017</year>) <volume>23</volume>(<issue>3</issue>):<fpage>398</fpage>&#8211;<lpage>404</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbmt.2016.11.018</pub-id><pub-id pub-id-type="pmid">27894857</pub-id></mixed-citation></ref><ref id="B186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooley</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Pitt</surname><given-names>M</given-names></name><name><surname>Gleason</surname><given-names>M</given-names></name><name><surname>McCullar</surname><given-names>V</given-names></name><name><surname>Bergemann</surname><given-names>TL</given-names></name><etal/></person-group>
<article-title>A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature</article-title>. <source>Blood</source> (<year>2007</year>) <volume>110</volume>(<issue>2</issue>):<fpage>578</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2006-07-036228</pub-id><?supplied-pmid 17392508?><pub-id pub-id-type="pmid">17392508</pub-id></mixed-citation></ref><ref id="B187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romagnani</surname><given-names>C</given-names></name><name><surname>Juelke</surname><given-names>K</given-names></name><name><surname>Falco</surname><given-names>M</given-names></name><name><surname>Morandi</surname><given-names>B</given-names></name><name><surname>D&#8217;Agostino</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>CD56(bright) CD16(-) killer Ig-like receptor(-) NK cells display longer telomeres and acquire features of CD56(dim) NK cells upon activation</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>8</issue>):<fpage>4947</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.8.4947</pub-id><pub-id pub-id-type="pmid">17404276</pub-id></mixed-citation></ref><ref id="B188"><label>188</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juelke</surname><given-names>K</given-names></name><name><surname>Killig</surname><given-names>M</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Romagnani</surname><given-names>C</given-names></name></person-group>. <article-title>Education of hyporesponsive NK cells by cytokines</article-title>. <source>Eur J Immunol</source> (<year>2009</year>) <volume>39</volume>(<issue>9</issue>):<fpage>2548</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200939307</pub-id><?supplied-pmid 19701893?><pub-id pub-id-type="pmid">19701893</pub-id></mixed-citation></ref><ref id="B189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>D</given-names></name><name><surname>Spanholtz</surname><given-names>J</given-names></name><name><surname>Sturtzel</surname><given-names>C</given-names></name><name><surname>Tordoir</surname><given-names>M</given-names></name><name><surname>Schlechta</surname><given-names>B</given-names></name><name><surname>Groenewegen</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>1</issue>):<fpage>e87131</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0087131</pub-id><?supplied-pmid 24498025?><pub-id pub-id-type="pmid">24498025</pub-id></mixed-citation></ref><ref id="B190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cany</surname><given-names>J</given-names></name><name><surname>van der Waart</surname><given-names>AB</given-names></name><name><surname>Spanholtz</surname><given-names>J</given-names></name><name><surname>Tordoir</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>JH</given-names></name><name><surname>van der Voort</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer</article-title>. <source>Oncoimmunology</source> (<year>2015</year>) <volume>4</volume>(<issue>7</issue>):<fpage>e1017701</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1017701</pub-id><pub-id pub-id-type="pmid">26140247</pub-id></mixed-citation></ref><ref id="B191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamura</surname><given-names>H</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Yutsudo</surname><given-names>M</given-names></name><name><surname>Hakura</surname><given-names>A</given-names></name><name><surname>Tanimoto</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Cloning of a new cytokine that induces IFN-gamma production by T-cells</article-title>. <source>Nature</source> (<year>1995</year>) <volume>378</volume>(<issue>6552</issue>):<fpage>88</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/378088a0</pub-id><pub-id pub-id-type="pmid">7477296</pub-id></mixed-citation></ref><ref id="B192"><label>192</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>JE</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name></person-group>. <article-title>The IL-1 family: regulators of immunity</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>(<issue>2</issue>):<fpage>89</fpage>&#8211;<lpage>102</lpage>.<pub-id pub-id-type="doi">10.1038/nri2691</pub-id><?supplied-pmid 20081871?><pub-id pub-id-type="pmid">20081871</pub-id></mixed-citation></ref><ref id="B193"><label>193</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sporri</surname><given-names>R</given-names></name><name><surname>Joller</surname><given-names>N</given-names></name><name><surname>Hilbi</surname><given-names>H</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name></person-group>. <article-title>A novel role for neutrophils as critical activators of NK cells</article-title>. <source>J Immunol</source> (<year>2008</year>) <volume>181</volume>(<issue>10</issue>):<fpage>7121</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.181.10.7121</pub-id><?supplied-pmid 18981133?><pub-id pub-id-type="pmid">18981133</pub-id></mixed-citation></ref><ref id="B194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastenmuller</surname><given-names>W</given-names></name><name><surname>Torabi-Parizi</surname><given-names>P</given-names></name><name><surname>Subramanian</surname><given-names>N</given-names></name><name><surname>Lammermann</surname><given-names>T</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name></person-group>. <article-title>A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread</article-title>. <source>Cell</source> (<year>2012</year>) <volume>150</volume>(<issue>6</issue>):<fpage>1235</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1016/j.cell.2012.07.021</pub-id><?supplied-pmid 22980983?><pub-id pub-id-type="pmid">22980983</pub-id></mixed-citation></ref><ref id="B195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oertli</surname><given-names>M</given-names></name><name><surname>Sundquist</surname><given-names>M</given-names></name><name><surname>Hitzler</surname><given-names>I</given-names></name><name><surname>Engler</surname><given-names>DB</given-names></name><name><surname>Arnold</surname><given-names>IC</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>DC-derived IL-18 drives Treg differentiation, murine <italic>Helicobacter pylori</italic>-specific immune tolerance, and asthma protection</article-title>. <source>J Clin Invest</source> (<year>2012</year>) <volume>122</volume>(<issue>3</issue>):<fpage>1082</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1172/JCI61029</pub-id><?supplied-pmid 22307326?><pub-id pub-id-type="pmid">22307326</pub-id></mixed-citation></ref><ref id="B196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizarro</surname><given-names>TT</given-names></name><name><surname>Michie</surname><given-names>MH</given-names></name><name><surname>Bentz</surname><given-names>M</given-names></name><name><surname>Woraratanadharm</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>MF</given-names></name><name><surname>Foley</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn&#8217;s disease: expression and localization in intestinal mucosal cells</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>162</volume>(<issue>11</issue>):<fpage>6829</fpage>&#8211;<lpage>35</lpage>.<?supplied-pmid 10352304?><pub-id pub-id-type="pmid">10352304</pub-id></mixed-citation></ref><ref id="B197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghayur</surname><given-names>T</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Hugunin</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>D</given-names></name><name><surname>Herzog</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production</article-title>. <source>Nature</source> (<year>1997</year>) <volume>386</volume>(<issue>6625</issue>):<fpage>619</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1038/386619a0</pub-id><?supplied-pmid 9121587?><pub-id pub-id-type="pmid">9121587</pub-id></mixed-citation></ref><ref id="B198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Kuida</surname><given-names>K</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Ku</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>K</given-names></name><name><surname>Fleming</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Activation of interferon-gamma inducing factor mediated by interleukin-1 beta converting enzyme</article-title>. <source>Science</source> (<year>1997</year>) <volume>275</volume>(<issue>5297</issue>):<fpage>206</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1126/science.275.5297.206</pub-id><?supplied-pmid 8999548?><pub-id pub-id-type="pmid">8999548</pub-id></mixed-citation></ref><ref id="B199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boraschi</surname><given-names>D</given-names></name><name><surname>Tagliabue</surname><given-names>A</given-names></name></person-group>. <article-title>The interleukin-1 receptor family</article-title>. <source>Semin Immunol</source> (<year>2013</year>) <volume>25</volume>(<issue>6</issue>):<fpage>394</fpage>&#8211;<lpage>407</lpage>.<pub-id pub-id-type="doi">10.1016/j.smim.2013.10.023</pub-id><?supplied-pmid 24246227?><pub-id pub-id-type="pmid">24246227</pub-id></mixed-citation></ref><ref id="B200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>K</given-names></name><name><surname>Koguchi</surname><given-names>Y</given-names></name><name><surname>Qureshi</surname><given-names>MH</given-names></name><name><surname>Miyazato</surname><given-names>A</given-names></name><name><surname>Yara</surname><given-names>S</given-names></name><name><surname>Kinjo</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>IL-18 contributes to host resistance against infection with <italic>Cryptococcus neoformans</italic> in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>165</volume>(<issue>2</issue>):<fpage>941</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.165.2.941</pub-id><?supplied-pmid 10878369?><pub-id pub-id-type="pmid">10878369</pub-id></mixed-citation></ref><ref id="B201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pien</surname><given-names>GC</given-names></name><name><surname>Satoskar</surname><given-names>AR</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Biron</surname><given-names>CA</given-names></name></person-group>. <article-title>Cutting edge: selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>165</volume>(<issue>9</issue>):<fpage>4787</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.165.9.4787</pub-id><?supplied-pmid 11046000?><pub-id pub-id-type="pmid">11046000</pub-id></mixed-citation></ref><ref id="B202"><label>202</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>CA</given-names></name><name><surname>Lertmemongkolchai</surname><given-names>G</given-names></name><name><surname>Bancroft</surname><given-names>A</given-names></name><name><surname>Haque</surname><given-names>A</given-names></name><name><surname>Lever</surname><given-names>MS</given-names></name><name><surname>Griffin</surname><given-names>KF</given-names></name><etal/></person-group>
<article-title>Critical role of type 1 cytokines in controlling initial infection with <italic>Burkholderia mallei</italic></article-title>. <source>Infect Immun</source> (<year>2006</year>) <volume>74</volume>(<issue>9</issue>):<fpage>5333</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1128/Iai.02046-05</pub-id><?supplied-pmid 16926428?><pub-id pub-id-type="pmid">16926428</pub-id></mixed-citation></ref><ref id="B203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haeberlein</surname><given-names>S</given-names></name><name><surname>Sebald</surname><given-names>H</given-names></name><name><surname>Bogdan</surname><given-names>C</given-names></name><name><surname>Schleicher</surname><given-names>U</given-names></name></person-group>. <article-title>IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by <italic>Leishmania infantum</italic> in vivo</article-title>. <source>Eur J Immunol</source> (<year>2010</year>) <volume>40</volume>(<issue>6</issue>):<fpage>1708</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200939988</pub-id><?supplied-pmid 20213736?><pub-id pub-id-type="pmid">20213736</pub-id></mixed-citation></ref><ref id="B204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegmann</surname><given-names>KA</given-names></name><name><surname>De Souza</surname><given-names>JB</given-names></name><name><surname>Riley</surname><given-names>EM</given-names></name></person-group>
<article-title>IL-18-induced expression of high-affinity IL-2R on murine NK cells is essential for NK-cell IFN-gamma production during murine <italic>Plasmodium yoelii</italic> infection</article-title>. <source>Eur J Immunol</source> (<year>2015</year>) <volume>45</volume>(<issue>12</issue>):<fpage>3431</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201546018</pub-id><pub-id pub-id-type="pmid">26420375</pub-id></mixed-citation></ref><ref id="B205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>CM</given-names></name><name><surname>Wolf</surname><given-names>AS</given-names></name><name><surname>Goodier</surname><given-names>MR</given-names></name><name><surname>Riley</surname><given-names>EM</given-names></name></person-group>
<article-title>Synergy between common gamma chain family cytokines and IL-18 potentiates innate and adaptive pathways of NK cell activation</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<fpage>101</fpage><pub-id pub-id-type="doi">10.3389/Fimmu.2016.00101</pub-id><pub-id pub-id-type="pmid">27047490</pub-id></mixed-citation></ref><ref id="B206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshimoto</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Ohkusu</surname><given-names>K</given-names></name><name><surname>Kashiwamura</surname><given-names>S</given-names></name><name><surname>Okamura</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>IL-12 up-regulates IL-18 receptor expression on T cells, Th1&#8201;cells, and B cells: synergism with IL-18 for IFN-gamma production</article-title>. <source>J Immunol</source> (<year>1998</year>) <volume>161</volume>(<issue>7</issue>):<fpage>3400</fpage>&#8211;<lpage>7</lpage>.<?supplied-pmid 9759857?><pub-id pub-id-type="pmid">9759857</pub-id></mixed-citation></ref><ref id="B207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardolino</surname><given-names>M</given-names></name><name><surname>Azimi</surname><given-names>CS</given-names></name><name><surname>Iannello</surname><given-names>A</given-names></name><name><surname>Trevino</surname><given-names>TN</given-names></name><name><surname>Horan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Cytokine therapy reverses NK cell anergy in MHC-deficient tumors</article-title>. <source>J Clin Invest</source> (<year>2014</year>) <volume>124</volume>(<issue>11</issue>):<fpage>4781</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1172/JCI74337</pub-id><?supplied-pmid 25329698?><pub-id pub-id-type="pmid">25329698</pub-id></mixed-citation></ref><ref id="B208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spolski</surname><given-names>R</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name></person-group>. <article-title>Interleukin-21: basic biology and implications for cancer and autoimmunity</article-title>. <source>Annu Rev Immunol</source> (<year>2008</year>) <volume>26</volume>:<fpage>57</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090316</pub-id><?supplied-pmid 17953510?><pub-id pub-id-type="pmid">17953510</pub-id></mixed-citation></ref><ref id="B209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>K</given-names></name><name><surname>Kikly</surname><given-names>K</given-names></name><name><surname>Michalovich</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>PR</given-names></name><name><surname>Leonard</surname><given-names>WJ</given-names></name></person-group>
<article-title>Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2000</year>) <volume>97</volume>(<issue>21</issue>):<fpage>11439</fpage>&#8211;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.200360997</pub-id><pub-id pub-id-type="pmid">11016959</pub-id></mixed-citation></ref><ref id="B210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrish-Novak</surname><given-names>J</given-names></name><name><surname>Dillon</surname><given-names>SR</given-names></name><name><surname>Nelson</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>A</given-names></name><name><surname>Sprecher</surname><given-names>C</given-names></name><name><surname>Gross</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function</article-title>. <source>Nature</source> (<year>2000</year>) <volume>408</volume>(<issue>6808</issue>):<fpage>57</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1038/35040504</pub-id><?supplied-pmid 11081504?><pub-id pub-id-type="pmid">11081504</pub-id></mixed-citation></ref><ref id="B211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korn</surname><given-names>T</given-names></name><name><surname>Bettelli</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Awasthi</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>TB</given-names></name><etal/></person-group>
<article-title>IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells</article-title>. <source>Nature</source> (<year>2007</year>) <volume>448</volume>(<issue>7152</issue>):<fpage>484</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/nature05970</pub-id><?supplied-pmid 17581588?><pub-id pub-id-type="pmid">17581588</pub-id></mixed-citation></ref><ref id="B212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sivori</surname><given-names>S</given-names></name><name><surname>Cantoni</surname><given-names>C</given-names></name><name><surname>Parolini</surname><given-names>S</given-names></name><name><surname>Marcenaro</surname><given-names>E</given-names></name><name><surname>Conte</surname><given-names>R</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>IL-21 induces both rapid maturation of human CD34(+) cell precursors towards NK cells and acquisition of surface killer Ig-like receptors</article-title>. <source>Eur J Immunol</source> (<year>2003</year>) <volume>33</volume>(<issue>12</issue>):<fpage>3439</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200324533</pub-id><pub-id pub-id-type="pmid">14635054</pub-id></mixed-citation></ref><ref id="B213"><label>213</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>J</given-names></name><name><surname>Hayakawa</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Nutt</surname><given-names>SL</given-names></name></person-group>. <article-title>IL-21 induces the functional maturation of murine NK cells</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>172</volume>(<issue>4</issue>):<fpage>2048</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.172.4.2048</pub-id><?supplied-pmid 14764669?><pub-id pub-id-type="pmid">14764669</pub-id></mixed-citation></ref><ref id="B214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roda</surname><given-names>JM</given-names></name><name><surname>Parihar</surname><given-names>R</given-names></name><name><surname>Lehman</surname><given-names>A</given-names></name><name><surname>Mani</surname><given-names>A</given-names></name><name><surname>Tridandapani</surname><given-names>S</given-names></name><name><surname>Carson</surname><given-names>WE</given-names><suffix>III</suffix></name></person-group>. <article-title>Interleukin-21 enhances NK cell activation in response to antibody-coated targets</article-title>. <source>J Immunol</source> (<year>2006</year>) <volume>177</volume>(<issue>1</issue>):<fpage>120</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.177.1.120</pub-id><?supplied-pmid 16785506?><pub-id pub-id-type="pmid">16785506</pub-id></mixed-citation></ref><ref id="B215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Connor</surname><given-names>JC</given-names></name><name><surname>McCusker</surname><given-names>RH</given-names></name><name><surname>Strle</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name><name><surname>Dantzer</surname><given-names>R</given-names></name><name><surname>Kelley</surname><given-names>KW</given-names></name></person-group>. <article-title>Regulation of IGF-I function by proinflammatory cytokines: at the interface of immunology and endocrinology</article-title>. <source>Cell Immunol</source> (<year>2008</year>) <volume>252</volume>(<issue>1&#8211;2</issue>):<fpage>91</fpage>&#8211;<lpage>110</lpage>.<pub-id pub-id-type="doi">10.1016/j.cellimm.2007.09.010</pub-id><?supplied-pmid 18325486?><pub-id pub-id-type="pmid">18325486</pub-id></mixed-citation></ref><ref id="B216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Fu</surname><given-names>BQ</given-names></name><name><surname>Wang</surname><given-names>FY</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name><etal/></person-group>
<article-title>IGF-1 promotes the development and cytotoxic activity of human NK cells</article-title>. <source>Nat Commun</source> (<year>2013</year>) <volume>4</volume>:<fpage>1479</fpage><pub-id pub-id-type="doi">10.1038/ncomms2484</pub-id><pub-id pub-id-type="pmid">23403580</pub-id></mixed-citation></ref><ref id="B217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>HJ</given-names></name><name><surname>Suh</surname><given-names>Y</given-names></name></person-group>
<article-title>Regulation of IGF-1 signaling by microRNAs</article-title>. <source>Front Genet</source> (<year>2014</year>) <volume>5</volume>:<fpage>472</fpage><pub-id pub-id-type="doi">10.3389/fgene.2014.00472</pub-id><pub-id pub-id-type="pmid">25628647</pub-id></mixed-citation></ref><ref id="B218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>YC</given-names></name><name><surname>Kerdiles</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>JH</given-names></name><name><surname>Yuan</surname><given-names>SZ</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name><name><surname>Chen</surname><given-names>XL</given-names></name><etal/></person-group>
<article-title>Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>42</volume>(<issue>3</issue>):<fpage>457</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2015.02.006</pub-id><?supplied-pmid 25769609?><pub-id pub-id-type="pmid">25769609</pub-id></mixed-citation></ref><ref id="B219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savai</surname><given-names>R</given-names></name><name><surname>Al-Tamari</surname><given-names>HM</given-names></name><name><surname>Sedding</surname><given-names>D</given-names></name><name><surname>Kojonazarov</surname><given-names>B</given-names></name><name><surname>Muecke</surname><given-names>C</given-names></name><name><surname>Teske</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension</article-title>. <source>Nat Med</source> (<year>2014</year>) <volume>20</volume>(<issue>11</issue>):<fpage>1289</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="doi">10.1038/nm.3695</pub-id><?supplied-pmid 25344740?><pub-id pub-id-type="pmid">25344740</pub-id></mixed-citation></ref><ref id="B220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name></person-group>
<article-title>Basic liver immunology</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>) <volume>13</volume>(<issue>3</issue>):<fpage>265</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2016.9</pub-id><pub-id pub-id-type="pmid">27041634</pub-id></mixed-citation></ref><ref id="B221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MW</given-names></name><name><surname>Harmon</surname><given-names>C</given-names></name><name><surname>O&#8217;Farrelly</surname><given-names>C</given-names></name></person-group>. <article-title>Liver immunology and its role in inflammation and homeostasis</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>) <volume>13</volume>(<issue>3</issue>):<fpage>267</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2016.3</pub-id><?supplied-pmid 27063467?><pub-id pub-id-type="pmid">27063467</pub-id></mixed-citation></ref><ref id="B222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisse</surname><given-names>E</given-names></name><name><surname>Vantnoordende</surname><given-names>JM</given-names></name><name><surname>Vandermeulen</surname><given-names>J</given-names></name><name><surname>Daems</surname><given-names>WT</given-names></name></person-group>
<article-title>Pit cell &#8211; description of a new type of cell occurring in rat-liver sinusoids and peripheral-blood</article-title>. <source>Cell Tissue Res</source> (<year>1976</year>) <volume>173</volume>(<issue>4</issue>):<fpage>423</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1007/BF00224305</pub-id><pub-id pub-id-type="pmid">991252</pub-id></mixed-citation></ref><ref id="B223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Racanelli</surname><given-names>V</given-names></name><name><surname>Rehermann</surname><given-names>B</given-names></name></person-group>. <article-title>The liver as an immunological organ</article-title>. <source>Hepatology</source> (<year>2006</year>) <volume>43</volume>(<issue>2</issue>):<fpage>S54</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1002/hep.21060</pub-id><?supplied-pmid 16447271?><pub-id pub-id-type="pmid">16447271</pub-id></mixed-citation></ref><ref id="B224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>BM</given-names></name><name><surname>Plitas</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>ZG</given-names></name><name><surname>Bamboat</surname><given-names>ZM</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Dupont</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The lytic potential of human liver NK cells is restricted by their limited expression of inhibitory killer Ig-like receptors</article-title>. <source>J Immunol</source> (<year>2009</year>) <volume>183</volume>(<issue>3</issue>):<fpage>1789</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.0900541</pub-id><?supplied-pmid 19587011?><pub-id pub-id-type="pmid">19587011</pub-id></mixed-citation></ref><ref id="B225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Jeong</surname><given-names>WI</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name></person-group>. <article-title>Liver: an organ with predominant innate immunity</article-title>. <source>Hepatology</source> (<year>2008</year>) <volume>47</volume>(<issue>2</issue>):<fpage>729</fpage>&#8211;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1002/hep.22034</pub-id><?supplied-pmid 18167066?><pub-id pub-id-type="pmid">18167066</pub-id></mixed-citation></ref><ref id="B226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiorentino</surname><given-names>DF</given-names></name><name><surname>Bond</surname><given-names>MW</given-names></name><name><surname>Mosmann</surname><given-names>TR</given-names></name></person-group>
<article-title>2 types of mouse T-helper cell 0.4. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones</article-title>. <source>J Exp Med</source> (<year>1989</year>) <volume>170</volume>(<issue>6</issue>):<fpage>2081</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1084/jem.170.6.2081</pub-id><pub-id pub-id-type="pmid">2531194</pub-id></mixed-citation></ref><ref id="B227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightbill</surname><given-names>HD</given-names></name><name><surname>Plevy</surname><given-names>SE</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name><name><surname>Smale</surname><given-names>ST</given-names></name></person-group>. <article-title>A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>164</volume>(<issue>4</issue>):<fpage>1940</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.164.4.1940</pub-id><?supplied-pmid 10657644?><pub-id pub-id-type="pmid">10657644</pub-id></mixed-citation></ref><ref id="B228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>MJ</given-names></name><name><surname>Thompson</surname><given-names>SAJ</given-names></name><name><surname>Tone</surname><given-names>Y</given-names></name><name><surname>Waldmann</surname><given-names>H</given-names></name><name><surname>Tone</surname><given-names>M</given-names></name></person-group>. <article-title>Posttranscriptional regulation of IL-10 gene expression through sequences in the 3&#8217;-untranslated region</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>165</volume>(<issue>1</issue>):<fpage>292</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.165.1.292</pub-id><?supplied-pmid 10861064?><pub-id pub-id-type="pmid">10861064</pub-id></mixed-citation></ref><ref id="B229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>JC</given-names></name><name><surname>Indelicato</surname><given-names>SR</given-names></name><name><surname>Narula</surname><given-names>SK</given-names></name><name><surname>Zavodny</surname><given-names>PJ</given-names></name><name><surname>Chou</surname><given-names>CC</given-names></name></person-group>. <article-title>Characterization of interleukin-10 receptors on human and mouse cells</article-title>. <source>J Biol Chem</source> (<year>1993</year>) <volume>268</volume>(<issue>28</issue>):<fpage>21053</fpage>&#8211;<lpage>9</lpage>.<?supplied-pmid 8407942?><pub-id pub-id-type="pmid">8407942</pub-id></mixed-citation></ref><ref id="B230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinushi</surname><given-names>M</given-names></name><name><surname>Takehara</surname><given-names>T</given-names></name><name><surname>Tatsumi</surname><given-names>T</given-names></name><name><surname>Kanto</surname><given-names>T</given-names></name><name><surname>Miyagi</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection</article-title>. <source>J Immunol</source> (<year>2004</year>) <volume>173</volume>(<issue>10</issue>):<fpage>6072</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.173.10.6072</pub-id><pub-id pub-id-type="pmid">15528343</pub-id></mixed-citation></ref><ref id="B231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinushi</surname><given-names>M</given-names></name><name><surname>Takehara</surname><given-names>T</given-names></name><name><surname>Tatsumi</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Sakamori</surname><given-names>R</given-names></name><name><surname>Hiramatsu</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4(+) CD25(+) T cells with PD-1-dependent regulatory activities</article-title>. <source>Immunology</source> (<year>2007</year>) <volume>120</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2567.2006.02479.x</pub-id><pub-id pub-id-type="pmid">17052247</pub-id></mixed-citation></ref><ref id="B232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Travis</surname><given-names>MA</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name></person-group>
<article-title>TGF-beta activation and function in immunity</article-title>. <source>Ann Rev Immunol</source> (<year>2014</year>) <volume>32</volume>:<fpage>51</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120257</pub-id><pub-id pub-id-type="pmid">24313777</pub-id></mixed-citation></ref><ref id="B233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MO</given-names></name><name><surname>Wan</surname><given-names>YY</given-names></name><name><surname>Sanjabi</surname><given-names>S</given-names></name><name><surname>Robertson</surname><given-names>AKL</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group>. <article-title>Transforming growth factor-beta regulation of immune responses</article-title>. <source>Annu Rev Immunol</source> (<year>2006</year>) <volume>24</volume>:<fpage>99</fpage>&#8211;<lpage>146</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.24.021605.090737</pub-id><?supplied-pmid 16551245?><pub-id pub-id-type="pmid">16551245</pub-id></mixed-citation></ref><ref id="B234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group>. <article-title>New regulatory mechanisms of TGF-beta receptor function</article-title>. <source>Trends Cell Biol</source> (<year>2009</year>) <volume>19</volume>(<issue>8</issue>):<fpage>385</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/j.tcb.2009.05.008</pub-id><?supplied-pmid 19648010?><pub-id pub-id-type="pmid">19648010</pub-id></mixed-citation></ref><ref id="B235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Attisano</surname><given-names>L</given-names></name></person-group>
<article-title>The TGFbeta superfamily signaling pathway</article-title>. <source>Wiley Interdiscip Rev Dev Biol</source> (<year>2013</year>) <volume>2</volume>(<issue>1</issue>):<fpage>47</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1002/wdev.86</pub-id><pub-id pub-id-type="pmid">23799630</pub-id></mixed-citation></ref><ref id="B236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<article-title>Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction</article-title>. <source>Cell Mol Immunol</source> (<year>2017</year>) <volume>14</volume>(<issue>5</issue>):<fpage>465</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2016.24</pub-id><pub-id pub-id-type="pmid">27238466</pub-id></mixed-citation></ref><ref id="B237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>QF</given-names></name><name><surname>Yin</surname><given-names>WW</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Yi</surname><given-names>YY</given-names></name><name><surname>He</surname><given-names>QF</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>).<pub-id pub-id-type="doi">10.1038/cmi.2016.28</pub-id></mixed-citation></ref><ref id="B238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Becknell</surname><given-names>B</given-names></name><name><surname>Trotta</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Boyd</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>24</volume>(<issue>5</issue>):<fpage>575</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2006.03.016</pub-id><?supplied-pmid 16713975?><pub-id pub-id-type="pmid">16713975</pub-id></mixed-citation></ref><ref id="B239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>BQ</given-names></name><name><surname>Gao</surname><given-names>YF</given-names></name><name><surname>Liao</surname><given-names>XF</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name><etal/></person-group>
<article-title>TGF-beta 1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence</article-title>. <source>PLoS Pathog</source> (<year>2012</year>) <volume>8</volume>(<issue>3</issue>):<fpage>e1002594</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002594</pub-id><pub-id pub-id-type="pmid">22438812</pub-id></mixed-citation></ref><ref id="B240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name></person-group>. <article-title>NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma</article-title>. <source>Cell Mol Immunol</source> (<year>2015</year>) <volume>12</volume>(<issue>3</issue>):<fpage>292</fpage>&#8211;<lpage>302</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2014.91</pub-id><?supplied-pmid 25308752?><pub-id pub-id-type="pmid">25308752</pub-id></mixed-citation></ref><ref id="B241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>. <article-title>miR-146a negatively regulates NK cell functions via STAT1 signaling</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>).<pub-id pub-id-type="doi">10.1038/cmi.2015.113</pub-id><?supplied-pmid 26996068?><pub-id pub-id-type="pmid">26996068</pub-id></mixed-citation></ref><ref id="B242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donatelli</surname><given-names>SS</given-names></name><name><surname>Zhou</surname><given-names>JM</given-names></name><name><surname>Gilvary</surname><given-names>DL</given-names></name><name><surname>Eksioglu</surname><given-names>EA</given-names></name><name><surname>Chen</surname><given-names>XH</given-names></name><name><surname>Cress</surname><given-names>WD</given-names></name><etal/></person-group>
<article-title>TGF-beta-inducible microRNA-183 silences tumor-associated natural killer cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2014</year>) <volume>111</volume>(<issue>11</issue>):<fpage>4203</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1319269111</pub-id><pub-id pub-id-type="pmid">24586048</pub-id></mixed-citation></ref><ref id="B243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castriconi</surname><given-names>R</given-names></name><name><surname>Cantoni</surname><given-names>C</given-names></name><name><surname>Della Chiesa</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>M</given-names></name><name><surname>Marcenaro</surname><given-names>E</given-names></name><name><surname>Conte</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2003</year>) <volume>100</volume>(<issue>7</issue>):<fpage>4120</fpage>&#8211;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0730604100</pub-id><?supplied-pmid 12646700?><pub-id pub-id-type="pmid">12646700</pub-id></mixed-citation></ref><ref id="B244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopman</surname><given-names>LA</given-names></name><name><surname>Kopcow</surname><given-names>HD</given-names></name><name><surname>Rybalov</surname><given-names>B</given-names></name><name><surname>Boyson</surname><given-names>JL</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name><name><surname>Schatz</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>198</volume>(<issue>8</issue>):<fpage>1201</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20030305</pub-id><pub-id pub-id-type="pmid">14568979</pub-id></mixed-citation></ref><ref id="B245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Piao</surname><given-names>HL</given-names></name><name><surname>Zhou</surname><given-names>WJ</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>CD56(bright) CD25(+) NK cells are preferentially recruited to the maternal/fetal interface in early human pregnancy</article-title>. <source>Cell Mol Immunol</source> (<year>2015</year>) <volume>12</volume>(<issue>1</issue>):<fpage>77</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2014.26</pub-id><pub-id pub-id-type="pmid">24793405</pub-id></mixed-citation></ref><ref id="B246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sargent</surname><given-names>IL</given-names></name><name><surname>Borzychowski</surname><given-names>AM</given-names></name><name><surname>Redman</surname><given-names>CWG</given-names></name></person-group>
<article-title>NK cells and human pregnancy &#8211; an inflammatory view</article-title>. <source>Trends Immunol</source> (<year>2006</year>) <volume>27</volume>(<issue>9</issue>):<fpage>399</fpage>&#8211;<lpage>404</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2006.06.009</pub-id><pub-id pub-id-type="pmid">16843067</pub-id></mixed-citation></ref><ref id="B247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Zhou</surname><given-names>WH</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Jiang</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>The galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal-fetal interface in early pregnancy</article-title>. <source>Cell Mol Immunol</source> (<year>2016</year>) <volume>13</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2014.126</pub-id><pub-id pub-id-type="pmid">25578313</pub-id></mixed-citation></ref><ref id="B248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuma-Myojo</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>S</given-names></name><name><surname>Sakai</surname><given-names>M</given-names></name><name><surname>Siozaki</surname><given-names>A</given-names></name><name><surname>Miwa</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Cytokine profile of natural killer cells in early human pregnancy</article-title>. <source>Am J Reprod Immunol</source> (<year>2005</year>) <volume>54</volume>(<issue>1</issue>):<fpage>21</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0897.2005.00279.x</pub-id><?supplied-pmid 15948769?><pub-id pub-id-type="pmid">15948769</pub-id></mixed-citation></ref><ref id="B249"><label>249</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>ZL</given-names></name><name><surname>Smith</surname><given-names>GN</given-names></name><name><surname>Croy</surname><given-names>BA</given-names></name></person-group>
<article-title>Natural killer cell-triggered vascular transformation: maternal care before birth?</article-title>
<source>Cell Mol Immunol</source> (<year>2011</year>) <volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2010.38</pub-id><pub-id pub-id-type="pmid">20711229</pub-id></mixed-citation></ref><ref id="B250"><label>250</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashkar</surname><given-names>AA</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Croy</surname><given-names>BA</given-names></name></person-group>. <article-title>Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy</article-title>. <source>J Exp Med</source> (<year>2000</year>) <volume>192</volume>(<issue>2</issue>):<fpage>259</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1084/jem.192.2.259</pub-id><?supplied-pmid 10899912?><pub-id pub-id-type="pmid">10899912</pub-id></mixed-citation></ref><ref id="B251"><label>251</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimi</surname><given-names>K</given-names></name><name><surname>Arck</surname><given-names>PC</given-names></name></person-group>. <article-title>Natural killer cells: keepers of pregnancy in the turnstile of the environment</article-title>. <source>Brain Behav Immun</source> (<year>2010</year>) <volume>24</volume>(<issue>3</issue>):<fpage>339</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbi.2009.09.015</pub-id><?supplied-pmid 19800965?><pub-id pub-id-type="pmid">19800965</pub-id></mixed-citation></ref><ref id="B252"><label>252</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluvihare</surname><given-names>VR</given-names></name><name><surname>Kallikourdis</surname><given-names>M</given-names></name><name><surname>Betz</surname><given-names>AG</given-names></name></person-group>. <article-title>Regulatory T cells mediate maternal tolerance to the fetus</article-title>. <source>Nat Immunol</source> (<year>2004</year>) <volume>5</volume>(<issue>3</issue>):<fpage>266</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1038/ni1037</pub-id><?supplied-pmid 14758358?><pub-id pub-id-type="pmid">14758358</pub-id></mixed-citation></ref><ref id="B253"><label>253</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XY</given-names></name><name><surname>Zhou</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>MY</given-names></name><name><surname>Jin</surname><given-names>LP</given-names></name><name><surname>Yuan</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>DJ</given-names></name></person-group>
<article-title>Blockade of CD86 signaling facilitates a Th2 bias at the maternal-fetal interface and expands peripheral CD4(+)CD25(+) regulatory T cells to rescue abortion-prone fetuses</article-title>. <source>Biol Reprod</source> (<year>2005</year>) <volume>72</volume>(<issue>2</issue>):<fpage>338</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1095/biolreprod.104.034108</pub-id><pub-id pub-id-type="pmid">15456701</pub-id></mixed-citation></ref><ref id="B254"><label>254</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guleria</surname><given-names>I</given-names></name><name><surname>Khosroshahi</surname><given-names>A</given-names></name><name><surname>Ansari</surname><given-names>MJ</given-names></name><name><surname>Habicht</surname><given-names>A</given-names></name><name><surname>Azuma</surname><given-names>M</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>A critical role for the programmed death ligand 1 in fetomaternal tolerance</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>202</volume>(<issue>2</issue>):<fpage>231</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20050019</pub-id><pub-id pub-id-type="pmid">16027236</pub-id></mixed-citation></ref><ref id="B255"><label>255</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>B</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Natural killer cells promote immune tolerance by regulating inflammatory T(H)17 cells at the human maternal-fetal interface</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2013</year>) <volume>110</volume>(<issue>3</issue>):<fpage>E231</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1206322110</pub-id><pub-id pub-id-type="pmid">23271808</pub-id></mixed-citation></ref><ref id="B256"><label>256</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vacca</surname><given-names>P</given-names></name><name><surname>Cantoni</surname><given-names>C</given-names></name><name><surname>Vitale</surname><given-names>M</given-names></name><name><surname>Prato</surname><given-names>C</given-names></name><name><surname>Canegallo</surname><given-names>F</given-names></name><name><surname>Fenoglio</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Crosstalk between decidual NK and CD14(+) myelomonocytic cells results in induction of Tregs and immunosuppression</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2010</year>) <volume>107</volume>(<issue>26</issue>):<fpage>11918</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1001749107</pub-id><pub-id pub-id-type="pmid">20547831</pub-id></mixed-citation></ref><ref id="B257"><label>257</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Dunk</surname><given-names>CE</given-names></name><name><surname>Kwan</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>RL</given-names></name><name><surname>Harris</surname><given-names>LK</given-names></name><name><surname>Keating</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Human dNK cell function is differentially regulated by extrinsic cellular engagement and intrinsic activating receptors in first and second trimester pregnancy</article-title>. <source>Cell Mol Immunol</source> (<year>2017</year>) <volume>14</volume>(<issue>2</issue>):<fpage>203</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2015.66</pub-id><?supplied-pmid 26277900?><pub-id pub-id-type="pmid">26277900</pub-id></mixed-citation></ref><ref id="B258"><label>258</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group>
<article-title>Transforming growth factor-beta signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>39</volume>(<issue>4</issue>):<fpage>687</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.019</pub-id><pub-id pub-id-type="pmid">24076049</pub-id></mixed-citation></ref><ref id="B259"><label>259</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggeri</surname><given-names>L</given-names></name><name><surname>Capanni</surname><given-names>M</given-names></name><name><surname>Urbani</surname><given-names>E</given-names></name><name><surname>Perruccio</surname><given-names>K</given-names></name><name><surname>Shlomchik</surname><given-names>WD</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants</article-title>. <source>Science</source> (<year>2002</year>) <volume>295</volume>(<issue>5562</issue>):<fpage>2097</fpage>&#8211;<lpage>100</lpage>.<pub-id pub-id-type="doi">10.1126/science.1068440</pub-id><?supplied-pmid 11896281?><pub-id pub-id-type="pmid">11896281</pub-id></mixed-citation></ref><ref id="B260"><label>260</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JS</given-names></name><name><surname>Soignier</surname><given-names>Y</given-names></name><name><surname>Panoskaltsis-Mortari</surname><given-names>A</given-names></name><name><surname>McNearney</surname><given-names>SA</given-names></name><name><surname>Yun</surname><given-names>GH</given-names></name><name><surname>Fautsch</surname><given-names>SK</given-names></name><etal/></person-group>
<article-title>Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer</article-title>. <source>Blood</source> (<year>2005</year>) <volume>105</volume>(<issue>8</issue>):<fpage>3051</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2004-07-2974</pub-id><?supplied-pmid 15632206?><pub-id pub-id-type="pmid">15632206</pub-id></mixed-citation></ref><ref id="B261"><label>261</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luevano</surname><given-names>M</given-names></name><name><surname>Madrigal</surname><given-names>A</given-names></name><name><surname>Saudemont</surname><given-names>A</given-names></name></person-group>. <article-title>Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy</article-title>. <source>Cell Mol Immunol</source> (<year>2012</year>) <volume>9</volume>(<issue>4</issue>):<fpage>310</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2012.17</pub-id><?supplied-pmid 22705914?><pub-id pub-id-type="pmid">22705914</pub-id></mixed-citation></ref><ref id="B262"><label>262</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Xiao</surname><given-names>WH</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>ZG</given-names></name></person-group>
<article-title>NK cell-based immunotherapy for malignant diseases</article-title>. <source>Cell Mol Immunol</source> (<year>2013</year>) <volume>10</volume>(<issue>3</issue>):<fpage>230</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2013.10</pub-id><pub-id pub-id-type="pmid">23604045</pub-id></mixed-citation></ref><ref id="B263"><label>263</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Lundqvist</surname><given-names>A</given-names></name><name><surname>McCoy</surname><given-names>P</given-names></name><name><surname>Samsel</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Tawab</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells</article-title>. <source>Cytotherapy</source> (<year>2009</year>) <volume>11</volume>(<issue>3</issue>):<fpage>341</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1080/14653240902807034</pub-id><pub-id pub-id-type="pmid">19308771</pub-id></mixed-citation></ref><ref id="B264"><label>264</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujisaki</surname><given-names>H</given-names></name><name><surname>Kakuda</surname><given-names>H</given-names></name><name><surname>Shimasaki</surname><given-names>N</given-names></name><name><surname>Imai</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Lockey</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Expansion of highly cytotoxic human natural killer cells for cancer cell therapy</article-title>. <source>Cancer Res</source> (<year>2009</year>) <volume>69</volume>(<issue>9</issue>):<fpage>4010</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3712</pub-id><pub-id pub-id-type="pmid">19383914</pub-id></mixed-citation></ref><ref id="B265"><label>265</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Weng</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15</article-title>. <source>Tissue Antigens</source> (<year>2010</year>) <volume>76</volume>(<issue>6</issue>):<fpage>467</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1111/j.1399-0039.2010.01535.x</pub-id><?supplied-pmid 20670353?><pub-id pub-id-type="pmid">20670353</pub-id></mixed-citation></ref><ref id="B266"><label>266</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melero</surname><given-names>I</given-names></name><name><surname>Johnston</surname><given-names>JV</given-names></name><name><surname>Shufford</surname><given-names>WW</given-names></name><name><surname>Mittler</surname><given-names>RS</given-names></name><name><surname>Chen</surname><given-names>LP</given-names></name></person-group>. <article-title>NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies</article-title>. <source>Cell Immunol</source> (<year>1998</year>) <volume>190</volume>(<issue>2</issue>):<fpage>167</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1006/cimm.1998.1396</pub-id><?supplied-pmid 9878117?><pub-id pub-id-type="pmid">9878117</pub-id></mixed-citation></ref><ref id="B267"><label>267</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>C</given-names></name><name><surname>Iwamoto</surname><given-names>S</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name></person-group>. <article-title>Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells</article-title>. <source>Blood</source> (<year>2005</year>) <volume>106</volume>(<issue>1</issue>):<fpage>376</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2004-12-4797</pub-id><?supplied-pmid 15755898?><pub-id pub-id-type="pmid">15755898</pub-id></mixed-citation></ref><ref id="B268"><label>268</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujisaki</surname><given-names>H</given-names></name><name><surname>Kakuda</surname><given-names>H</given-names></name><name><surname>Imai</surname><given-names>C</given-names></name><name><surname>Mullighan</surname><given-names>CG</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name></person-group>
<article-title>Replicative potential of human natural killer cells</article-title>. <source>Br J Haematol</source> (<year>2009</year>) <volume>145</volume>(<issue>5</issue>):<fpage>606</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.07667.x</pub-id><pub-id pub-id-type="pmid">19344420</pub-id></mixed-citation></ref><ref id="B269"><label>269</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapteva</surname><given-names>N</given-names></name><name><surname>Durett</surname><given-names>AG</given-names></name><name><surname>Sun</surname><given-names>JL</given-names></name><name><surname>Rollins</surname><given-names>LA</given-names></name><name><surname>Huye</surname><given-names>LL</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications</article-title>. <source>Cytotherapy</source> (<year>2012</year>) <volume>14</volume>(<issue>9</issue>):<fpage>1131</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.3109/14653249.2012.700767</pub-id><?supplied-pmid 22900959?><pub-id pub-id-type="pmid">22900959</pub-id></mixed-citation></ref><ref id="B270"><label>270</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayello</surname><given-names>J</given-names></name><name><surname>Hochberg</surname><given-names>J</given-names></name><name><surname>Flower</surname><given-names>A</given-names></name><name><surname>Chu</surname><given-names>YY</given-names></name><name><surname>Baxi</surname><given-names>LV</given-names></name><name><surname>Quish</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: potential for adoptive cellular immunotherapy</article-title>. <source>Exp Hematol</source> (<year>2017</year>) <volume>46</volume>:<fpage>38</fpage>&#8211;<lpage>47</lpage>.<pub-id pub-id-type="doi">10.1016/j.exphem.2016.10.003</pub-id><pub-id pub-id-type="pmid">27765614</pub-id></mixed-citation></ref><ref id="B271"><label>271</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>YZ</given-names></name><name><surname>Voong</surname><given-names>N</given-names></name><name><surname>Sabatino</surname><given-names>M</given-names></name><name><surname>Stroncek</surname><given-names>DF</given-names></name><name><surname>Morisot</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells</article-title>. <source>J Immunother</source> (<year>2011</year>) <volume>34</volume>(<issue>2</issue>):<fpage>187</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1097/CJI.0b013e31820d2a21</pub-id><pub-id pub-id-type="pmid">21304401</pub-id></mixed-citation></ref><ref id="B272"><label>272</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>NN</given-names></name><name><surname>Baird</surname><given-names>K</given-names></name><name><surname>Delbrook</surname><given-names>CP</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Kohler</surname><given-names>ME</given-names></name><name><surname>Rampertaap</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation</article-title>. <source>Blood</source> (<year>2015</year>) <volume>125</volume>(<issue>5</issue>):<fpage>784</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2014-07-592881</pub-id><?supplied-pmid 25452614?><pub-id pub-id-type="pmid">25452614</pub-id></mixed-citation></ref><ref id="B273"><label>273</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denman</surname><given-names>CJ</given-names></name><name><surname>Senyukov</surname><given-names>VV</given-names></name><name><surname>Somanchi</surname><given-names>SS</given-names></name><name><surname>Phatarpekar</surname><given-names>PV</given-names></name><name><surname>Kopp</surname><given-names>LM</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><etal/></person-group>
<article-title>Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>(<issue>1</issue>):<fpage>e30264</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0030264</pub-id><?supplied-pmid 22279576?><pub-id pub-id-type="pmid">22279576</pub-id></mixed-citation></ref><ref id="B274"><label>274</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegler</surname><given-names>U</given-names></name><name><surname>Meyer-Monard</surname><given-names>S</given-names></name><name><surname>Jorger</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Tichelli</surname><given-names>A</given-names></name><name><surname>Gratwohl</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients</article-title>. <source>Cytotherapy</source> (<year>2010</year>) <volume>12</volume>(<issue>6</issue>):<fpage>750</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.3109/14653241003786155</pub-id><?supplied-pmid 20491532?><pub-id pub-id-type="pmid">20491532</pub-id></mixed-citation></ref><ref id="B275"><label>275</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlens</surname><given-names>S</given-names></name><name><surname>Gilljam</surname><given-names>M</given-names></name><name><surname>Chambers</surname><given-names>BJ</given-names></name><name><surname>Aschan</surname><given-names>J</given-names></name><name><surname>Guven</surname><given-names>H</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><etal/></person-group>
<article-title>A new method for in vitro expansion of cytotoxic human CD3(-)CD56(+) natural killer cells</article-title>. <source>Hum Immunol</source> (<year>2001</year>) <volume>62</volume>(<issue>10</issue>):<fpage>1092</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/S0198-8859(01)00313-5</pub-id><pub-id pub-id-type="pmid">11600215</pub-id></mixed-citation></ref><ref id="B276"><label>276</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>RJ</given-names></name><name><surname>Chong</surname><given-names>LK</given-names></name><name><surname>Wilkinson</surname><given-names>GWG</given-names></name><name><surname>Wang</surname><given-names>ECY</given-names></name></person-group>. <article-title>A high-efficiency system of natural killer cell cloning</article-title>. <source>J Immunol Methods</source> (<year>2005</year>) <volume>307</volume>(<issue>1&#8211;2</issue>):<fpage>24</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1016/j.jim.2005.08.015</pub-id><?supplied-pmid 16271362?><pub-id pub-id-type="pmid">16271362</pub-id></mixed-citation></ref><ref id="B277"><label>277</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alici</surname><given-names>E</given-names></name><name><surname>Sutlu</surname><given-names>T</given-names></name><name><surname>Bojrkstrand</surname><given-names>B</given-names></name><name><surname>Gilljam</surname><given-names>M</given-names></name><name><surname>Stellan</surname><given-names>B</given-names></name><name><surname>Nahi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components</article-title>. <source>Blood</source> (<year>2008</year>) <volume>111</volume>(<issue>6</issue>):<fpage>3155</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2007-09-110312</pub-id><?supplied-pmid 18192509?><pub-id pub-id-type="pmid">18192509</pub-id></mixed-citation></ref><ref id="B278"><label>278</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotzova</surname><given-names>E</given-names></name><name><surname>Savary</surname><given-names>CA</given-names></name><name><surname>Champlin</surname><given-names>RE</given-names></name></person-group>
<article-title>Genesis of human oncolytic natural-killer-cells from primitive Cd34+Cd33- bone-marrow progenitors</article-title>. <source>J Immunol</source> (<year>1993</year>) <volume>150</volume>(<issue>12</issue>):<fpage>5263</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7685792</pub-id></mixed-citation></ref><ref id="B279"><label>279</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giarratana</surname><given-names>MC</given-names></name><name><surname>Verge</surname><given-names>V</given-names></name><name><surname>Schmitt</surname><given-names>C</given-names></name><name><surname>Bertho</surname><given-names>JM</given-names></name><name><surname>Kobari</surname><given-names>L</given-names></name><name><surname>Barret</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Presence of primitive lymphoid progenitors with NK or B potential in ex vivo expanded bone marrow cell cultures</article-title>. <source>Exp Hematol</source> (<year>2000</year>) <volume>28</volume>(<issue>1</issue>):<fpage>46</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/S0301-472x(99)00131-9</pub-id><?supplied-pmid 10658676?><pub-id pub-id-type="pmid">10658676</pub-id></mixed-citation></ref><ref id="B280"><label>280</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Hagihara</surname><given-names>M</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Gansuvd</surname><given-names>B</given-names></name><name><surname>Matsuzawa</surname><given-names>H</given-names></name><name><surname>Tsuchiya</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Enhancement of human cord blood CD34(+) cell-derived NK cell cytotoxicity by dendritic cells</article-title>. <source>J Immunol</source> (<year>2001</year>) <volume>166</volume>(<issue>3</issue>):<fpage>1590</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.166.3.1590</pub-id><pub-id pub-id-type="pmid">11160200</pub-id></mixed-citation></ref><ref id="B281"><label>281</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalberer</surname><given-names>CP</given-names></name><name><surname>Siegler</surname><given-names>U</given-names></name><name><surname>Wodnar-Filipowicz</surname><given-names>A</given-names></name></person-group>
<article-title>Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34(+) cells</article-title>. <source>Blood</source> (<year>2003</year>) <volume>102</volume>(<issue>1</issue>):<fpage>127</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2002-07-2024</pub-id><pub-id pub-id-type="pmid">12637322</pub-id></mixed-citation></ref><ref id="B282"><label>282</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>SA</given-names></name><name><surname>Sotiropoulou</surname><given-names>PA</given-names></name><name><surname>Gkika</surname><given-names>DG</given-names></name><name><surname>Mahaira</surname><given-names>LG</given-names></name><name><surname>Niarchos</surname><given-names>DK</given-names></name><name><surname>Gritzapis</surname><given-names>AD</given-names></name><etal/></person-group>
<article-title>A novel myeloid-like NK cell progenitor in human umbilical cord blood</article-title>. <source>Blood</source> (<year>2003</year>) <volume>101</volume>(<issue>9</issue>):<fpage>3444</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2002-05-1501</pub-id><?supplied-pmid 12506032?><pub-id pub-id-type="pmid">12506032</pub-id></mixed-citation></ref><ref id="B283"><label>283</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanholtz</surname><given-names>J</given-names></name><name><surname>Tordoir</surname><given-names>M</given-names></name><name><surname>Eissens</surname><given-names>D</given-names></name><name><surname>Preijers</surname><given-names>F</given-names></name><name><surname>van der Meer</surname><given-names>A</given-names></name><name><surname>Joosten</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy</article-title>. <source>PLoS One</source> (<year>2010</year>) <volume>5</volume>(<issue>2</issue>):<fpage>e9221</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0009221</pub-id><?supplied-pmid 20169160?><pub-id pub-id-type="pmid">20169160</pub-id></mixed-citation></ref><ref id="B284"><label>284</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanholtz</surname><given-names>J</given-names></name><name><surname>Preijers</surname><given-names>F</given-names></name><name><surname>Tordoir</surname><given-names>M</given-names></name><name><surname>Trilsbeek</surname><given-names>C</given-names></name><name><surname>Paardekooper</surname><given-names>J</given-names></name><name><surname>de Witte</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>(<issue>6</issue>):<fpage>e20740</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0020740</pub-id><pub-id pub-id-type="pmid">21698239</pub-id></mixed-citation></ref><ref id="B285"><label>285</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Cottalasso</surname><given-names>F</given-names></name><name><surname>Montaldo</surname><given-names>E</given-names></name><name><surname>Moretta</surname><given-names>L</given-names></name><name><surname>Mingari</surname><given-names>MC</given-names></name></person-group>
<article-title>Methylprednisolone induces preferential and rapid differentiation of CD34(+) cord blood precursors toward NK cells</article-title>. <source>Int Immunol</source> (<year>2008</year>) <volume>20</volume>(<issue>4</issue>):<fpage>565</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1093/intimm/dxn014</pub-id><pub-id pub-id-type="pmid">18310065</pub-id></mixed-citation></ref><ref id="B286"><label>286</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>PS</given-names></name><name><surname>Kwilas</surname><given-names>AR</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Alter</surname><given-names>S</given-names></name><name><surname>Jeng</surname><given-names>EK</given-names></name><name><surname>Wong</surname><given-names>HC</given-names></name><etal/></person-group>
<article-title>IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>(<issue>13</issue>):<fpage>16130</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.18632/oncotarget.7470</pub-id><pub-id pub-id-type="pmid">26910920</pub-id></mixed-citation></ref><ref id="B287"><label>287</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glienke</surname><given-names>W</given-names></name><name><surname>Esser</surname><given-names>R</given-names></name><name><surname>Priesner</surname><given-names>C</given-names></name><name><surname>Suerth</surname><given-names>JD</given-names></name><name><surname>Schambach</surname><given-names>A</given-names></name><name><surname>Wels</surname><given-names>WS</given-names></name><etal/></person-group>
<article-title>Advantages and applications of CAR-expressing natural killer cells</article-title>. <source>Front Pharmacol</source> (<year>2015</year>) <volume>6</volume>:<fpage>21</fpage>.<pub-id pub-id-type="doi">10.3389/Fphar.2015.00021</pub-id><?supplied-pmid 25729364?><pub-id pub-id-type="pmid">25729364</pub-id></mixed-citation></ref><ref id="B288"><label>288</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahm</surname><given-names>C</given-names></name><name><surname>Schonfeld</surname><given-names>K</given-names></name><name><surname>Wels</surname><given-names>WS</given-names></name></person-group>. <article-title>Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor</article-title>. <source>Cancer Immunol Immunother</source> (<year>2012</year>) <volume>61</volume>(<issue>9</issue>):<fpage>1451</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1007/s00262-012-1212-x</pub-id><?supplied-pmid 22310931?><pub-id pub-id-type="pmid">22310931</pub-id></mixed-citation></ref><ref id="B289"><label>289</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>DM</given-names><suffix>Jr</suffix></name><name><surname>Bakan</surname><given-names>CE</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>SM</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect</article-title>. <source>Blood</source> (<year>2011</year>) <volume>118</volume>(<issue>24</issue>):<fpage>6387</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-06-360255</pub-id><?supplied-pmid 22031859?><pub-id pub-id-type="pmid">22031859</pub-id></mixed-citation></ref><ref id="B290"><label>290</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggeri</surname><given-names>L</given-names></name><name><surname>Urbani</surname><given-names>E</given-names></name><name><surname>Andre</surname><given-names>P</given-names></name><name><surname>Mancusi</surname><given-names>A</given-names></name><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Topini</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells</article-title>. <source>Haematologica</source> (<year>2016</year>) <volume>101</volume>(<issue>5</issue>):<fpage>626</fpage>&#8211;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.3324/haematol.2015.135301</pub-id><?supplied-pmid 26721894?><pub-id pub-id-type="pmid">26721894</pub-id></mixed-citation></ref><ref id="B291"><label>291</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Connolly</surname><given-names>J</given-names></name><name><surname>Shimasaki</surname><given-names>N</given-names></name><name><surname>Mimura</surname><given-names>K</given-names></name><name><surname>Kono</surname><given-names>K</given-names></name><name><surname>Campana</surname><given-names>D</given-names></name></person-group>. <article-title>A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells</article-title>. <source>Cancer Res</source> (<year>2013</year>) <volume>73</volume>(<issue>6</issue>):<fpage>1777</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-3558</pub-id><?supplied-pmid 23302231?><pub-id pub-id-type="pmid">23302231</pub-id></mixed-citation></ref><ref id="B292"><label>292</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>SS</given-names></name><name><surname>Carol</surname><given-names>H</given-names></name><name><surname>Biro</surname><given-names>M</given-names></name></person-group>. <article-title>TriKEs and BiKEs join CARs on the cancer immunotherapy highway</article-title>. <source>Hum Vaccin Immunother</source> (<year>2016</year>) <volume>12</volume>(<issue>11</issue>):<fpage>2790</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1080/21645515.2016.1198455</pub-id><?supplied-pmid 27322989?><pub-id pub-id-type="pmid">27322989</pub-id></mixed-citation></ref><ref id="B293"><label>293</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmohl</surname><given-names>JU</given-names></name><name><surname>Felices</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>F</given-names></name><name><surname>Lenvik</surname><given-names>AJ</given-names></name><name><surname>Lebeau</surname><given-names>AM</given-names></name><name><surname>Panyam</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity</article-title>. <source>Cancer Res Treat</source> (<year>2017</year>).<pub-id pub-id-type="doi">10.4143/crt.2016.491</pub-id><?supplied-pmid 28231426?><pub-id pub-id-type="pmid">28231426</pub-id></mixed-citation></ref></ref-list></back></article>